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10Abstract
This thesis investigates the hypothesis that dysfunction of the hypothalamo-pituitary 
axis is important in headache in patients with pituitary disorders. The observation that 
patients with small functional pituitaiy tumours may suffer with severe headache 
syndromes, and the dramatic analgesic effect that may be seen with somatostatin 
analogues, are central to the thesis. In the first study, I showed that there was no 
correlation between pituitary volume or cavernous sinus invasion with headache in 
pituitary tumours. In this study, prolactinomas and growth hormone- secreting 
tumours were found to be associated with the highest degree of headache, suggesting 
that biochemical mechanisms may be more important than structural ones in the 
pathophysiology of pituitary tumour-associated headache. In the second study, the 
presence of potentially nociceptive peptides CGRP and substance P within pituitary 
tumours was investigated; there was no association between the presence of these 
peptides and headache. In the third study, the clinical characteristics of pituitary 
tumour-associated headache were investigated. The commonest presentation of 
headache was migraine. The rare primary headache, Short lasting Unilateral 
Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT), 
was exclusively associated with acromegaly or prolactinoma. In the fourth study, the 
possibility that cessation of somatostatin infusion could be a useful non-vascular way 
of triggering headache was investigated; the headache induction was not reliable. In 
the final study, the potential use of octreotide in the management of primary headache 
was investigated. Octreotide was unhelpful for migraine, but was efficacious in the 
acute treatment of cluster headache. The findings suggest that functional disturbances 
in the hypothalamo-pituitary axis may have a pathophysiological role in some 
headache types.
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13The role of the hypothalamo-pituitary axis in headache
1.1  An introduction to headache
There have been major advances in the scientific understanding of the 
pathophysiology of headache in recent years, both through clinical and animal 
research. One of the primary shifts in emphasis has been to move away from the view 
that headache is a 'vascular disorder' towards the view that it is a central nervous 
disorder (May and Goadsby, 1999). The trigeminal nucleus has been shown to be 
crucially involved in head pain and the classical human experiments performed by 
Wolff (1963) demonstrated that direct stimulation of the cerebral cortex and other 
central structures were not painful, whereas stimulation of areas innervated by the 
trigeminal nerve, such as the dura mater and cerebral blood vessels, produced pain.
Although the primary disturbance in headache syndromes is believed to be in the 
central nervous system, many patients report a vascular component to their symptoms 
(Drummond and Lance, 1983). This is believed to be a result of activation of the 
‘trigeminovascular’ pathway, which describes an anatomical connection between 
trigeminal neurones and the cranial blood vessels. Stimulation of the trigeminal 
ganglion in the cat leads to an increase in vasoactive peptides such as substance P 
(SP) and calcitonin gene related peptide (CGRP; Goadsby et al., 1988) and 
stimulation of more specific pain-producing structures, such as the superior sagittal 
sinus, also results in the release of CGRP but not SP (Zagami et al., 1990). During 
migraine (Goadsby et al., 1990; Gallai et al. 1995), cluster headache (Goadsby et al., 
1990; Fanciullacci et al., 1995) and other primary headache syndromes (Goadsby and 
Edvinsson,  1996), CGRP has been shown to be elevated, which strongly implicates a 
role for this peptide in the pathophysiology of headache. CGRP (Steel et al., 1992; 
Nakamura et al.,  1998) and SP (Arita et al., 1994; Liu, 1995) have both been isolated 
in the pituitary gland, as will be discussed later in the introduction.
Headache is a common feature of pituitary tumours and is a major cause of morbidity 
in this group of patients (Suwanwela et al., 1994; Abe et al., 1998). Acromegaly and 
prolactinoma appear to be particularly associated with headache (Abe et al., 1998;
14Ezzat et al., 1994; Couch, 1986). As well as the high prevalence of headache in 
pituitary tumours, rare headache syndromes have been described in association with 
small hormonally active lesions (Massiou et. al, 2002; Ferrari et al., 1988). An 
impressive analgesic effect of somatostatin analogues on pituitary tumour-associated 
headache has been described in the absence of reduction tumour size (Sandler et al., 
1987; Williams et al., 1987; Musolino et al., 1990). The mechanism of this analgesic 
action is unknown, although it has been suggested that the suppression of a 
nociceptive peptide may be involved (Williams et al., 1987).
The title of this thesis is ‘The role of the hypothalamo-pituitary axis in headache’. It is 
hoped that the subject matter within this thesis will facilitate information exchange 
between the endocrinologist interested in pituitary disease, and the neurologist 
interested in headache. This introduction attempts to draw together the current data 
regarding the involvement of the hypothalamo-pituitary axis in primary headache 
syndromes, the clinical presentation and proposed mechanisms of pituitary tumour- 
associated headache, and the perceived role of somatostatin in headache.
The first part of the introduction is a clinical and pathophysiological review of 
headache, with particular emphasis on the involvement of the hypothalamo-pituitary 
axis. This section includes a series of case histories of patients with pituitary tumours 
presenting with headache that exemplify the important issues that were generated 
whilst planning the work. The individual cases are fully described in the Appendix. In 
the second part of the introduction, a general background to the subject of pituitary 
tumours is given, with particular emphasis on headache. This section reviews the 
previous clinical reports of pituitary tumour-associated headache and includes a 
discussion of the potential pathophysiological mechanisms involved. The final part of 
the introduction discusses the topic of somatostatin and headache, following which is 
a summary of the aims of the individual studies in this thesis.
1.2  Case Histories
One of the impetuses for this project was a series of observations made by two 
independent groups (the Endocrine Unit, Charing Cross Hospital, London and the 
Headache Group, Institute of Neurology, London). The cases described in the 
Appendix exemplify the type of presentations that aroused interest in this subject, and
15are summarised here.
Cases 1  and 2 (Appendix) describe two similar patients presenting with very small 
pituitary tumours with severe headache (Levy et al., 2003a). These cases suggest that 
factors other than tumour size may be important in pituitary tumour-associated 
headache. Both had microprolactinomas and presented with rare headache syndromes 
at the same time as the onset of menstrual disturbance and galactorrhoea. Case 1  had a 
diagnosis of short lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing (SUNCT; Goadsby and Lipton, 1997; I.H.S code 3.3, Headache 
Classification Committee of The International Headache Society, 2004) and case 2 
had symptoms suggestive of hemicrania continua (Pareja et at., 2001; I.H.S code 4.7, 
Headache Classification Committee of The International Headache Society, 2004), 
the clinical features of which are discussed later in this introduction. The interesting 
aspect of these cases is the manner in which the administration of dopamine agonists 
significantly altered and exacerbated the headache phenotype without causing a 
change in the size of the lesions. The importance of size in pituitary tumour- 
associated headache is studied in Chapter 2.
Case 3 (Appendix) describes a patient with acromegaly who presented with severe 
unilateral headache (Levy et al., 2003b). The striking aspects of this case were the 
dramatic analgesic effect of octreotide and the unresponsiveness of the headache to 
lanreotide, despite adequate growth hormone suppression with both. The fact that 
lanreotide successfully reduced growth hormone but not headache suggests that 
octreotide possesses a specific analgesic property that is ‘uncoupled’ from growth 
hormone. The possibility that pituitary tumours might secrete a nociceptive peptide is 
investigated in Chapter 3.
Case 4 (Appendix) describes a 37 year-old man with a macroprolactinoma presenting 
with SUNCT (Matharu et al., 2003). The headache symptoms were ipsilateral to the 
side of cavernous sinus invasion and these symptoms completely resolved in response 
to dopamine agonist therapy. The clinical features of SUNCT and other rare headache 
syndromes are discussed later, and the range of headache phenotypes seen with 
pituitary tumours is investigated in Chapter 4.
16Case 5 (Appendix) describes octreotide dependency (Levy and Goadsby, 2004), 
which has been previously reported (Popovic et al., 1988; May et al., 1994) although 
this is not widely recognised. The presence of rebound headache and tachyphylaxis in 
this patient indicates that overexposure to somatostatin can cause worsening 
headache. The potential usefulness of this observation for research purposes are 
studied in Chapter 5, and the potential role of octreotide as an abortive analgesic agent 
in primary headache is studied in Chapter 6.
In summary, pituitary tumours appear to give rise to a range of headache syndromes 
that may be caused by factors over and above simple structural mechanisms. The 
observation that headache can be alleviated or excerbated by the administration of 
dopamine agonists or somatostatin analogues suggests that previously unexplained 
neuro-endocrine pathways may be important in the pathophysiology of certain 
headaches.
1.3  The hypothalamo-pituitary axis and headache
In order to understand the significance of pituitary tumour-associated headache, it is 
important to have a clinical and pathophysiological perspective of headache in 
general. An important aspect of headache in clinical practice is the recognition that 
pain is only a small part of the presentation of most headache syndromes (Silberstein 
et al., 2002). Many of the non-painful clinical features associated with primary 
headache suggest that there are alterations in the hypothalamo-pituitary axis before, 
during and after a headache attack (Giffin et al., 2003). The following is a discussion 
of the different headache phenotypes mentioned in this thesis, with particular 
emphasis on the relevance of the hypothalamo-pituitary axis to each phenotype.
1.4  Migraine
Migraine is a common clinical problem, having a one-year prevalence of 
approximately 17 % among women and 10 % among men (Steiner et al., 2003). 
Migraine has many facets other than pain in its clinical presentation, and this is well 
recognised by patients (Silberstein et al., 2002). To establish a diagnosis of migraine, 
as defined by the Headache Classification Committee of the International Headache 
Society (1988), having regard to its recent revision (2004), five attacks are needed, 
each lasting 4-72 hours and having two of the following four pain characteristics:
17unilateral location, throbbing quality, moderate to severe intensity and aggravation 
with movement. In addition, the attacks must have at least one of the following: 
nausea or vomiting or photophobia and phonophobia. Functional imaging studies 
have suggested that the brain stem is activated during a migraine attack (Weiller et al., 
1995; Bahra et al., 2001; Matharu et al., 2004) supporting the view that migraine is a 
central nervous system rather than a peripheral disorder. There are characteristic 
clinical features of migraine that implicate the hypothalamo-pituitary axis in the 
pathophysiology of migraine which are now discussed.
1.4.1  Sex hormones and migraine
Migraine is approximately twice as common in women (Stewart et al., 1994) and 
there is a known association between alterations in the female endocrine axis and 
migraine. Women commonly experience migraine peri-menstrually, which may be 
due to oestrogen withdrawal (Somerville,  1975; Silberstein, 2001). The role of 
fluctuating oestrogen levels in migraine is further evidenced by the observation that 
migraine attacks occur during the 'pill free interval’ in women on the combined oral 
contraceptive pill (MacGregor, 1997) implying that oestrogen withdrawal is important 
in the pathopysiology of migraine. There are also a group of patients who experience 
oestrogen-induced migraine (Silberstein, 2000a) indicating that migraine may be 
exacerbated by both increases and decreases in oestradiol concentration. Migraine 
often improves during the second and third trimester of pregnancy when oestrogen 
and progesterone levels are persistently elevated, often exacerbating soon after 
delivery (Silberstein, 2000b). Migraine commonly worsens at the peri-menopause 
(Neri et al., 1993) further indicating the importance of fluctuations in oestradiol levels 
in relation to migraine. A well-recognised time for women to experience their first 
migraine attack is at menarche (Facchinetti et al., 2000), when there is much change 
in activity of the hypothalamo-pituitary axis (Styne, 1994).
1.4.2  Premonitory symptoms
Premonitory symptoms are probably under-recognised, partly due to their subtle 
nature (Santoro et al., 1990) and implicate hypothalamic disturbances in migraine. 
They should not be confused with aura, which occurs up to 60 minutes before the 
onset of pain, and occurs in 15% of migraineurs (Russell et al., 2002). Premonitory 
symptoms include increased yawning, tiredness, mood disturbances, polyuria,
18polydipsia and altered food cravings (Drummond and Lance, 1984), strongly pointing 
towards hypothalamic disturbance (Kupfermann, 1985; Zurak, 1997). The incidence 
of premonitory symptoms ranges from 7-88% of migraine sufferers (Drummond and 
Lance, 1984; Waelkens, 1985; Rasmussen and Olesen, 1992) and these symptoms are 
highly predictive of attacks in affected patients (Giffin et al., 2003).
1.4.3  Dopamine-prolactin axis
Premonitory symptoms may be due to alterations in dopaminergic pathways 
(Peroutka, 1997). Yawning may be a prominent premonitory symptom (Russell et al., 
1996) and there is in vivo evidence that dopamine (D2) receptor activation can lead to 
experimentally-induced yawning (Mogilnicka and Klimek, 1977; Protais et al., 1983; 
Serra et al., 1986; Yamada et al., 1986). D2 agonists may induce both yawning and 
headache in migraineurs (Blin et al., 1991; Del Bene et al., 1994). Migraine is less 
common in patients with Parkinson’s disease than those without, and the frequency of 
migraine in Parkinsonian patients increases with administration of D2 agonists 
(Sabatini et al., 1990). Migraineurs may have increased dopamine sensitivity (Cassidy 
et al., 2003) and abnormalities of D2 receptors (Peroutka et al., 1997; Dichgans et al., 
1998). There is clinical evidence that dopamine antagonists are helpful in the acute 
treatment of a migraine attack beyond their anti-emetic effects (Sharma et al., 2002; 
Silberstein et al., 2003).
Because of the intricate relationship between dopamine and prolactin (dopamine is 
‘prolactin inhibitory factor’ when produced by the hypothalamus), there has been 
interest in the relationship between serum prolactin per se and migraine (Murialdo 
and Pollen, 1987). Peres et al. (2001) showed a reduction in serum prolactin in 
chronic migraine, whilst other groups have shown an elevation in serum prolactin in 
episodic migraine (Murialdo et al., 1986; Nattero et al., 1986). It is unclear whether 
this difference in findings is related to the episodicity of migraine. There is an 
increased prolactin response after pituitary stimulation in episodic migraineurs 
compared to healthy controls (Awaki et al.,  1989) and an increased prolactin response 
to dopamine antagonists in the follicular phase of migraineurs (Murialdo et al., 1986). 
Conversely the inhibitory effect of nomifensine, a dopamine reuptake inhibitor, on 
prolactin secretion is dampened in migraineurs compared with controls (Murialdo et 
al.,  1986). These findings may demonstrate an increased prolactin reserve in migraine
19and suggest the existence of a dopaminergic supersensitivity of the lactotrophic 
postsynaptic D2 receptors. A further link between dopamine and migraine is the 
observation that bromocriptine may exert an analgesic effect in primary migraine 
(Herzog, 1997) and in pituitary tumour-associated migraine (Hartman et al., 1995; 
Gabrielli et al., 2002).
1.4.4  Migraine genetics
One of the key features of migraine is its strong familial tendency. This was noted as 
far back as the eighteenth century (Tissot, 1790) and numerous subsequent studies 
have confirmed this. Familial studies support the familial aggregation of migraine 
(Merikangas, 1990; Merikangas, 1996) and twin studies also support the role of 
genetic factors (Merikangas, 1996). The observation that there is only an 
approximately 50% concordance in monozygotic twin studies suggests that the 
aetiology of migraine is multifactorial. It is unlikely that there is a single 'migraine 
gene' and abnormalities in the following genes have been linked to migraine: 
dopamine receptors (Peroutka et al., 1997), Notch 3 (Davous, 1998), mitochondrial 
genes (Klopstock et al., 1996), endothelin type A receptor (Tzourio et al., 2001), 
Xq24-28 linked gene (Nyholt et al., 2000) and the insulin receptor gene (McCarthy et 
al., 2001). There has been interest in the CACNA1A gene on chromosome 19pl3 
(Ophoff et al., 1996). This gene encodes the aiA subunit, which forms the calcium- 
selective pore of voltage gated P/Q-type calcium channels. CACNA1A mutations are 
associated with familial hemiplegic migraine, a rare autosomal dominant form of 
migraine with prolonged aura, hemiparesis and, in some families, cerebellar ataxia 
and atrophy. There has also been an association between familial hemiplegic migraine 
and the ATP1A2 gene on chromosome lq23 (De Fusco et al., 2003; Vanmolkot et al., 
2003). This gene encodes the 012 subunit of the sodium-potassium pump, further 
implying that certain forms of migraine may be due to abnormalities in the function of 
ionic channels (so-called ‘channelopathies’).
In summary, there is evidence that patients with migraine have an inherited tendency 
to a condition that includes central neuroendocrine disturbances. This knowledge may 
be important in understanding the reasons why certain patients with functional 
pituitary tumours are particularly prone to headache.
201.5  Trigeminal Autonomic Cephalgias
One of the observations made in the clinical cases described in the Appendix, 
supported by the literature (Ferrari, 1988; Massiou, 2002; Milos, 1996), is that cranial 
autonomic symptoms may be a feature of pituitary tumour-associated headache. 
Cranial autonomic symptoms are a particularly prominent clinical feature of a group 
of primary headaches known as the trigeminal autonomic cephalgias, of which cluster 
headache is the most commonly described (Goadsby and Lipton, 1997). The cranial 
autonomic symptoms include ipsilateral parasympathetic activation (lacrimation, 
rhinorrhoea, nasal congestion, and eyelid oedema) and sympathetic hypofunction 
(ptosis and miosis). The mechanism of autonomic activation has been well described 
(Goadsby and Lipton, 1997). Stimulation of trigeminal efferent neurones can result in 
increased cranial autonomic outflow (May and Goadsby, 1999; Frese et al., 2003), 
known as the trigeminal-autonomic reflex. The trigeminal-autonomic reflex refers to a 
functional reflex between the trigeminal nucleus caudal is and the parasympathetic 
outflow from the superior salivatory nucleus.
1.5.1  Cluster Headache
The tendency of cyclical/ seasonal expression in episodic cluster headache is strongly 
suggestive of hypothalamic involvement because the suprachiasmatic nucleus of the 
hypothalamus is believed to be the pivotal area of the brain controlling biological 
rhythms (Swaab et al., 1996). Functional imaging techniques, such as functional fMRI 
and Positron Emission Tomography (PET), along with evidence from biochemical 
investigation of patients with cluster headache, have shown that the hypothalamus 
plays a central role in the pathophysiology of this rare headache disorder. Therefore 
cluster headache gives numerous insights into the potential role of the hypothalamo- 
pituitary axis in headache.
1.5.1.1 Clinical features of cluster headache
A typical cluster attack is characterised by severe unilateral orbital/ supraorbital/ 
temporal pain lasting 15 to 180 minutes if untreated. Headache is usually associated 
with pronounced cranial autonomic features and the frequency of attacks varies from 
1  every other day to 8 per day (Headache Classification Committee of the 
International Headache Society, 2004). Cluster headache may be episodic, occurring
21in periods lasting 7 days to one year separated by pain free periods lasting 14 days. 
Cluster headache may also be chronic, occuring for more than one year without 
remission or remission lasting less than 14 days. In episodic cluster headache, a 
cluster period usually lasts between 2 weeks and 3 months. Unlike migraineurs 
(during a migraine attack patients are generally sedate and prefer to lie in a darkened 
room), patients with cluster headache are often extremely agitated and unable to lie 
down during an attack. Patients with cluster headache describe rocking, applying 
pressure to their head, banging their heads against walls, and other restless activities 
during an attack (Blau, 1993). This behavioural difference from migraine may not be 
just a reflection of the higher pain severity, but may be due to hypothalamic 
activation. It is known that hypothalamic centres are important for autonomic fight/ 
flight responses (Palkovits, 1999) and aggressive behaviour (Panksepp, 1971; Kruk et 
al., 1983; Roeling et al., 1993) and this may explain the extreme agitation observed 
during a cluster attack.
1.5.1.2  Biochemical abnormalities in cluster headache 
Hypothalamo-Pituitary Adrenal Axis
There is evidence that cortisol diurnal variation is lost in cluster headache, and this 
does not appear to be related to whether the attacks are nocturnal or during the day 
(Ferrari et al., 1983; Chazot et al., 1984; Facchinetti et al., 1986).
Twenty-four hour urinary cortisol production is increased in cluster headache during a 
bout compared with controls (Facchinetti et al., 1986; Waldenlind et al., 1987) 
implying activation of the adrenal axis. There is a reduced cortisol response to painful 
stimuli compared to healthy controls (Chazot et al., 1984; Waldenlind et al., 1987) as 
well as a reduced cortisol / ACTH response to CRH both in the cluster period and 
during remission (Leone et al., 1991), and reduced response to insulin-induced 
hypoglycaemia (Leone et al., 1991). The raised resting activity of the hypothalamo- 
adrenal axis in cluster headache suppresses normally in response to low-dose 
dexamethasone (Devoize et al., 1986; Frediani et al., 1988; Leone et al., 1992) 
suggesting that there is no autonomous secretion of cortisol in cluster headache.
22Gonadal Axis
Cluster headache is more common in males, with a male: female ratio of 7:1 in middle 
age (Ekbom et al., 2002) although the ratio may be closer to 2.5:1 (Bahra et al., 2002; 
Torelli et al., 2003). The male predominance of cluster headache and the observation 
that it is very rare in puberty (Manzoni et al.,  1991) suggests that the FSH/ LH/ 
testosterone axis may be important in cluster headache.
There is reduced basal LH (Kudrow, 1977; Klimek et al., 1984) and elevated FSH 
levels (Murialdo et al., 1989) in episodic and chronic cluster headache, although 
groups have also reported normal levels (Parati et al., 1980; Murialdo et al., 1989; 
Klimek et al., 1984). The LH response to LHRH has been reported as normal 
(Facchinetti et al., 1988) and reduced (Klimek et al., 1984; Murialdo et al., 1989), 
whilst an increased FSH response in both episodic and chronic cluster headache has 
been observed (Murialdo et al., 1989). A reduction in LH peaks over 24 hours has 
been demonstrated in both chronic and episodic cluster headache (Micieli et al.,
1987), further indicating an abnormality in the central control of LH secretion.
Testosterone levels have been reported as normal (Nelson, 1978) and low (Kudrow, 
1976; Klimek, 1982; Micieli et al., 1987) during the cluster period, the reported low 
levels possibly being secondary to reduced central LH production. There is evidence 
of increased responsiveness to exogenous testosterone in cluster headache sufferers 
compared to controls (Nicolodi et al., 1993) suggesting increased sensitivity to 
testosterone. Refractory cluster headache has been resolved by gonadotropin releasing 
hormone (GnRH) analogues, suggesting that suppression of the hypothalamo- 
pituitary-gonadal axis can restore a patient to the pain-free state (Nicolodi et al., 
1993b).
Growth Hormone Axis
There have been reports of abnormalities in the growth hormone axis in cluster 
headache. An abnormal evening growth hormone peak has been reported in episodic 
cluster headache (Chazot et al., 1984) and Klimek (1985) reported an increased 
growth hormone response to dopamine agonists, with a simultaneous reduction in 
prolactin. Because hypothalamic dopaminergic neurones have been shown to facilitate
23growth hormone release and inhibit prolactin (Anden et al., 1967), these observations 
may point to increased hypothalamic dopaminergic tone in cluster headache (Leone 
and Bussone, 1993).
Thyroid Axis
Although basal thyroid stimulating hormone (TSH) levels are predominantly normal 
in cluster headache (Waldenlind and Gustafsson, 1987; Bussone et al., 1988; Leone et 
al., 1990) there is evidence of reduced TSH responsiveness to thyrotropin releasing 
hormone (TRH) in both episodic (Bussone et al., 1988; Leone et al., 1990) and 
chronic cluster headache (Waldenlind and Gustafsson, 1987) compared with healthy 
controls.
Dopamine-Prolactin Axis
The diurnal rhythm of prolactin has been reported as normal (Ferrari et al., 1979; 
Chazot et al., 1984) with a loss in prolactin release rhythms (Polleri et al., 1982; 
Ferrari et al., 1983). Waldenlind et al. (1987) demonstrated reduced 24-hour prolactin 
production in episodic cluster headache both in remission and during the cluster 
period, which was independent of sleep deprivation. This reduction in prolactin 
secretion may be related to increased dopaminergic tone in cluster headache 
(Waldenlind and Gustafsson, 1987). A blunted prolactin response to dopamine 
antagonists has been demonstrated in episodic cluster headache during a bout, 
(Klimek, 1985) and Bussone et al. (1988) demonstrated no alteration in prolactin 
response to TRH, which may indicate that dopaminergic pathways are specifically 
altered in cluster headache.
In summary, the literature suggests that there are alterations in all five hypothalamo- 
pituitary axes in patients with cluster headache, both in the resting state and during a 
bout, compared with controls as summarised in Table 1. It is conceivable that by 
studying the headache phenotypes characterised by specific perturbations in the 
hypothalamo-pituitary axis in functional pituitary tumours, further light may be shed 
on the precise biochemical mechanisms involved in primary headache. Further 
exciting and more direct evidence of the importance of hypothalamic activation in CH 
arises from functional imaging studies, which is now discussed.
24Tabic 1. Biochemical abnormalities in cluster headache
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1.5.1.3  Functional Imaging Abnormalities
Activation of the ipsilateral posterior hypothalamic grey matter has been 
demonstrated using PET scans during nitroglycerin-induced cluster headache attacks 
(May et al., 1998a). Evidence that this hypothalamic activation is specific to cluster 
headache and not a secondary marker of pain, is illustrated by the lack of this pattern 
of activation in migraine (Weiller et al., 1995) or experimentally induced ophthalmic 
division pain (May et al., 1998b). Voxel-based morphometric analysis of the 
structural T1-weighted MRI scans of 25 patients with cluster headache (May et al., 
1999a) showed that cluster patients had an increase in hypothalamic volume 
compared to healthy controls, and the inferior posterior hypothalamus was the specific 
area of enlargement. This area closely correlates with the PET appearances and adds 
consistency to the view that this nucleus is involved in cluster headache (Figure 1).
25Leone et al. (2001) reported a patient with intractable cluster headache who 
experienced a dramatic resolution in symptoms after stereotactic stimulation of the 
posterior hypothalamus. Subsequent to this, five patients have responded well to the 
insertion of deep brain hypothalamic stimulators (Franzini et al., 2003).
Figure 1. lpsilateral hypothalamic activation in cluster headache on PET
Taken from May et al. (1998a)
In summary, primary cluster headache appears to involve structural / functional 
disturbances of the hypothalamo-pituitary axis. As will be discussed in section 1.8.3, 
there are reported cases of cluster headache occurring in association with pituitary 
tumours (Milos et al., 1996; Tfelt-Hansen et al., 1982; Greve and Mai, 1988; Porta- 
Etessam et al., 2001), and a key question is whether this is due to functional or 
structural abnormalities within the pituitary gland.
961.5.2  Short lasting Unilateral Neuralgiform headache attacks with 
Conjunctival injection and Tearing (SUNCT)
The syndrome of short lasting unilateral neuralgiform headache attacks, conjunctival 
injection and tearing (SUNCT) is characterised by short attacks of pain, lasting 
between 5-250 seconds, with a mean duration of 49 seconds (Pareja et al., 1996) 
Patients are generally pain-free in between episodes (Pareja et al., 1996). The 
frequency of attacks varies from one per day to 30 attacks per hour (Pareja and 
Sjaastad, 1997), and episodes predominantly occur during the day unlike cluster 
headache where nocturnal attacks are common. Attacks can be precipitated by 
touching the face or scalp, eating, washing, shaving or talking, making it clinically 
very similar to trigeminal neuralgia (Pareja and Sjaastad, 1997). Functional imaging 
studies have suggested that SUNCT attacks involve the ipsilateral hypothalamus (May 
et al.  1999; Figure 2). SUNCT is clinically similar to trigeminal neuralgia, although 
the presence of a refractory period, the relative absence of cranial autonomic features, 
the shorter lasting attacks and response to carbamazepine are features that favour a 
diagnosis of trigeminal neuralgia rather than SUNCT (Matharu and Goadsby, 2002). 
SUNCT may also be confused with primary stabbing headache (Pareja et al., 1999). 
This refers to sharp jabbing pains, usually in the ophthalmic distribution of the 
trigeminal nerve, that are often associated with a concurrent primary headache 
syndrome. It is thought that primary stabbing headache represents a general reflection 
of abnormal trigeminal activity and does not in itself have a large pathophysiological 
significance. Primary stabbing headache is seen more commonly in women than men, 
and often responds to indomethacin (Pareja et al., 1999). As will be discussed in 
section 1.8.2, SUNCT has been described in assocation with pituitary tumours 
(Massiou et al., 2002; Levy et al., 2003a; Matharu et al., 2003).
Figure 2. Ipsilateral hypothalamic activation in SUNCT on fMRI 
Taken from May et al. (1999)1.5.3  Paroxysmal Hemicrania
Paroxysmal hemicrania lies between cluster headache and SUNCT in terms of the 
duration and frequency of headache attacks. Paroxysmal hemicrania is characterised 
by excruciating unilateral pain and autonomic features that last 10-30 minutes, the 
length of attack ranging from 2-45 minutes (Antonaci and Sjaastad, 1989). The 
frequency of attacks is typically greater than five per day, the reported range being 1  - 
40 per day (Antonaci and Sjaastad, 1989). The female preponderance and dramatic 
response to indomethacin distinguish paroxysmal hemicrania from cluster headache 
The differences between the short-lasting headaches are summarised in Table 2.
Table 2. Clinical features of short lasting headaches.
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281.6  Chronic Daily Headache
Chronic daily headache is not a diagnostic term, but is useful in clinical practice in a 
similar way to the phrase ‘anaemia’, in that it describes a clinical phenomenon 
without having pathophysiological implications (Goadsby and Boes, 2002). Chronic 
daily headache is defined as headache on 15 days or more per month for more than 
three months (Goadsby and Boes, 2002). The first step in classifying chronic daily 
headache is to determine if it is a primary or secondary headache. Secondary 
headache implies an underlying pathology and the causes are numerous, including 
traumatic, inflammatory, infective or neoplastic (Goadsby and Boes, 2002; Table 3).
Table 3. Classification of chronic daily headache.
Adapted from Welch and Goadsby (2002)
Primary Secandnrv
> 4  h par day < 4  h par day
Chronic migraine Chronic cluster headache
Post-traumatic 
Head injury 
Iatrogenic 
Post-infectious 
Neoplastic
Chronic tension-type headache Chronic paroxysmal hemicrania
Inflammatory 
Giant cell arteritis 
Sarcoidosis 
Behcet’s
Hemicrania continua SUNCT CNS infection
New daily persistent 
Headache
Hypnic headache* Substance overuse
*  Included for completion. A rare primary headache syndrome that awakes patient from sleep lasting 5 -  60 minutes
with no autonomic features
1.6.1  Primary chronic daily headache
291.6.1.1 Chronic migraine
Migraine may be viewed as an increased sensitivity to both internal and external 
stimuli during an exacerbation (Goadsby and Boes, 2002). In the past, chronic 
migraine, transformed migraine and chronic daily headache were used 
interchangeably and it has been suggested that the term chronic migraine is now used 
for patients with frequent headache on a migrainous basis (Welch and Goadsby, 
2002). The term ‘transformed migraine’ was previously used to describe the 
observation of episodic migraine ‘transforming’ into a less discrete entity 
characterised by frequent headache with less obvious migrainous characteristics. This 
term does not acknowledge the difference between cause and association (Mathew et 
al., 1982). Welch et al. (2001) reported increased tissue iron levels in the peri­
aqueductal gray matter (PAG) in patients with chronic migraine and analgesia 
overuse, suggesting a specific pathophysiological basis to this condition.
1.6.1.2 Chronic Tension-Type Headache
Chronic tension-type headache is characterised by a featureless frequent headache. 
Tenderness of the pericranial muscles is the most commonly reported symptom in 
tension-type headache, possibly mediated by increased sensitivity of mechano- 
sensitive afferent neurones projecting to the dorsal horn of the trigeminal nucleus 
(Jensen and Olesen, 1996). Episodic tension-type headache may progress to chronic 
tension-type headache as a result of persistent and prolonged sensory input (Bendtsen 
and Ashina, 2000). Unlike migraine chronic tension-type headache is not associated 
with supraspinal dysmodulation of trigeminal pain transmission (Lipchik et al., 2000). 
CGRP levels are elevated in tension-type headache with throbbing (Ashina et al., 
2000) and it may more helpful to consider the latter as a form of migraine, particularly 
as there may be a therapeutic response to triptans (Lipton et al., 2000; Welch and 
Goadsby, 2002).
What is the point of this discussion in relation to pituitary tumour-associated headache 
and this thesis? The primary purpose is to recognise that patients with chronic daily 
headache in association with pituitary tumours may have concurrent chronic tension 
type headache or chronic migraine, and in order to parse out the specific role of the 
pituitary gland in patients presenting with headache, it is important to have a balanced 
perspective on the commoner causes of chronic daily headache.
301.6.1.3  Hemicrania continua
Hemicrania continua is a rare primary headache characterised by unilateral side- 
locked pain, whose severity may wax and wane (Pareja et al., 2001). Hemicrania 
continua was a thought to be a featureless headache, but it is now recognised that 
migrainous features may be associated with this condition (Peres et al., 2002). 
Hemicrania continua has a striking indomethacin-responsiveness in the absence of 
improvement with other non-steroidal anti-inflammatory agents. There is debate as to 
whether hemicrania continua can be safely diagnosed in a non-indomethacin 
responsive patient even if the other features are highly suggestive of hemicrania 
continua (Goadsby and Lipton, 2002). Case 2 in the Appendix (Levy et al., 2003a) 
describes a prolactinoma presenting with hemicrania continua after the administration 
of dopamine agonists, suggesting that the hypothalamo-pituitary axis may play a role 
in this headache phenotype.
In summary, there is a range of headache syndromes that appear to involve the 
hypothalamo-pituitary axis in their pathophysiology. The following part of the 
introduction summarises the headache syndromes that have been observed in 
association with pituitary tumours, and the potential mechanisms involved will be 
discussed.
311.7  An Introduction to Pituitary Tumours
1.7.1  The Normal Pituitary Gland
The pituitary gland is a small structure, which sits in the pituitary fossa at the base of 
the brain. Embryologically, the pituitary gland is a combination of primitive gut and 
neural tissue (Dorton, 2000). The anterior pituitary gland is derived from an up­
growth of gastrointestinal ectodermal tissue (Rathke’s Pouch), which is pinched off to 
form the anterior lobe. The posterior lobe is derived from neural ectoderm, which 
extends from the floor of the primitive forebrain to lie adjacent to the anterior lobe. 
The anterior lobe gives off two ventral processes that surround the upper end of the 
neural stalk forming the ‘pars tuberalis’. The mature pituitary is thus formed, 
consisting of the anterior lobe, which is primarily endocrinologically active glandular 
tissue, and the posterior lobe, which is primarily neural tissue (Figure 3).
Figure 3. Development of the pituitary gland
Taken from Netter (1965)
The pituitary stalk consists of neurones originating from the hypothalamus and the 
vascular hypophysial portal system, and this connection between the hypothalamus 
and pituitary gland comprises the hypothalamo-pituitary axis. The central dogma of 
endocrinology is that the hypothalamus communicates with the posterior pituitary via
Rathke’s pouch (primitive gut tissue)
Downgrowth of primitive neural tissue
Anterior lobe derived from Rathke’s pouch
T9neural pathways, and with the anterior pituitary via the secretion of‘releasing 
hormones’ into the portal system (Faglia and Ambrosi, 1992). Although the anterior 
pituitary is primarily composed of glandular tissue, there are data to show that each 
glandular cell is innervated by hypothalamic neurones containing substance P and 
CGRP, suggesting that the anterior lobe is under direct neural as well as humoral 
regulation (Ju and Liu, 1989; Ju and Zhang, 1990; Ju et al., 1993; Liu, 1995; Liu and 
Gao, 1998), which may be relevant to pituitary tumour-associated headache.
1.7.3  Anatomical Relations
The adult pituitary gland measures approximately 12mm transversely, 8mm in the 
antero-posterior diameter, and 6mm in its vertical dimension (Figure 4). The roof of 
the pituitary fossa is formed by a circular fold of dura mater (the diaphragma sella). 
The latter is pierced by a small central aperture, through which the pituitary stalk 
passes, and this separates the anterior part of the upper surface of the gland from the 
optic chiasm. Laterally, the pituitary gland is bounded on each side by the cavernous 
sinus and the structures within it. The lateral wall of the cavernous sinus contains the 
ophthalmic and maxillary divisions of the trigeminal nerve (V). The cavernous sinus 
also containes the internal carotid artery, which is surrounded by filaments of 
sympathetic fibres (Netter, 1965). Hence, the cavernous sinus contains numerous 
pain-producing structures that may be important in pituitary-associated headache.
33Figure 4. Anatomical relations of the pituitary gland
Taken from Netter (1965)
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^41.8  Pituitary Tumours and Headache: a Clinical Review
The prevalence of headache in pituitary tumours ranges from 33-72% (Comtois et al., 
1991; van Lindert et al., 1991; Suwanwela et al., 1994; Abe et al., 1998). The 
mechanisms of pituitary tumour-associated headache are poorly understood and little 
studied. The literature suggests that headache is particularly problematic in 
functionally active pituitary tumours, with prolactinomas and growth hormone- 
secreting tumours having the highest reported prevalence of headache (Abe et al., 
1998, Couch, 1986; Ezzat et al., 1994).
1.8.1  Migraine
Millan-Guerrero (1999) reports 20 patients with micro-prolactinomas presenting with 
episodic headache of changing laterality, ten having had headache as their sole 
symptom. In all cases, headache disappeared upon receiving appropriate medical or 
surgical treatment for the microadenoma. The headache phenotypes in these cases are 
described as migrainous and the author comments that ‘this “migraine-type” pain is 
probably related to hormonal activity as it is difficult to relate to nerve terminal 
stimulation of the trigeminal nerve or stimulation of pain structures within the 
cavernous sinus...due to the very small dimensions of the tumour’. This sentiment is 
echoed by Gabrielli (2002) who reports the case of migraine without aura in a patient 
with a micro-prolactinoma. Having had eight attacks per month for 6 years, this 
patient’s headache disappeared within 2 months of bromocriptine therapy. The author 
argues, ‘as bromocriptine did not affect the size of the pituitary adenoma, a decrease 
in mass effect or traction on adjacent structures appears unlikely’. Lee (1990) reports 
a 47 year-old female with a five-year history of episodic migraine with aura, each 
episode lasting 2-3 hours and occurring once a month. After removal of the tumour, 
which was a non-functioning adenoma, the episodes of migraine with aura completely 
disappeared.
Shah and Frejj (1999) report a pituitary macroadenoma presenting with bilateral 
throbbing headache associated with photophobia that was dramatically relieved by 
sumatriptan, despite being unresponsive to analgesics including opioids. Pascual 
(2000) suggests that the analgesic effect of sumatriptan in this case could be due to 
‘inhibition of the secretion of algesic peptides by the tumour’ such as calcitonin gene
35related peptide (CGRP).
1.8.2  SUNCT
Massiou et al. (2002) report SUNCT syndrome in two patients with prolactinomas 
presenting with bromocriptine-induced attacks. The second case had a micro­
prolactinoma associated with attacks of pain after bromocriptine and lisuride 
administration. This is very similar to Case 1  described in this Appendix (Levy et al., 
2003a). Ferrari et al. (1988) report a microprolactinoma presenting with ‘trigeminal 
neuralgia’ with pronounced autonomic features in response to bromocriptine therapy. 
However, this patient almost certainly had SUNCT syndrome, and the headache 
diagnosis is probably a reflection of the time of writing of the article when SUNCT 
syndrome was not yet described. Ferrari et al. (1988) acknowledge the association 
between the D2 agonist and the headache onset, arguing that chemical or micro- 
vascular changes within the pituitary gland may have been responsible. Case 5 
(Appendix) describes SUNCT in association with a macroprolactinoma (Matharu et 
al., 2003), which resolved soon after the administration of cabergoline, indicating that 
D2 agonists may exacerbate or alleviate pituitary-associated SUNCT.
1.8.3  Cluster Headache
Milos et al. (1996) describe a 37 year-old man presenting with left-sided cluster 
headache that was refractory to medical therapy. Five years after presentation, a 
diagnosis of acromegaly was made, and a left-sided macro-adenoma was confirmed. 
After transphenoidal removal of the tumour, ‘the patient (has) been absolutely free 
from further headache attacks’. Cluster headache has also been reported in the 
presence of prolactinoma (Tfelt-Hansen et al., 1982; Greve and Mai, 1988; Porta- 
Etessam et al., 2001; Menguzzi et al., 2003) and in each case, attacks resolved after 
treatment of the pituitary pathology. Although Greve & Mai describe their case as 
cluster headache, the high frequency of attacks (10 per day) and short duration (15 to 
30 minutes) suggests that paroxysmal hemicrania may have been the diagnosis.
1.8.4  trigeminal Neuralgia’
The classification of headache has evolved in recent years. As has been described in 
Ferrari et al.’s SUNCT case (1988), the term ‘trigeminal neuralgia’ may have been
36incorrectly used for short-lasting stabbing headaches associated with pronounced 
autonomic features. Other authors have similarly reported ‘trigeminal neuralgia’ in 
association with pituitary adenomas (Friedman et al., 1982; Gelabert Gonzalez et al., 
1990; Gazioglu et al., 2000), the symptoms resolving after appropriate management of 
the pituitary pathology. Friedman et al. (1982) argue that their case ‘most likely had 
facial pain because of tumour invasion of the cavernous sinus’, although they do not 
explain the episodic nature of the pain in this patient. On closer analysis of this case, 
attacks lasted 30 minutes to 3 hours and were associated with ipsilateral ‘tearing..and 
increased nasal vasomotor activity’, suggesting that a trigeminal autonomic cephalgia 
may have been present. Trigeminal neuralgia is characterised by very short lasting 
jabs of pain, typically in the maxillary or mandibular divisions of the trigeminal 
nerve, typically precipitated by minor irritation of areas innervated by the trigeminal 
nerve, such as touching the face or scalp, washing, chewing or talking and the 
accuracy of this diagnosis in the above cases should be taken with a degree of caution. 
A summary of the headache phenotypes associated with pituitary tumours is given in 
Table 4.
37Table 4. Headache phenotypes described with pituitary tumours
Aether (dale) TaaeearType RepM M totrataat 
(+)hepre*ed 
(-) exacerbated
Gabrielli et al. (2002) Prolactinoma dopamine agonist (+)
Shah & Freij (1999) NFA sumatriptan (+)
Millan Guerrero (1999) Prolactinoma dopamine agonist (+)
Lee (1990) NFA hypophysectomy (+)
SUNCT
Levy et al. (2003) Prolactinoma dopamine agonist (-)
Matharu et al. (2003) Prolactinoma dopamine agonist (+)
Massiou et al. (2002) Prolactinoma dopamine agonist (-)
CM er Headache
Porta-Etessam (2001) Prolactinoma dopamine agonist (+)
Milos et al. (1996) GH hypophysectomy (+)
Greve & Mai** (1988) Prolactinoma dopamine agonist (+)
Tfelt-Hansen et al. (1982) NFA/ Prolactinomatt hypophysectomy  (+)
‘TripaUail » ■ »--- n m p i
Gazioglu et al. (2000) Mixed GH and prolactin secreting hypophysectomy (+)
Ferrari et al. (1998)* Prolactinoma dopamine agonist (-)
Galabert Gonzalez et al. 
(1990)
Craniopharyngioma hypophysectomy (+)
Friedman et al. NFA hypophysectomy and 
radiotherapy (+)
* SUNCT was the probable diagnosis in this case 
** Paroxysmal hemicrania probable diagnosis
1.8.S  Octreotide
Musolino et al. (1990) report two cases of acromegalic headache displaying dramatic 
improvement after the administration of octreotide. Case 2 of Musolino’s paper 
presents with a ‘“pinprick” sensation accompanied by lacrimation, redness of the eye, 
and nasal congestion as seen in cluster headache’. In these cases, there was an 
immediate analgesic response to octreotide, although with time, the length of 
analgesia ‘decreased progressively to the point that administration of the drug was 
necessary every 2 hours, with recrudescence of the pain after this interval’. This 
description of octreotide tolerance and dependency is similar to our own Case 5 
(Appendix; Levy and Goadsby, 2004) and other observations (Popovic et al., 1988; 
May et al., 1994). Pascual et al. (1991) report a patient with acromegaly who had 
intractable headache ‘unrelated to tumour size’, which dramatically resolved with
38octreotide. They suggest that the analgesic action of octreotide ‘could not be related to 
a simultaneous decrease in growth hormone or prolactin...and furthermore, octreotide 
analgesic effects cannot be explained by tumour shrinkage’. They also comment that 
‘by understanding how octreotide relieves pain in these cases, the pathophysiology of 
pituitary adenoma-related headache could be clarified.’ In this excellent paper, they 
provide evidence that the analgesia is not due to the placebo effect, by double-blind 
placebo controlled administration of octreotide, and they also show a lack of 
reversibility with naloxone, suggesting that octreotide-induced analgesia is not via 
opioidergic mechanisms.
Williams et al. (1987) present six patients with pituitary tumour-associated headache, 
five of whom had acromegaly and one a prolactinoma. All patients were withdrawn 
from analgesics and admitted to hospital. Using a visual analogue scale, patients 
scored their headache after double blind administration of octreotide 100 pg or 
placebo. Three of the five acromegalics, and the single prolactinoma case, responded 
dramatically to octreotide but not placebo. The authors comment that ‘though 
headache is traditionally attributed to the space occupying effects of the tumour, other 
factors must contribute as severity of headache correlates poorly with size...(and) 
analgesia with octreotide occurs too rapidly to be explicable by tumour 
shrinkage..and...an interesting possibility is that octreotide may suppress secretion by 
the pituitary tumour of “algesic” peptides which may cause pain’.
Schmidt et al. (1993) report a double-blind placebo controlled analgesic response to 
octreotide 100 pg in two acromegalics. They observed pain relief within 4-15 
minutes that lasted 2 -  8.5 hours after injection with no evidence of tachyphylaxis.
Webb et al. (1989) report an acromegalic female whose disease ‘remained active and 
induced invalidating headache in spite of previous treatment with surgery and 
radiotherapy’. After the administration of octreotide, ‘headache was improved in a 
matter of minutes, even if normalisation of hormone hypersecretion was not 
demonstrated’. This uncoupling of growth hormone and headache in response to 
octreotide has been described earlier in our own Case 3 (Appendix; Levy et al., 
2003b) suggesting that octreotide has a specific analgesic effect unrelated to growth
39hormone suppression. Webb et al. (1989) acknowledge that octreotide may be a 
‘therapeutic option in patients with headache unresponsive to common analgesics’. A 
discussion of the potential mechanisms of octreotide-induced analgesia occurs in 
section 1.18. A summary of the reports of octreotide-analgesia and octreotide 
dependency is given in Table 5.
Table 5. Octreotide analgesia and dependency in pituitary tumours
AntfmrCdate) Placebo-controlled analgesic respoaae
(+/-)
Octreotide dependency
<+/-)
Levy et al. (2003)t - -
May et al. (1994) - +
Schmidt et al. (1993) + -
Pascual et al. (1991 )f + -
Musolino et al. (1990) - +
Webb et al. (1989)t - -
Popovic (1988) - +
Williams etal. (1987) + -
t  In these cases, analgesic action of octreotide was not coupled to growth hormone suppression
401.9 Structural Explanations for Headache in Pituitary Tumours
1.9.1  Cavernous Sinus Invasion
The cavernous sinus contains pain-producing structures and it is not unreasonable to 
suppose that distortion of these would cause headache. The walls of the cavernous 
consist of dura mater which are densely innervated by trigeminal afferent neurones 
(Levy and Strassman, 2002), and irritation of the latter could cause trigeminal 
irritation. The walls of the venous plexi within the cavernous sinus are homologous to 
the cerebral venous sinuses, and activation of nociceptive pathways with stimulation 
of the superior sagittal sinus is well documented experimentally (Goadsby et al., 
1991). The internal carotid artery is densely innervated with autonomic fibres, and 
encasement of the carotid artery by an invasive pituitary tumour could explain pain 
(Friedman et al., 1982). Stimulation of cranial arterial structures, especially the 
middle meningeal artery, is known to activate the trigeminal system (Hoskin et al.,
1999). The ophthalmic and maxillary branches of the trigeminal nerve lie within the 
cavernous sinus, and direct irritation of these structures would be expected to cause 
activation of the trigeminovascular system.
Non-pituitary para-sellar lesions
Evidence that pituitary tumour-associated headache may simply be due to structural 
irritation of the cavenous sinus comes from reported cases of non-pituitary parasellar 
lesions invading the cavernous sinus.
Tolosa-Hunt syndrome is a rare disorder caused by granulomatous infiltration into the 
cavernous sinus, presenting with severe headache and cranial nerve palsies (Tolosa 
1954; Hunt et al. 1961). Hannerz et al. (1984) reported that conventional imaging 
techniques may not show an abnormality in the cavernous sinus, although venography 
may show occlusion or slowing of venous drainage within the cavernous sinus and 
ophthalmic veins. Tolosa-Hunt can present with severe headache syndromes with 
minimal changes on MRI and has led some groups to believe that the prima facie 
pathology in cluster headache lies within the cavernous sinus. To support this, there is 
evidence of abnormal orbital phlebography in patients with cluster headache (Hannerz
41et al., 1987), SUNCT syndrome (Hannerz et al., 1992; Kruszewski, 1992) and chronic 
paroxysmal hemicrania (Antonaci, 1994). Magnetic Resonance Angiography (MRA) 
performed during spontaneous attacks of cluster headache has shown marked dilation 
of the ophthalmic artery ipsilateral to the pain (Waldenlind et al., 1993; Ekbom and 
Greitz, 1970). Harbedo et al. (1991) argue that the abnormal orbital phlebography 
seen in cluster headache, the fact that potent vasodilators such as nitrogycerine can 
trigger an attack, and the finding that cluster headache patients have narrow middle 
cranial fossae, and by extrapolation slower drainage of the cavernous sinuses (Afra et 
al., 1998), are evidence that cluster headache is a disease of the cavernous sinus. PET 
studies during induced cluster attacks have shown pooling of tracer bilaterally within 
the cavernous sinus, with increased pooling ipsilateral to the pain (May et al., 1999a) 
which is thought to represent increased flow in the cavernous section of the internal 
carotid arteries.
Those that favour a central rather than peripheral cause for cluster headache argue that 
MRI studies of cluster patients show no pathological changes in the cavernous sinuses 
(Sjaastad and Rinck, 1990). Also, PET studies show activation of the cavernous sinus 
in capsaicin-induced experimental head pain, which is strong evidence that cavernous 
sinus changes are secondary to activation of the trigeminovascular system (May et al., 
1998b).
Other non-pituitary para-sellar lesions involving the cavernous sinus have been 
associated with trigeminal autonomic cephalgias. Greve & Mai (1988) describe a 
cluster patient with a cavernous carotid artery aneurysm. Sjaastad et al. (1988) report 
a patient with cluster headache in a patient with an aneurysm of the cavernous section 
of the anterior communicating carotid artery. Hannerz (1989) reports a parasellar 
meningioma, and Narbone et al. (1991) present a calcified third ventricle lesion of 
unknown pathology, both patients presenting with cluster headache. Vijayan (1992) 
reports a 34 year-old female with chronic paroxysmal hemicrania who had a tumour 
in the sella turcica that invaded the cavernous sinus.
Hence the cavernous sinus plays a prominent part in both primary and secondary 
cluster headache, and many physicians have not looked beyond this structure when 
considering the mechanism of headache in pituitary tumours. However, the only
42systematic study that has looked at the relationship between cavernous sinus invasion 
and headache in pituitary tumour found there to be no association (Abe et al., 1998). 
Moreover, there is no adequate accepted explanation for the severe headache 
syndromes caused by micro-adenomas, nor an explanation for the immediate 
somatostatin-responsiveness of pituitary tumour-associated headache without 
reduction in tumour size. Whilst clinical experience suggests that there is a sub-group 
of patients who have headache as a significant problem with cavernous sinus invasion 
(de Groot & Jameson, 2000) there are patients who do not suffer with headache 
despite extensive invasion into this structure. Hence, there may be some other 
factor(s) involved, such as the properties of the tumour itself.
1.9.2  Miscellaneous Structural Explanations
In addition to cavernous sinus invasion, traction and displacement of the diaphragma 
sella by suprasellar extension of a pituitary tumour is commonly used to explain 
headache (Wirth and Van Buren, 1971; Dalessio, 1978), although Abe et al.’s study 
(1998) showed no relationship between pituitary tumour size and headache. Arafah et 
al. (2000) suggest that intrasellar pressure is important in the aetiology of headache. 
This group looked at 49 patients presenting with pituitary tumours, of which 25 had 
headache. They measured intra-sellar pressure peri-operatively, using a pressure 
transducer, and found that an association between raised intra-sellar pressure and 
headache. They also suggest that the headache observed in micro-adenomas is due to 
pressure within a small volume, rather than volume itself. It is conceivable that, for 
example in dopamine agonist induced headache in prolactinomas (Ferrari et al., 1988; 
Massiou et al., 2002; Levy et al., 2003a), there is some critical change in pressure 
within the lesion that causes headache, rather than a biochemical explanation. Other 
authors explain the episodicity of pituitary tumour-associated headache as being due 
to a ‘ball-valve’ effect that could cause transient structural abnormalities after a 
critical change in volume or pressure that eventually resolves (Lee, 1990).
431.10 Biochemical Explanations for Headache in Pituitary Tumours
Some groups believe that structural factors alone are not a sufficient explanation for 
pituitary tumour-associated headache, arguing that pituitary tumours may secrete a 
nociceptive peptide (Pascual, 2000; Williams et al., 1986). Several candidate peptides 
exist, which are now discussed.
1.11  Calcitonin Gene Related Peptide
Calcitonin gene related peptide (CGRP) is a 37- amino acid peptide that is widely 
expressed in the central and peripheral nervous system. CGRP acts via G protein- 
coupled receptors (CGRPi and CGRP2 receptors) and is thought to have diverse 
biological activities (van Rossum et al., 1997). CGRP-immunoreactive cells constitute 
40-50% of dorsal root ganglia cells (Gibson et al., 1984a), and are the major site of 
termination of nociceptive neurones and are abundant brain areas believed to be 
important in nociceptive processing such as the hypothalamus, periaqueductal grey, 
nucleus raphe magnus and thalamus (van Rossum et al., 1997).
1.11.1  CGRP and the pituitary
The role of CGRP in the anterior pituitary is unclear, although there are numerous 
CGRP binding sites in the hypothalamus and anterior pituitary gland (Tschopp et al., 
1985; Wimalawansa et al., 1987). CGRP-immunoreactive nerve fibres have been 
demonstrated by electron-microscopy in the anterior pituitary gland and direct neural 
synapses have been shown to be in contact with corticotrophs, somatotrophs and 
lactotrophs (Ju, 1999). The origin of these nerve fibres has not been unequivocally 
determined, although Ju (1997) reports that they may originate from trigeminal or 
hypothalamic sources.
CGRP and growth hormone
CGRP has been shown to have stimulatory and inhibitory effects on growth hormone 
production. Tannenbaum and Goltzman (1985) demonstrated that CGRP suppresses 
growth hormone release when injected intracerebroventricularly. This was confirmed 
by Netti et al (1989), who showed suppression of growth hormone release after 
intracarotid injection of CGRP. Fahim et al. (1990) demonstrated that 
intracerebroventricular injection of CGRP suppressed growth hormone release, whilst
44the injection of highly specific antiserum caused a transient elevation in growth 
hormone. However, Nakamura et al. (1998) found that the addition of CGRP to 
cultured human and rodent somatotrophs caused an increase in growth hormone 
secretion both with non-tumorous and pituitary adenoma cells. These data suggest that 
CGRP acts on growth hormone in an inhibitory manner when applied to central 
nervous structures, whilst acting as a growth hormone secretagogue when added 
locally. Netti et al. (1989) suggest that CGRP exerts its central inhibitory action on 
growth hormone via stimulation of somatostatin release.
CGRP and prolactin
CGRP has both inhibitory and neutral effects on prolactin secretion. Prolactin levels 
are inhibited when CGRP is added to cultured and TRH-stimulated pituitary cells 
(Shah et al., 1988). Netti et al. (1989) found no alteration in prolactin after 
intracerebroventricular injection of CGRP, although Fahim et al. (1990) found 
inhibition of prolactin secretion. The prolactin response to stress is blunted in rodents 
after subcutaneous or intraperitoneal CGRP infusion (Elie et al., 1990).
CGRP and gonadotropins
Gon et al. (1990) demonstrated CGRP immunoreactivity in gonadotrophs in 
developing rat embryos and neonates, particularly increasing post-natally between 
days 5 and 14. Adult rat gonadotrophs were found to have low CGRP 
immunoreactivity, which was increased during lactation and by oestrogen 
administration. Van Leeuwen et al. (1992) studied CGRP levels in 8 women with pre­
menstrual syndrome and found no significant fluctuations in CGRP throughout the 
menstrual cycle. Wang et al. (1994) found intravenous CGRP administration to cause 
an inhibition of serum LH and testosterone in rodents.
CGRP and thyrotrophin
Intravenous administration of CGRP with calcitonin reduces the ability of TSH to 
stimulate thyroxine production in mice (Ahren, 1989). Hanna et al. (1995), having 
observed that the administration of calcitonin causes an increase in a-subunit TSH- 
secreting tumours in rats, characterised a high affinity binding site for CGRP in the rat 
a-TSH thyrotroph cell line. The finding of a high affinity binding site for CGRP has
45been demonstrated in mouse thyrotroph cell lines, further implicating a functional role 
for CGRP in thyrotroph activity (Perry et al., 1997).
CGRP and adrenocorticotrophin
Kovacs et al. (1995) reported increased plasma cortisol levels following intracererbal 
CGRP injection, the responses being blocked by pre-treatment with CRH antiserum 
and concluded that CGRP causes pituitary-adrenal activation via CRH (Kovacs et al., 
1995). lino et al. (1998) demonstrated a stimulatory effect of CGRP on ACTH in 
cultured rat pituitary cells. They observed both a direct effect on basal ACTH 
production, and an additive effect with CRH (lino et al., 1998). Dhillo et al. (2003) 
injected CGRP intracerebroventricularly and found this to stimulate hypothalamic 
CRH production.
CGRP and pituitary tumours
CGRP causes increased growth hormone release when added to somatotroph 
adenomas (Nakamura et al., 1998). Wimalawansa et al. (1994) has shown an 
increased expression of CGRP in pituitary adenomas, with preferential expression in 
growth hormone- and prolactin- secreting lesions (personal communication).
A summary of the effects of CGRP on the hypothalamo-pituitary axis is shown in 
Table 6.
46Table 6. Effects of CGRP on the HP axis
HP « l» CGRP aMHtanrttoa Effect KtfefMMC
GH
in vitro T Nakamura et al.,1998
Central injection i Tannenbaum et al., 1985; Netti et al., 1989; 
Fahim et al., 1990
ProfaMttai
in vitro 1 Shah et al., 1988
Central injection Fahim et al., 1990, Netti et al., 1989
s/c and iv infusion 1 Elie et al., 1990
PS&L& iv infusion in male rat 1 Wang et al., 1994
TSH iv infusion with CGRP + 
calcitonin in mouse
i Ahren, 1989
ACTH in vitro T lino et al., 1998
Central injection T Dhillo et al., 2003
1.11.2  CGRP and headache
CGRP-containing sensory nerve fibres innervate cerebral arteries in animals (Uddman 
et al., 1985) and humans (Edvinsson et al., 1994; Edvinsson et al., 1987). 
Pharmacological experiments have shown a pronounced vasodilatory effect of CGRP 
on cerebral arteries (Jansen et al., 1986). CGRP-immunoreactive fibres are present 
within the walls of the cerebral venous sinuses, and ‘free’ within the tissue matrix of 
the dura mater (Keller and Marfurt, 1991). The majority of these fibres derive from 
sensory neurons of the trigeminal ganglion.
A rise in CGRP has been demonstrated in patients undergoing thermocoagulation for 
trigeminal neuralgia (Goadsby et al., 1988). External jugular venous samples have 
shown a significant increase in CGRP during the headache phase of migraine with 
and without aura (Goadsby et al., 1990). CGRP levels returned to normal after 
headache resolution caused by sumatriptan administration (Goadsby and Edvinsson, 
1993). Gallai et al. (1995) demonstrated increased CGRP levels during attacks of 
migraine with and without aura, with a greater increase in patients with aura.
47Goadsby et al. (1994) showed CGRP levels to rise significantly during a cluster 
headache attack, as was observed by Fanciullacci et al. (1995) during nitroglycerin- 
induced cluster attacks. In both studies, spontaneous or sumatriptan-induced 
remission of attacks was associated with normalisation of CGRP levels strongly 
implicating a role for CGRP in cluster headache (Goadsby and Edvinsson, 1994; 
Fanciullacci et al., 1995).
Ashina et al. (2000) demonstrated elevated CGRP levels in chronic tension type 
headache associated with throbbing. CGRP was not demonstrated in patients with 
non-pulsating tension-type headache.
There is currently much interest in CGRP antagonists as potential new treatments for 
migraine and other primary headache disorders. The preliminary evidence that they 
may be efficacious is encouraging (Ramadan, 2001; Moreno et al., 2002; Olesen et 
al., 2004).
1.12  Substance P
Substance P (SP) is an 11-amino acid peptide that may play an important role in 
nociceptive transmission (Harrison and Geppetti, 2001). SP is part of the tachykinin 
family, along with neurokinin A and neurokinin B, which share a similar chemical 
structure (Otsuka and Yoshioka, 1993). SP acts on a G-protein coupled receptor (the 
NKi receptor) and can also act on the receptors specific for neurokinin A and 
neurokinin B, termed NK2 and NK3 receptors, respectively (Regoli et al., 1994). SP is 
widely distributed within the central and peripheral nervous system and is frequently 
co-localised with CGRP in nociceptive areas (Ribeiro-da-Silva and Hokfelt, 2000). It 
is present in high concentrations in the dorsal horn (particularly laminae 1  and II), 
dorsal ganglion and dorsal root of spinal neurones (Ribeiro-da-Silva and Hokfelt,
2000)  and is abundant in other areas of the central nervous system important in pain 
modulation such as the hypothalamus, periaqueductal grey, nucleus raphe magnus and 
the thalamus (Ribeiro-da-Silva and Hokfelt, 2000). The co-localisation of CGRP and 
SP may either reflect a necessary interaction between these peptides in nociceptive 
transmission, for example CGRP has been shown to inhibit the breakdown of SP (Le 
Greves et al., 1985), or it may preserve its own unique biological effect (Snijdelaar et 
al., 2000). Capsaicin, the irritant chemical in red-hot chilli peppers, acts on the
48Vanilloid 1  (VR1) receptor (Szallasi and Blumberg, 1999) and has been shown to 
have a direct and selective stimulatory effect on C- and A8- nociceptive fibres via the 
release of SP (Holzer, 1991).
1.12.1  Substance P and the pituitary
SP is present in the hypothalamo-pituitary axis (Jessop et al., 1992) and is found 
within the anterior pituitary gland with its receptors (Larsen et al., 1989).
Substance P and growth hormone
Kato et al. (1976) demonstrated that SP is stimulatory to growth hormone secretion in 
the rat, which was confirmed by Rivier et al. (1977). Central administration of SP 
elevated growth hormone in ovariectomised rats (Vijayan and McCann, 1980) 
although other groups have shown an inhibitory effect (Arisawa et al., 1989a). 
Houben and Denef (1993) demonstrated that that low doses of in vitro SP caused 
inhibition of growth hormone, whilst higher doses cause significant stimulation, 
which may explain the above differences. Systemic infusion of SP in humans causes 
elevation of basal growth hormone, and increases the stimulatory effect of GHRH 
(Coiro et al., 1992). However, Houben and Denef (1993) failed to demonstrate an 
alteration in growth hormone release after in vitro administration of SP antagonists. 
Immunohistochemical studies have shown that the majority of SP positive cells in the 
rat anterior pituitary also contain growth hormone (Brown et al., 1991) and there is 
electron microscopic demonstration that SP-containing fibres are in direct contact 
with somatotrophs in primates (Ju, 1999) supporting a functional interaction between 
SP and growth hormone.
Substance P and prolactin
Intravenous infusion of SP in rats was initially shown to elevate serum prolactin (Kato 
et al.,  1976) a finding that has also been shown after the in vitro administration of SP 
to cultured rat pituitary cells (Vijayan and McCann, 1980). Central injection of SP 
into the third ventricle (Vijayan and McCann,  1979; Eckstein et al., 1980) and the 
medial pre-optic area (Picanco-Diniz et al., 1990) resulted in an elevation of serum 
prolactin. Similar to its effect on growth hormone, low doses of SP may have an 
inhibitory effect on prolactin, whilst higher doses may be stimulatory (Arisawa et al., 
1990). Larsen et al. (1992) demonstrated that a SP analogue binds specifically to
49lactotrophs in vitro (Larsen et al., 1992). Traczyk et al. (1992) demonstrated a 
stimulatory effect of SP on prolactin when injected intracerebroventricularly. The 
withdrawal of dopamine has been shown to prolong SP-induced translocation of 
protein kinase C isozymes and subsequent release of prolactin in rat pituitary 
lactotrophs (Mau, 1997). Duvilanski et al. (2000) demonstrated that a specific NKi 
receptor antagonist reduces the TRH-stimulation of prolactin, suggesting that SP 
plays an important role in TRH-mediated prolactin release.
Substance P and gonadotropins
Intracerebroventricular injection of SP was initially shown to stimulate LH release in 
rats (Vijayan and McCann, 1979) whilst SP antagonists reduced serum LH and FSH 
(Arisawa et al., 1990b). Intravenous infusion of SP does not affect serum LH or FSH 
(Arisawa et al., 1990b) suggesting that SP acts centrally to release LHRH. There is a 
direct synaptic contact between SP fibres and cell bodies containing LHRH in the rat 
hypothalamus (Hoffman, 1985; Tsuruo et al., 1991). Serum levels of SP are known to 
fluctuate with the menstrual cycle in rats (Jakubowska-Naziemblo et al., 1985), and 
levels of SP within the anterior gland increase following ovariectomy (Coslovsky et 
al., 1984) further suggesting a functional link with gonadal hormones. High affinity 
SP receptors have been identified in the human anterior pituitary, and intravenous SP 
infusion stimulates LH release (Coiro et al., 1992). There is evidence in primates that 
endogenous SP potentiates the preovulatory LH and FSH surges during the menstrual 
cycle (Kerdelhue et al., 2000).
Substance P and thyrotrophin
Intracerebroventricular injection of SP causes an elevation in serum TSH in 
oestrogen-primed rats (Arisawa et al., 1989b). Brown et al. (1990) found no increase 
TSH secretion after in vitro administration of SP, although Moura et al. (1999) 
observed a significant increase in pituitary TSH release following treatment of 
incubated hemi-pituitaries with SP. There is an increase in rat pituitary SP following 
thyroidectomy, and a decrease following thyroxine administration (Aronin et al.,
1984; Aronin et al.,  1986; Jones et al., 1994). This observation is unaffected by 
transection of the pituitary stalk (Aronin et al., 1988). Intravenous infusion of 
incremental doses of SP did not influence TSH secretion in humans, suggesting that it 
may have no effect on TSH production outside the blood-brain barrier (Coiro et al.,
501995). SP-immunoreactive varicosities have been observed in close proximity to 
thyrotropes in primates (Ju and Liu, 1989; Liu and Gao, 1998) and there is co-secreted 
with TSH in both rats (Arita et al., 1994) and humans (Roth and Krause, 1990)
Substance P and adrenocorticotrophin
Chowdrey et al. (1990) demonstrated that intracerebroventricular SP injection inhibits 
ACTH release from the rat anterior pituitary. SP-immunoreactive neurones are 
present in the paraventricular nucleus of the hypothalamus, which is the main area for 
CRH production and release. Larsen et al. (1993) demonstrated that 
intracerebroventricular administration of a SP antagonist increases serum ACTH and 
cortisol and CRH mRNA in the paraventricular nucleus, suggesting that SP has a 
tonic inhibitory effect on hypothalamic CRH production. Melzig et al. (1995) 
demonstrated that the addition of substance P to pituitary tumour cells inhibits CRH- 
induced ACTH release, further indicating an inhibitory action of SP. Adrenalectomy 
can reduce pituitary SP content by 50% (Jones et al., 1990) and SP immuno-reactive 
fibres are in direct contact with anterior pituitary cells in the dog, about 60% of 
contacts occurring with corticotrophs (Ju and Zhang, 1990). Desiderio et al. (1993) 
observed human ACTH-secreting pituitary tumours to contain significantly higher 
levels of SP than non ACTH-secreting adenomas. A summary of the effects of SP on 
the hypothalamo-pituitary axis are shown in Table 7.
51Table 7. Effects of substance P on the HP axis
HP axis MMmhs P ataMrtrallM KM* ftsfanM*
GH i.v infusion in rat T Kato, 1976; Rivier, 1977
Central injection 
(high dose)
T Vijayan, 1979;Houben, 1993
Central injection 
(low dose)
i Arisawa, 1989; Houben, 1993
iv infusion in humans T Coiro, 1992
in vitro — * Houben, 1993
iv infusion rats T Kato, 1976
in vitro t Vijayan, 1980
Central injection (high dose) T Traczyk, 1992; Picanco-Diniz, 1990
Central injection (low dose) i Arisawa, 1990
fW LH Central injection t Vijayan, 1979
iv infusion rats -* Arisawa, 1990
TSH Central injection r Arisawa, 1989
in vitro -* Brown, 1990
ACTH Central injection i Chowdrey, 1990; Larsen, 1993
1.12.2  Substance P and headache
As with CGRP, SP-immunoreactive fibres richly innervate the cerebral arteries of 
animals (Uddman et al., 1985) and humans (Edvinsson et al., 1994) and this is 
supported by radioimmunassay (Edvinsson et al., 1987) and pharmacological data 
(Jansen et al., 1986). The pattern of distribution of SP appears to be similar to CGRP 
in its innervation of the venous sinuses and the dura mater (Keller and Marfurt, 1991).
SP increases with CGRP in patients undergoing thermocoagulation for trigeminal 
neuralgia (Goadsby et al., 1988) but does not rise during migraine with and without 
aura (Goadsby et al., 1990; Gallai et al., 1995) or cluster headache attacks (Goadsby 
and Edvinsson,  1994; Fanciullacci et al., 1995). Unlike CGRP, SP levels were not 
found to change in patients with throbbing chronic tension type headache (Ashina et 
al., 2000).
The effect of neurokinin-1  (NKi) receptor antagonists has been investigated on animal 
models of trigeminal nociception and in clinical trials. Polley et al. (1997)
52demonstrated that a potent NKi receptor antagonist (GR205171) resulted in a dose- 
dependent inhibition of plasma protein extravasation in dura mater, in response to 
electrical stimulation of the trigeminal ganglion. Shepheard et al. (1995) demonstrated 
that the non-peptide NKI receptor selective antagonist (CP-99,994) causes peripheral 
blockade of dural extravasation and central inhibition of nociceptive pathways, 
implying potential anti-migraine activity. However, Goadsby et al. (1998) found that 
SP blockade with GR205171 did not alter central trigeminal activity after superior 
sagittal sinus stimulation. Clinical trials investigating the potential use of NKi 
receptor antagonists in acute migraine have been disappointing. Goldstein et al. found 
no useful effect in the acute (1997) or preventive (2001) treatment of migraine. Diener 
et al. (2003) similarly found no effect of RPR100893, a SP-antagonist, in the acute 
treatment of migraine. Other negative studies investigating the intravenous use of NKi 
receptor antagonists in acute migraine include those from Connor et al. (1998) and 
Norman et al. (1998).
1.13  Neuropeptide Y
Neuropeptide Y (NPY) is a 36-amino acid peptide and functions as a neurotransmitter 
and neuromodulator (Adrian et al., 1983). It mediates its actions via six NPY 
receptors (Y1-Y6), consisting of seven transmembrane G-protein coupled receptors. 
NPY is highly expressed in the hypothalamus, periaqueductal gray area, thalamus, 
trigeminal ganglion and dorsal horn of the spinal cord (Gibson et al., 1984b) 
suggesting a role in nociception. Both the Y and the Y1 receptor are upregulated in rat 
spinal cord and dorsal root ganglia in response to pain (Ji et al., 1994). Intrathecal 
administration of NPY facilitates nociceptive neurones at low doses and inhibits them 
at higher doses (Xu et al., 1994). Similarly, intracerebroventricular administration is 
pro-nociceptive at low doses and antinociceptive at higher doses (Mellado et al., 
1993). Other groups have shown only anti-nociceptive effects of NPY (Hua et al., 
1991; Broquaetal., 1996).
1.13.1  Neuropeptide Y and the pituitary
NPY is present in abundance in the hypothalamo-pituitary axis (Ciofi et al., 1990; 
Byrne et al., 1992; Dumont et al., 1992) and an exhaustive discussion of its role is 
outside the scope of this thesis. It is thought to have an important role in energy 
homeostasis and is a potent stimulator of feeding in animals (Gehlert, 1999).
53Neuropeptide Y and growth hormone
McDonald et al. (1985) demonstrated that intracerebroventricular injection of NPY 
inhibits growth hormone secretion in ovariectomised rats, and stimulates it when 
applied to anterior pituitary cells in vitro. Adams et al. (1987) found NPY inhibited 
growth hormone secretion when added to cultured human pituitary somatotropic 
tumours, implying a different action on tumorous somatotrophs compared to non- 
tumorous rat pituitary. In contrast, the intravenous infusion of NPY into humans with 
prolactinomas caused an elevation in serum growth hormone (Watanobe and Tamura,
1996). Watanobe and Tamura (1997) also demonstrated that intravenous NPY given 
to acromegalics had a stimulatory effect in patients with pure somatotroph tumours 
and an inhibitory effect in somato-mammotrophs, thus contradicting the in vitro 
findings. The inhibitory action of centrally-administered NPY on growth hormone 
secretion in rats may be mediated via Yi and Y2 receptors, an effect that is abolished 
after deafferentation of the hypothalamus (Suzuki et al., 1996). Growth hormone 
secretagogues have been shown to inhibit growth hormone at supra-physiological 
doses, an effect that is probably mediated by NPY (Korbonits et al., 1999). Despite 
the inhibitory effect of central administration of NPY in the rat, it appears to have a 
stimulatory effect on growth hormone release in the cow (Thomas et al., 1999) and 
the ewe (Morrison et al., 2003).
Neuropeptide Y and prolactin
Centrally administered NPY may stimulate prolactin release at low doses and inhibit 
its secretion at high doses (Chao et al.,  1987). After the central injection of several 
NPY receptor agonists in the lateral ventricle of the rat, Garcia de Yebenes et al. 
(1995) demonstrated that Y2 receptor agonists increased prolactin gene expression in 
the male rat anterior pituitary gland, whilst Y1 receptor agonists had no effect. The 
administration of NPY to anterior pituitary cells appears to inhibit prolactin secretion, 
possibly by amplifying the action of dopamine (Wang et al., 1996), although an 
earlier group found no in vitro effect of NPY on prolactin secretion in bovine pituitary 
cells (Chao et al., 1987).
Neuropeptide Y and gonadotropins
54Central and intravenous injection in animals (Allen et al., 1985; Sahu et al., 1987) and 
intravenous infusion in humans (Watanobe et al., 1994) causes increased LH, partly 
by increasing the pituitary response to LHRH (Crowley et al., 1985; Bauer-Dantoin et 
al., 1991; Denniston et al., 2003). Intravenous NPY administration causes a greater 
than two-fold elevation in LH secretion (Rodriguez-Sierra et al.,1987) although this 
effect is not in vitro (Chao et al., 1987; Rodriguez-Sierra et al., 1987). Bauer-Dantoin 
et al. (1992) suggest that NPY only exerts its stimulatory effect on LH release in the 
presence of adequate concentrations of oestrogen and progestogen and Sahu et al. 
(1995) demonstrated that NPY mRNA expression increases before the preovulatory 
LH surge. That NPY plays an important role in the preovulatory LH surge is 
evidenced by increased hypothalamic NPY levels in young, but not middle aged rats 
during the LH surge (Sahu and Kalra, 1998).
Neuropeptide Y and thyrotrophin
Thyroidectomy in the rat is associated with elevation in anterior pituitary NPY (Jones 
et al., 1994). Intracerebroventricular injection of NPY suppreses circulating T3 and 
T4 (Fekete et al., 2001) and this inhibitory effect has been shown to involve Yi and 
Y5 receptors. It is believed that the inhibitory effect of NPY on the thyroid axis is 
particularly important during fasting (Fekete et al., 2001).
Neuropeptide Y and adrenocorticotrophin
Intracerebroventricular (Brooks et al., 1994) and intravenous administration (Inoue et 
al., 1989) of NPY stimulates ACTH and cortisol production in a variety of species. 
Synaptic contacts exist between NPY- and ACTH-immunoreactive neurones in the 
hypothalamus (Csiffary et al., 1990) suggesting a functional role for neuropeptide Y 
in this axis. The stimulatory effect of NPY is inhibited by CRH antagonists (Inoue et 
al.,  1990), suggesting that its effect on ACTH is partly mediated via CRH. This is 
further supported by the finding that centrally administered NPY increases CRH 
mRNA in the hypothalamus (Suda et al., 1993). In vitro NPY administration to 
pituitary cells has no effect on ACTH release, suggesting its effect on pituitary 
corticotrophs is not direct (Small et al.,  1998). The only study investigating the 
intravenous effect of NPY on humans demonstrated an inhibitory effect on nocturnal 
ACTH and cortisol levels (Antonijevic et al., 2000).
55Neuropeptide Y and pituitary tumours
Grouzman et al. (1988) demonstrated NPY-immunoreactivity in 33% of human 
pituitary adenomas, compared with  1 2% of non-tumorous pituitaries but there was no 
correlation with tumour activity. Knerr et al. (2001) also demonstrated NPY mRNA in 
pituitary adenomas. A summary of the effects of NPY on the hypothalamo-pituitary 
axis is shown in Table 8 .
Table 8. Effects of NPY on the HP axis
HP axis fiflthsd if 
.  adndnfetmtsa
Effect Rcfercacc
m Central injection T  1 McDonald et al., 1985; Thomas et al., 1999; Morrison et al., 2003
iv infusion 
(acromegaly)
T  1 Watanobe et al., 1997
iv infusion 
(prolactinoma)
T Watanobe et al., 19%
in vitro T McDonald et al., 1985
in vitro 
(somatotroph tumour)
i Adams etal., 1987
Prolactin Central injection 
(low dose)
t Chaoet al., 1987
Centra] injection 
(high dose)
i Chaoet al., 1987
in vitro i Chao et al., 1987; Wang et al., 1996
LH Central injection T Allen et al., 1985
iv infusion 
(including humans)
T Rodriguez-Sierra et al., 1987; Bauer-Dantoin et al., 1991; Bauer- 
Dantoin et al., 1992; Watanobe et al., 1994
TSH Central injection 1 Fekete et al., 2001
ACTH Central injection t Brooks et al., 1994; Wahlested et al., 1987
iv infusion t Inoue et al., 1989
iv infusion 
(humans)
i Antonijevic et al., 2000
1.13.2  Neuropeptide Y and headache
NPY plays an important role in the sympathetic innervation of the cerebral 
vasculature (Edvinsson et al., 1983). NPY-immunoreactive varicose nerve fibres have 
been demonstrated in cerebral arteries (Edvinsson et al., 1983), cortical veins
56(Edvinsson et al., 1984) and free within the dura mater (Keller and Marfrirt, 1991). 
Denervation experiments have shown that most of the sympathetic fibres arise from 
the ipsilateral superior cervical ganglion (Uddman et al., 1989). Radioimmunoassay 
studies have also demonstrated the presence of NPY in cerebral arteries, and the 
addition of NPY to cerebral arteries causes vasoconstriction in a dose-dependent 
manner (Uddman et al., 1989).
Goadsby et al. (1990) did not find elevated NPY levels during a migraine attack, 
although Gallai et al. (1994) demonstrated a significant rise in serum NPY during 
migraine with and without aura in juveniles. NPY levels are not elevated during a 
cluster attack (Goadsby and Edvinsson, 1994) or in patients with chronic tension type 
headache (Ashina et al., 1999).
1.14  Vasoactive Intestinal Polypeptide
VIP is a 28-amino acid peptide that acts on G protein-coupled receptors that activate 
adenylate cyclase and phospholipase cascades. Three VIP receptors have been cloned 
that share many biological properties to pituitary adenylate cyclase activating 
polypeptide (PACAP) receptors, and they are named PACAP/ VIP receptors (PVRs; 
Nussdorfer and Malendowicz, 1998). VIP and PVRs are widely distributed within the 
central and peripheral nervous systems and are believed to have a variety of biological 
actions (Dickinson and Fleetwood-Walker, 1999). VIP-immunoreactive fibres have 
been localised in laminae I and II of spinal cord dorsal horn, and mRNA expression 
has been demonstrated in dorsal root ganglion neurones, implicating this peptide in 
nociception (Noguchi et al., 1989). Intrathecal application of VIP at the spinal cord 
level has been shown to facilitate nociceptive reflexes (Xu and Wiesenfeld-Hallin,
1991)  and the iontophoretic application of VIP causes a marked excitation of rat 
trigeminal caudalis neurones as well as intact rat (Dickinson et al., 1999) and cat 
(Jeftinija et al., 1982) spinal cord neurones.
1.14.1  VIP and the pituitary
VIP has been isolated in high concentrations in both the hypothalamus and the 
anterior pituitary gland (Lam, 1991). It is a neurotransmitter and neuromodulator 
within the hypothalamo-pituitary axis, and has a paracrine effect within the pituitary 
gland itself (Lam, 1991). VIP-containing neurones are present in the suprachiasmatic
57nucleus of the hypothalamus as well as the periventricular and paraventricular nuclei 
(Dai et al., 1997), and VIP immunoreactivity has been demonstrated in the anterior 
pituitary of several mammalian species (Fahrenkrug and Schaffalitzky de Muckadell, 
1978; Besson et al., 1979; Koves et al., 1990; Lam et al., 1990; Carrillo and Dluzen,
1993).
VIP and growth hormone
VIP causes a marked increase in growth hormone release when added to growth- 
hormone secreting pituitary tumour cells in vitro (Matsushita et al., 1981; Chihara et 
al., 1982; Fazekas et al., 2000). The stimulatory effect of VIP in acromegaly has also 
been confirmed in vivo (Chihara et al., 1984; Kato et al., 1984).
VIP and prolactin
VIP stimulates prolactin in vitro (Gourdji et al., 1979; Nicosia et al., 1980; Rotsztejn 
et al., 1980; Matsushita et al., 1983) in vivo in humans (Bataille et al., 1981; Falsetti et 
al., 1988; Yiangou et al., 1988) which does not appear to be via dopaminergic 
inhibitory mechanisms (Tater et al., 1983; Haisenleder et al., 1988). Centrally injected 
VIP into the hypothalamus stimulates both prolactin secretion (Akema et al., 1988) 
and mRNA production (Bredow et al., 1994; Di et al., 1997) whilst infusion of anti- 
VIP serum into the portal vein in rats suppresses serotonin-induced prolactin secretion 
(Shimatsu et al., 1984). VIP enhances the secretion of prolactin in pituitary tumours 
both in vitro (Kato et al., 1984; Prysor-Jones et al., 1984) and in vivo (Kato et al., 
1984). Fazekas et al. (2000) demonstrated that addition of VIP to growth hormone- 
secreting pituitary tumours and prolactinomas caused increased prolactin release and 
an increase in the presence of secretory granules within the adenoma cells.
VIP and gonadotropins
In vitro treatment of pituitary tissue with VIP does not affect the release of LH or FSH 
(Enjalbert et al., 1980; Rotsztejn et al., 1980; Sawangjaroen et al., 1997) although 
micro-injection of VIP into the hypothalamus and the third ventricle inhibits LH 
pulses (Akema et al., 1988; Weick et al., 1992). Falsetti et al. (1988) demonstrated 
that the intravenous VIP administration in women does not modify serum LH or FSH, 
although Hammond et al. (1993) showed that it may modulate the responsiveness of
58the gonadotroph to LHRH. It has been suggested that VIP plays a modulatory, rather 
than ‘deterministic’, role in the regulation of LH secretion (Weick and Stobie, 1995).
VIP and thyrotrophin
Central VIP injection may stimulate the hypothalamo-pituitary-thyroid axis in rats 
(Mitsuma et al., 1984) although in vitro treatment of pituitary tissue with VIP 
(Baranowska et al., 1999) and intravenous administration in humans (Falsetti et al., 
1988) does alter serum TSH levels. Thyroidectomy increases anterior pituitary VIP 
(Michalkiewicz et al., 1987; Buhl et al., 1995) suggesting that some hypothalamic 
factor is involved in mediating the effect of hypothyroidism on pituitary VIP 
expression and secretion.
VIP and adrenocorticotrophin
Central VIP injection increases ACTH secretion (Itoh et al., 1982; Itoh and Hirota, 
1983; Alexander and Sander, 1994). In humans, intravenous VIP infusion does not 
alter serum ACTH in healthy volunteers (Ambrosi et al., 1987; Watanobe and 
Tamura, 1994; Chiodera et al., 1996). VIP elevates ACTH in patients with ATCH- 
secreting pituitary tumours (Ambrosi et al., 1987; Watanobe and Tamura, 1994) 
suggesting that neoplastic transformation of pituitary cells may be associated with 
their capacity to express PACAP/ VIP receptors (PVRs). In vitro investigations have 
shown no effect of VIP or peptide histidine-methionine (PHM, a compound derived 
from a VIP precursor molecule with similar biological actions to VIP) on ACTH 
secretion in normal perfused pituitary cells or incubated hemipituitaries of rats and 
mice (Nicholson et al., 1984; Tilders et al., 1984; Vigh and Schally, 1984) although a 
stimulatoiy effect is observed in the presence of CRH (Tilders et al., 1984; Vigh and 
Schally,  1984). Experiments on pituitary adenoma tissue support the finding that VIP 
has a stimulatory effect on ACTH secretion in corticotrope pituitary tumour cells 
compared to the normal pituitary gland (White et al., 1982; Westendorf et al., 1983)
VIP and pituitary tumours
PVRs are differentially expressed in pituitary adenomas, suggesting that abnormal 
regulation of VIP-related pathways are important in the pathogenesis of certain 
pituitary tumours (Oka et al., 1998). Hsu et al. (1989) demonstrated strong VIP
59immuno-reactivity in human pituitary tumours. They found significant quantities of 
VIP in 16 of 17 prolactinomas, 12 of 14 growth hormone-secreting tumours, 4 of 12 
ACTH-secreting tumours and 14 of 18 non-functioning adenomas. Double immuno- 
labelling demonstrated VIP-immunoreactivity in many lactotrophs, thyrotrophs, 
corticotrophs and the occasional gonadotroph (Hsu et al., 1989). A summary of the 
effects of VIP on the hypothalamo-pituitary axis is shown in Table 9.
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HP Axis VIP adHMMvofiMi Effect Refcrcocc
GH in vitro 
(acromegaly)
T Matsushita et al., 1981; Chihara et al., 1982; Fazekas 
et al., 2000
iv infusion 
(acromegaly)
T Chihara et al., 1984; Kato et al., 1984
Prolactin in vitro T Gourdji et al., 1979; Nicosia et al., 1980; Rotsztejn et 
al., 1980
in vitro 
(acromegaly, 
prolactinoma)
T Prysor-Jones et al., 1984; Kato et al., 1984
Central injection T Akema et al., 1988; Bredow et al., 1994; Di et al., 
1997
iv infusion 
(healthy volunteers)
T Bataille et al., 1981; Falsetti et al., 1988; Yiangou et 
al., 1988
iv infusion 
(acromegaly, 
prolactinoma)
T Kato e tal., 1984
LH/FSH in vitro Enjalbert et al., 1980; Rotsztejn et al., 1980; 
Sawangjaroen et al., 1997
Central injection 1 Akema e tal., 1988; Weick et al., 1992
iv humans -T Falsetti et al., 1988; Hammond et al., 1993
TSH Central injection T Mitsuma et al., 1984
in vitro — ► Baranowska et al., 1999
iv humans Falsetti et al., 1988
ACTH Central injection T Itoh et al., 1982; Itoh et al., 1983
iv humans 
(healthy volunteers)
Ambrosi et al., 1987; Chiodera et al., 1996; Watanobe 
et al., 1994
iv humans 
(Cushings disease)
T Ambrosi et al., 1987; Watanobe et al., 1994
in vitro — ► Nicholson et al., 1984; Tilders et al, 1984; Vigh et al., 
1984
in vitro 
(with CRH)
T Tilders et al., 1984; Vigh et al., 1984
In vitro 
(Cushings)
T Westendorf et al., 1983; White et al., 1982
611.14.2  VIP and headache
VIP-immunoreactive nerve fibres are present in the parasympathetic innervation of 
the cerebral arteries, and these fibres may originate from the pterygopalatine, otic and 
internal carotid ganglia (Gibbins et al., 1984; Suzuki et al., 1988; Hara et al., 1989). 
Radioimmuno-assay studies confirm the presence of VIP in human cerebral and 
middle meningeal arteries (Edvinsson et al., 1987) and pharmacological studies show 
VIP to be a potent vasodilator of the latter (Edvinsson et al., 1987). VIP- 
immunoreactive fibres have been demonstrated in cerebral venous sinuses and free 
within the dura mater (Keller and Marfurt, 1991). VIP levels are elevated following 
superior sagittal sinus stimulation (Zagami et al., 1990) as a result of trigeminal- 
autonomic activation. Neither peripheral nor jugular VIP levels are altered during 
migraine with or without aura in humans (Blegvad et al., 1986; Goadsby et al., 1990) 
and Nicolodi et al. (1990) demonstrated reduced salivary VIP levels in migraine. 
Conversely, salivary (Nicolodi and Del Bianco, 1990) and external jugular (Goadsby 
and Edvinsson, 1994) VIP levels are elevated during cluster headache and chronic 
paroxysmal hemicrania attacks (Goadsby and Edvinsson, 1996) with resolution to 
normal levels after the attacks are finished.
Summary
There are several neuropeptides that may play an important role in headache 
pathophysiology (Table 10) that also appear to have paracrine activity within the 
hypothalamo-pituitary axis, and are differentially expressed in pituitary tumours. It is 
conceivable that the secretion of these peptides may be involved in pituitary-tumour 
associated headache.
Table 10. Neuropeptide changes in primary headache
Migraine Cluster Headache Chronic Tension Type Headache
CGRP T T -* / T  *
Substance P - - -
Neuropeptide Y -n - -
VIP -n T -
* CGRP increased with throbbing tension-type headache only
621.15  Somatostatin and Headache
The final part of this introduction is a review of the literature regarding the role of 
somatostatin and headache. Somatostatin was initially isolated as a 14-amino acid 
peptide that reduced the release of growth hormone from the pituitary gland (Brazeau 
et al., 1973). In addition to its neuroendocrine role, somatostatin has subsequently 
been found to have diverse neurophysiological effects (Epelbaum et al., 1994; 
Schindler et al., 1996). This discussion will be limited to its role in nociception, 
primaiy headache and pituitary-associated headache.
1.15.1  Non-Clinical Data
Somatostatin is translated as a pre-propeptide, of which two predominant biologically 
active metabolites have been found, somatostatin-14 and the amino-terminally 
extended form, somatostatin-28. A family of five somatostatin receptor genes have 
been cloned, termed sst 1-5, and based on pharmacological properties and sequence 
analysis, the receptors have been divided into two groups (Table 11). The 
somatostatin receptor- 1 group consists of sst2, sst3 and ssts, and the somatostatin 
receptor-2 group consists of ssti and sst* (Hoyer et al., 1995). In mice and rats, the sst2 
receptor is found as two splice variants, sst2 (a>  and sst2 (b), which differ in length and 
composition of their respective carboxy-terminal (Hoyer et al., 1995). The 
somatostatin receptors are G-protein coupled seven-transmembrane receptors, which 
interact with a wide range of downstream signalling targets that includes cAMP 
(Selmer et al., 2000).
Table 11. Classification of sst receptors
Grovp 1 Groap2
sst2 ssti
sst3 sst4
sst5
Somatostatin is located within sensory ganglia (Smith et al., 1993) as well as in the 
trigeminal ganglion and the trigeminal nucleus caudalis (Alvarez and Priestley, 1990; 
Lazarov and Chouchkov, 1990; Del Fiacco and Quartu, 1994; Yin, 1995). 
Somatostatin is also localised within the substantia gelatinosa of the dorsal horn of the 
spinal trigeminal nucleus (Johansson et al., 1984; Kiyama and Emson, 1990; Mengod 
et al., 1992) strongly suggesting that this peptide has a role in trigeminal nociception.
63It is believed that the sst2(a) receptor is particularly important in somatostatin- 
associated analgesia. Humphrey’s group in Cambridge has done much of the work on 
the immuno-localisation of somatostatin receptors, demonstrating sst2a receptors in the 
periaqueductal gray and dorsal horn neurones (Schindler et al., 1997; Schindler et al., 
1998).
The precise mechanism of the analgesic action of somatostatin has not been 
elucidated, but there is animal evidence that its actions are probably central. The 
peptide nature of somatostatin renders it vulnerable to breakdown by endogenous 
peptidases, and its short half-life of several minutes (Harris, 1994) has led to the 
development of longer acting analogues, such as octreotide. Intrathecal and 
subcutaneous injection of somatostatin and octreotide respectively, have been shown 
to inhibit the firing of dorsal horn neurones (Chapman and Dickenson, 1992) and 
direct micro-injection of somatostatin into the periaqueductal gray of the cat has been 
shown to produce inhibition of heat-induced electrophysiological recordings in the 
spinal cord (Helmchen et al., 1995). Micro-injection of somatostatin into the caudate 
putamen has also been shown to be anti-nociceptive (Tashev et al., 2001). Song et al. 
(2 0 0 2 ) showed that sst2 (a) receptors are preferentially involved in thermo-nociception 
but not mechano-nociception and Su et al. (2001) demonstrated that octreotide has no 
peripheral modulatory action in visceral nociception, suggesting that its site of action 
is central rather than peripheral. Heyles et al. (2001) demonstated that somatostatin 
analogues inhibit mustard oil-evoked neurogenic plasma extravasation and inhibition 
of the release of substance P and CGRP in response to electrical stimulation which 
suggests an anti-inflammatory role for somatostatin. Earlier studies have also 
supported an anti-inflammatory role for somatostatin. For example, Matsubara et al.
(1992) demonstrated that octreotide is able to block plasma protein leakage within 
dura mater.
Octreotide has been shown to inhibit substance P release from sensory nerve endings 
and to inhibit substance P-induced vasodilation (Gazelius et al., 1981). This has led 
certain groups to believe that the analgesic action of somatostatin analogues, 
particularly in relation to headache, is via direct vascular mechanisms rather than a 
central action. Sicuteri et al. (1984) showed that when the dorsal hand vein is locally 
injected with native somatostatin, it spasms visibly. This study showed that
64tachyphylaxis develops following 2-4 injections of somatostatin, and this is reversed 
by the local injection of naloxone. That somatostatin may have a direct effect on 
blood vessels is evidenced by the finding of its receptors on human vasculature, ssti 
having a significantly higher level of expression than sst2 and ssU (Curtis et al., 2000).
Octreotide is known to have poor penetration of the blood-brain barrier (Kitazawa et 
al., 1998; Schmidt et al., 1998) due to its non-lipophylic properties, which has been 
used by some as circumstantial evidence of a peripheral action of octreotide in 
headache (Kemper et al., 2000). Kemper et al. (2000) looked at capsaicin-induced c- 
Fos expression in an animal model of trigeminal nociception. This group showed that 
the intracistemal administration of octreotide does not alter capsaicin-induced c-Fos 
expression and they suggest that this argues against a central role for somatostatin 
receptors in the processing of trigeminovascular signals. Conversely, Berieter (1997) 
demonstrated that the intracerebroventricular administration of octreotide reduced c- 
Fos expression in the trigeminal subnucleus in response to corneal stimulation in the 
rat. Furthermore, Berieter (1997) demonstrated that the co-administration of sub- 
therapeutic doses of morphine potentiated this analgesic effect, suggesting that 
somatostatin and opiates may have interacting or overlapping properties. Somatostatin 
analogues have been previously shown to have affinity for opiate receptors (Rezek et 
al., 1978; Maurer et al., 1982; Pelton et al.,  1985; Pelton et al., 1985) and there is 
evidence to suggest that somatostatin and opiate receptors may heterodimerise 
(Pfeiffer et al., 2002). Samsam et al. (2002) electrically stimulated the trigeminal 
ganglia of rats and studied the subsequent immuno-reactivity for methionine 
enkephalin, neurotensin and somatostatin. They observed a decrease in 
immunoreactivity for all three peptides ipsilateral to the side of stimulation, and they 
suggest that this may be evidence for their potential role as antinociceptive agents 
during trigeminal activation.
At the cellular electrophysiological level, somatostatin has been shown to have both 
excitatory as well as inhibitory actions on neurones (Dodd and Kelly, 1978; Pittman 
and Siggins, 1981; Mueller et al., 1986). Somatostatin appears to have a reciprocal 
relationship with glutamate (Hathway et al., 2001). Glutamate is believed to play an 
important role in the transmission of trigemino-vascular nociceptive information 
(Storer and Goadsby, 1999) and the inhibitory action of somatostatin on trigeminal
65neuronal activity may be partly explained by its modulation of glutamate-mediated 
nociceptive signals (Gardette et al., 1995; Lanneau et al., 1998; Peineau et al., 2003). 
There is also evidence of an interaction between somatostatin and y-aminobutyric acid 
(GABA). The GABAa receptor appears to be involved in pain transmission within the 
trigeminal system (Storer et al., 2001) and somatostatin has been shown to have a 
functional interaction with the GABAa receptor (Vincens et al., 1998) making it 
possible that the analgesic effect of somatostatin involves enhancement in the activity 
of this receptor.
1.15.2  Clinical Data
Somatostatin and Peripheral Pain
There is evidence in the clinical literature that somatostatin and its analogues may be 
potent analgesic agents in the management of a variety of conditions characterised by 
acute and chronic pain. Chrubasik et al. (1984) first reported in the Lancet a series of 
eight patients with terminal metastatic cancer pain who received both intrathecal and 
epidural infusions of native somatostatin. In this open label study, somatostatin was 
found to be an effective analgesic agent when administered in the epidural space, and 
the effect was not reversed with naloxone which suggests a non-opioidergic 
mechanism of action. The same group found continuous epidural infusions of 
somatostatin to be effective in providing complete post-operative pain relief in eight 
patients who had undergone abdominal surgery. In two of these patients, epidural 
somatostatin also provided adequate intraoperative analgesia (Chrubasik et al., 1985). 
In a larger placebo controlled study of 40 patients undergoing abdominal surgery, 
epidural somatostatin was found to be significantly better than placebo for pain relief 
and the need for additional analgesia was higher in the placebo group (Taura et al., 
1994). Fioravanti et al. (1995) injected somatostatin intra-articularly in 41 patients 
with rheumatoid arthritis in an open label study, and found a significant reduction in 
pain and markers of inflammation.
Octreotide, a somatostatin analogue that acts predominantly on sst2 and ssts (Patel and 
Srikant, 1994) has been shown to be as equally useful intrathecally as native 
somatostatin in the management of severe cancer pain (Penn et al., 1992). Octreotide 
is also known to be effective in the treatment of musculoskeletal symptoms associated 
with carcinoid syndrome (Smith et al., 1990), the latter tumours being known to
66secrete CGRP (Takami et al., 1990), substance P (Emson et al., 1984), neuropeptide Y 
(Waeber et al., 1995) and VIP (Virgolini et al., 1994).
Somatostatin and Primary Headache
There have been few clinical trials studying the usefulness of somatostatin and its 
analogues in the management of primary headache syndromes, although the 
preliminary evidence suggests that they may be effective agents for both cluster 
headache and migraine. Sicuteri et al. (1984) published one of two currently available 
studies concerning the effect of somatostatin in cluster headache. This group 
investigated eight males with cluster headache and hospitalised them during their 
cluster bout. All patients were withdrawn from preventative treatment 4 days prior to 
the study. Patients received 3 double-blind treatments of somatostatin, ergotamine and 
placebo during a cluster attack. Pain intensity was assessed by a visual analogue scale 
every 10 minutes, and the ‘area of pain’ was studied for each treatment. The study 
found somatostatin to reduce the pain area by 32%, whilst ergotamine reduced this by 
45%. The differences between somatostatin and ergotamine were not significant, and 
both were significantly more effective than placebo. In the discussion section of the 
paper, Sicuteri et al. (1984) acknowledge the difficulty in studying a large number of 
patients with cluster headache and concede that ‘strictly controlled clinical studies 
(are) still required’. The second randomised study was a non-placebo controlled 
double blind study comparing the efficacy of somatostatin with ergotamine in cluster 
headache (Geppetti et al., 1985). Five patients were treated for three attacks by each 
drug. Subcutaneous somatostatin and ergotamine were equally beneficial as regards 
effects on maximal pain intensity and pain area, but somatostatin was less effective in 
reducing the duration of pain. This limited evidence of the beneficial effect of 
somatostatin in cluster headache needs to be explored further in properly controlled 
and adequately powered studies.
The only available study concerning the effect of somatostatin receptor activation on 
migraine was conducted by Kapicioglu et al. (1997). In this double-blind parallel 
study, octreotide (lOOpg) was given subcutaneously to 17 patients with migraine with 
and without aura, and placebo was given to 12 matched patients. At 2, 4 and 6  hours, 
headache relief, defined as reduction in severity from grade 3 or 2 (severe or
67moderate) to  1 or 0  (mild or none), was found to be significantly better in patients 
taking octreotide than placebo. By 6  hours, headache relief was experienced in 77% 
of octreotide-treated patients, and 25% of the placebo-treated group. The authors’ 
rationale for the study was that octreotide ‘causes a marked reduction in the 
concentration of substance P and VIP...(which) may be involved in the pathogenesis 
of migraine attacks’. They conclude that octreotide ‘is very effective and well 
tolerated for the treatment of a migraine attack, but additional studies will be 
necessary to verify these conclusions’.
Since that study, no other groups have followed up this potentially interesting 
observation.
Somatostatin and pituitary tumour-associated headache 
Although the reports on the use of somatostatin analogues directly aimed at the 
treatment of primary headaches are not numerous, there are an increasing number of 
clinical studies describing the effectiveness of these agents in the treatment of the 
headache associated with acromegaly.
The two somatostatin analogues most commonly used in the treatment of acromegaly 
are octreotide and lanreotide. Large-scale placebo-controlled trials have shown that 
short-acting octreotide can reduce headache in approximately 75-80% of patients with 
acromegaly (Ezzat et al., 1992; Newman et al., 1995; Newman et al., 1998) and the 
use of monthly slow-release octreotide has been shown to give a reduction in 
symptoms after the sixth injection (Lancranjan and Atkinson, 1999). The prospective 
trials of lanreotide therapy have also shown a significant reduction in headache in 
addition to the other symptoms of acromegaly, including fatigue, perspiration, joint 
pains and parasthesia (Cannavo et al., 2000; Cannavo et al., 2001) although a sub­
group of patients is recognised who prefer to be transferred to octreotide therapy 
because only the latter agent significantly ameliorates headache (Cannavo et al., 
2000). Our own Case 3 (Appendix; Levy et al., 2003b) is a good example of such a 
patient, and suggests that there is a different mechanism for the analgesic effect of 
octreotide from its growth hormone lowering action.
Octreotide and lanreotide predominantly bind to sst2 and ssts (Patel and Srikant, 1994). 
Functional pituitary tumours have been shown to express ssti, sst2, sst3 and ssts (Schaer
68et al., 1997; Shimon and Melmed, 1997) Using tumour cell cultures, it has been 
shown that both sst2 and ssts are involved in the regulation of growth hormone release 
from growth hormone-secreting pituitary tumours, whereas ssts appears to be 
exclusively involved in the regulation of prolactin secretion from prolactinoma cells 
(Shimon et al., 1997). Octreotide has significantly better binding to sst3 than 
lanreotide (Patel and Srikant, 1994) and it is possible that the subgroup of patients 
who respond only to octreotide in terms of headache, but both octreotide and 
lanreotide in terms of growth hormone, do so because their tumours express sst3, 
coupled to suppression of the pain pathway, and ssts receptors, coupled to the control 
of GH release (Levy et al., 2003b). This hypothesis requires further study.
Although somatostatin analogues are predominantly used in clinical practice for their 
ability to lower growth hormone in acromegaly, there is evidence that they also have 
an analgesic effect in non-growth hormone secreting pituitary tumours, including 
prolactinomas (Williams et al., 1986), non-functioning adenomas (Turpin et al., 1991) 
and TSH-secreting tumours (Yoenem et al., 1999). It is possible that the analgesic 
action of octreotide in these cases is similarly related to the somatostatin receptor 
status of the tumour.
An alternative explanation for the differential analgesic effect of octreotide and 
lanreotide in headache is related to central anti-nociceptive mechanisms rather than 
direct effects on the pituitary gland. As discussed previously, the periaqueductal gray, 
hypothalamus and trigeminal nucleus are known to possess sst2a receptors (Schindler 
et al., 1997) and represent potential targets for the analgesic action of somatostatin 
analogues. However, octreotide and lanreotide both exhibit limited permeability to the 
blood-brain barrier (Gillespie et al., 1998; Fricker et al., 2002) and differences in 
action seem more likely to be related to pharmacodynamics than pharmacokinetics. 
This situation is analogous to the triptans, which also have the combination of 
apparent poor central nervous system accessibility (De Vries et al., 1999) and 
undoubted efficacy in primary headache (Ferrari et al., 2002). It has been suggested 
that there may be an altered vascular permeability during activation of the 
trigeminovascular system when compared to the resting state to account for the 
paradox between poor permeability of the blood brain barrier and apparent efficacy
69during headache (Harper et al., 1977; Alvarez-Cermeno et al., 1986; Kaube et al.,
1993).
Finally, it is of interest that pegvisomant, a new agent that has been developed for the 
treatment for acromegaly, appears to be less helpful for headache than somatostatin 
analogues. Unlike somatostatin analogues, pegvisomant is a peripheral growth 
hormone-receptor blocker and does not act centrally on the hypothalamo-pituitary 
axis. This agent is very effective in reducing all the typical symptoms of acromegaly 
apart from headache (van der Lely et al., 2001) which supports a central and specific 
analgesic action of somatostatin analogues, separate from the ability to improve other 
symptoms related to growth hormone excess.
Somatostatin and Headache Induction
Although the majority of the literature regarding somatostatin as regards pain 
concerns its anti-nociceptive properties, there is evidence that repeated and prolonged 
exposure to somatostatin may be pro-nociceptive. There have been two reports of 
rebound headache and dependency to octreotide (Popovic et al., 1988; May et al.,
1994) suggesting that there is an up-regulation of trigeminal nociceptive pathways 
after excessive exposure and subsequent withdrawal of this agent. Octreotide 
dependency is also described in our own Case 5 (Appendix; Levy and Goadsby 2004). 
Octreotide has been shown to trigger cluster headache attacks in certain patients 
(Otsuka et al., 1998) in stark contrast to other reports of the abortive effects of 
somatostatin in this condition (Sicuteri et al., 1984; Geppetti et al., 1985). The 
administration of native somatostatin to healthy individuals causes suppression of 
growth hormone, which rebounds when it is discontinued, and endocrinologists have 
observed that patients commonly experience headache after somatostatin withdrawal 
during metabolic studies (Lightman, unpublished observations). Despite this 
observation, there have been no previous studies directly observing the effects of 
somatostatin infusion and withdrawal on headache, and to correlate this with 
neuroendocrine changes. One of the problems of studying primary headache 
syndromes such as migraine and cluster headache in clinical research, is the episodic 
nature of these conditions, and to have a reliable way of triggering headache in these 
conditions is very attractive. Nitroglycerin (Thomsen et al., 1994) and histamine 
(Krabbe and Olesen, 1980) have both been used to induce migraine and cluster
70headache attacks. Patients with migraine develop symptoms usually several hours 
after exposure to nitroglycerin (Iversen, 2 0 0 1 ), whilst cluster patients (during a cluster 
period) may have an attack within minutes (Ekbom, 1968). A problem with these 
existing models is that the most reliable and best studied model, that of nitroglycerin- 
triggering, is complicated by vasodilatation (Thomsen et al., 1994) and dissecting the 
non-vascular mechanisms in these headache types is a considerable challenge. It 
would thus be desirable to have a non-vasoactive method for triggering migraine or 
cluster headache, or both. Somatostatin may therefore represent a compound that may 
be of use in the further study and potential triggering of primary headache.
In summary, this introduction has outlined the currently available evidence to support 
the view that hypothalamo-pituitary axis and somatostin are relevant to the study of 
headache. The clinical features and classification of the headache phenotypes 
encountered in this thesis have been discussed. The range of headache syndromes 
previously described in association with pituitary tumours have been presented, and 
the proposed mechanisms of headache in pituitary tumours have been reviewed, with 
particular emphasis on certain vasoactive neuropeptides that appear to play a role both 
in the pituitary gland and headache pathpophysiology. Finally, the relevance of 
somatostatin to primary and pituitary-associated headache has been discussed.
711.16  Thesis Aims
The aims of the thesis are as follows:
(i.)  To determine the importance of structural factors in pituitary tumour-
associated headache (Chapter 2)
(ii.)  To determine the importance of certain neuropeptides in pituitary tumour-
associated headache (Chapter 3)
(iii.)  To describe the headache phenotypes and treatment characteristics in a cohort 
of patients with pituitary tumour-associated headache (Chapter 4)
(iv.)  To test the hypothesis that somatostatin withdrawal may be used as a means of 
triggering headache (Chapter 5)
(v.)  To investigate the usefulness of octreotide in migraine and cluster headache 
(Chapter 6 )
72. Pituitary tumours and headache: structural factors2.1. Study 1: the relationship between pituitary tumour volume, 
cavernous sinus invasion and headache
Levy MJ, JSger HR, Powell M, Matharu MS, Meeran K, Goadsby PJ
Abstract ref: Cephalalgia 2002; 22: 592
Paper ref: Archives of Neurolology 2004; 61(5): 721-5
2.1.1  Abstract
Background: Pituitary tumours are commonly associated with disabling headache.
The accepted mechanisms for headache are dural stretch and cavernous sinus 
invasion.
Methods: Sixty-three patients presenting with pituitary tumours were studied 
prospectively. Headache scores, pituitary tumour volume and extent of cavernous 
sinus invasion were obtained for each patient.
Results: The prevalence of headache was 70%. There was no positive correlation 
between headache score and pituitary volume (r =-0.32, P = 0.01). There was no 
association between cavernous sinus invasion and headache. There was a strong 
association between pituitary tumour-associated headache and a family history of 
headache (x2 =8.36, P = 0.004).
Conclusion: Pituitary tumour-associated headache cannot be just a structural problem. 
Other factors, such as the presence of a family history of headache and the endocrine 
activity of the tumour, may be equally important in this phenomenon.
742.1.2  Introduction
As discussed in Section 1.9, it has long been considered that headache is related to 
tumour size and dural stretch (Forsyth and Posner, 1993; Suwanwela et al., 1994). 
The explanation for dural stretch as a cause of headache is that the expansion of a 
pituitary tumour within the sella turcica may stimulate afferent fibres innervating the 
dura mater. Involvement of the cavernous sinus has also been invoked to explain 
headache (de Groot & Jameson, 2000) since the sinus contains the ophthalmic branch 
of the trigeminal nerve and the internal carotid artery, both of which are important 
structures in head pain and cranial autonomic function respectively.
The numerous reports of a variety of headache phenotypes associated with pituitary 
tumours, which include severe and intractable migraine (Lee, 1990), cluster headache 
(Milos et al., 1996; Porta-Etessam et al., 2001), ‘trigeminal neuralgia’ (Gazioglu, 
2000; Gelabert Gonzalez, 1990) and SUNCT (Ferrari et al., 1988; Massiou et al., 
2002), have been described in detail in the general introduction. In such cases, 
conventional preventive and abortive headache management can often prove to be 
ineffective, yet medical treatment of the pituitary disease can completely resolve the 
symptoms. The reported cases of micro-prolactinomas presenting with severe 
headache that resolve immediately with the administration of dopamine agonists 
(Hartman et al., 1995; Gabrielli et al., 2002) and the impressive analgesic effects of 
somatostatin analogues in acromegaly (Musolino et al., 1990; Pascual et al., 1991) 
suggest that biochemical mechanisms may be involved in pituitary tumour-associated 
headache. Also, the reports of significant headache exacerbations associated with the 
administration of dopamine-agonists in prolactinomas, in the absence of a change in 
physical properties of the tumour (Massiou, 2002; Levy 2003), suggest that non­
mechanical factors may be involved in the pathophysiology of pituitary tumour- 
associated headache.
The aim of the study was to systematically look at the relative importance of size and 
cavernous sinus invasion in pituitary-associated headache to directly test both 
hypotheses for the cause of headache.
752.1.3  Subjects and methods
Sixty-three consecutive patients (16 male, 47 female; mean age 44 ± 14 years) 
presenting with pituitary disease from February 2000 to August 2002 were 
prospectively included in the study. All patients were seen at the same unit (QS) for 
treatment of newly diagnosed pituitary disease, which included both surgical and 
medical management options. The study was approved by the Joint Ethical 
Committee of the National Hospital for Neurology and Neurosurgery and the Institute 
of Neurology (Study Reference 01/ N022). The following criteria were assessed at 
presentation:
Headache
Before commencement of treatment, all patients were interviewed by a trained 
headache fellow (the candidate). The clinical data collected included the presence or 
absence of headache, the frequency and severity of symptoms. A retrospective 
headache score was calculated using the following:
Headache frequency (days/wk) x Headache Duration (hrs/day) x Headache Severity 
(0-10)
In order to validate this measurement, 22 of the recruited patients were asked to 
complete prospective headache diaries, in which an hourly headache score was 
documented for a period of two weeks. These diaries were sent to a separate headache 
specialist (collaborator Dr MS Matharu) who blindly calculated a mean headache 
score for each patient. The diary score and the retrospective score were then 
compared. The presence of a family history of headache was also documented.
Assessment of Pituitary Volume and Cavernous Sinus Invasion 
The structural factors measured in this study were pituitary tumour size and cavernous 
sinus invasion. In the only previous study investigating headache in pituitary tumours 
(Abe et al., 1998) pituitary size was estimated using maximum tumour diameter, and 
objective classification criteria were not described in the assessment of cavernous 
sinus invasion. I sought to improve on this by determining pituitary volume rather 
than diameter, and by using objective rather than subjective criteria for cavernous 
sinus invasion.
76The pre-treatment MRI scans were performed on a number of different MRI scanners, 
all at 1.5T. All examinations included coronal and sagittal T1-weighted spin echo 
sequences with a maximum slice thickness of 3mm, before and after intravenous 
administration of a gadolinium-based contrast medium. All MRI scans were assessed 
by a consultant neuro-radiologist (Dr HR JSger, Institute of Neurology, London UK) 
as well as myself. For the assessment of tumour volume it was assumed that pituitary 
tumours have an ellipsoid shape, in response to a previous study which reported this 
to be an accurate assessment of pituitary size (Lundin and Pedersen, 1992).
Pituitary Volume
Using Cavalieri’s principle, pituitary tumour volume was calculated after performing 
measurements of tumour diameter in three orthogonal planes (Lundin and Pederson,
1992)  using the following equation:
Volume = 4/3 7t .a/2 .b/2 .°/2
If the tumour was large and multi-lobed, the tumour volume was assumed to consist 
of separated ellipses, and the sum of each lobe volume was calculated (Figure 5).
Cavernous Sinus Invasion
Three different parameters were used for the assessment of presence and degree of 
cavernous sinus involvement, based on previous radiological data (Cottier et al., 
2000):
1.  Encasement of the internal carotid artery, distinguishing four grades:
a.  no encasement,
b.  < 25% encasement
c.  > 50 - 75% encasement
d.  >15 - 100% encasement
2.  Crossing of the three lines connecting the cross sections through the distal 
internal carotid arteries (inter-carotid lines): medial, median and lateral inter­
carotid lines.
3.  Extension of the tumour into the venous compartments of the cavernous sinus.
Based on a modification of the classification system described by Cottier et al. (2000) 
tumour extension was divided into the superior, lateral and inferior venous
77compartments (Figure 6 ). Because invasion of the medial compartment has not proven 
to be a significant radiological sign of cavernous sinus invasion (Cottier et al., 2000) 
this compartment was not included in our classification system. If a normal pituitary 
gland was observed between the adenoma and the intracavemous internal carotid 
artery, the cavernous sinus was considered to be free of invasion (Scotti et al., 1988; 
Knosp et al., 1993). The inferolateral venous and carotid sulcus compartments 
described by Cottier et al. (2002) were grouped together as the inferior compartment 
for simplicity (Figure 6 ). Using previously published data comparing MRI 
classification with surgical findings (Knosp et al., 1993; Cottier et al., 2000) the 
following criteria were used to diagnose cavernous sinus invasion (Figure 7):
1.  Tumour crosses lateral inter-carotid line
2.  Tumour encases >75% internal carotid artery
3.  Tumour extends into inferior compartment
Examples of superior, inferior, lateral and absent cavernous sinus invasion are shown 
in Figure 8 .
78Figure 5. Calculation of pituitary volume
Volume = 4/j *.V2.V / 2
Multi-lobed tumours are assumed to be the sum of separate ellipses
Figure 6. Simplification of cavernous sinus invasion into superior, inferior and lateral 
compartments
cranial
L left
cranial
Cottier’s classification (2000):
1  = medial,
2 = superior
3 = lateral
4 = inferolateral,
5 = carotid sulcus
Simplified classification: 
pink = superior 
mauve = inferior 
blue = lateral
7QFigure 7. Criteria for cavernous sinus invasion
PIT
Tumour crosses LL
PIT
>75% encasement of ICA
Intercarotid lines: MdL = medial, MdnL = median, LL = lateral 
ICA = internal carotid artery
Cavernous compartments: 1  = inferior, 2 = superior, 3 = lateral 
Comp = Compartment
L
Tumour invades inferior comp
Figure 8. Examples of cavernous sinus invasion
Inferior (top left), superior (top right), lateral (bottom left) and no invasion (bottom right)
80Study design
All of the MRI images were reviewed by consensus whilst blinded to the headache 
status of the patient. All images were reviewed prospectively before patients 
underwent their operation. The presence or absence of cavernous sinus invasion, as 
defined by the above criteria, were treated as binary variables. Pituitary volume was 
correlated with a quantitative retrospective headache score.
Statistics
Non-parametric correlations were used (Spearman’s) because headache scores were 
not normally distributed.  tests were used to look for associations between 
cavernous sinus invasion and the presence or absence of headache. Statistical 
significance was assessed at the P < 0.05 level. Statistical analyses were computed on 
commercial software: SPSS version 9.0.
2.1.4  Results
Headache
The prevalence of headache was 70% (44/63) and the raw data are shown in Table 12. 
The clinic headache scores closely matched the scores obtained from the prospective 
headache diaries (Figure 9; r = 0.93, P < 0.005) thus validating the semi-quantitative 
assessment of headache. The headache scores within each tumour sub-type are shown 
in Table 13. There was a significant association between pituitary tumour- associated 
headache and the presence of a family history of headache (%2= 8.36, P  =  0.004, 
Table 14).
Pituitary volume
There was no positive correlation between pituitary volume and headache (r = -0.32, 
P = 0.01; Figure 6).
Cavernous Sinus Invasion
There was no association between headache and any compartment of cavernous sinus 
invasion (Table 14).
81Table 12. Headache score, tumour volume and cavernous sinus invasion
Patient
eode
Tumour  .■
*yp*
Tumour Volume
(■a*)
C.S luvacion
Y/N Score Lateral Inferior Superior
1 NFA 1 240 5.1 l l l
2 Cushings 1 32 0.4 0 0 0
3 NFA 1 384 1.3 0 0 0
4 Cranio 1 344 17.8 0 0 0
5 Cranio 1 672 15 1 0 0 0
6 NFA 0 0 3.1 0 0 0
7 Prl 1 1536 0.2 0 0 0
8 NFA 1 224 1.2 1 1 1
9 Prl 1 240 0.9 0 1 0
10 Prl 1 390 2.1 0 0 0
11 Cushings 1 64 0.1 0 0 0
12 NFA 0 0 0.6 0 0 0
13 Aero 0 0 0.5 0 0 0
14 Prl l 2021 0.2 0 0 0
15 NFA l 24 6.6 0 1 1
16 Aero 0 0 1.2 0 0 0
17 Aero 0 0 10.2 1 0 1
18 Cranio 1 880 2.4 0 0 0
19 Prl 1 75 4.2 1 1 1
20 NFA 0 0 13.2 0 0 0
21 Prl 1 1728 0.3 0 0 0
22 Prl 1 720 6.5 1 1 1
23 Prl 1 20 3.2 0 0 0
24 Aero 1 194 7.0 0 1 0
25 Cushings 0 0 1.0 0 0 0
26 NFA 0 0 14.9 1 0 1
27 NFA 1 520 3.3 1 1 1
28 Prl 1 305 0.07 0 0 0
29 NFA 0 0 3.1 0 0 0
30 NFA 0 0 10.3 0 0 0
31 Prl 1 384 0.1 0 0 0
32 Aero 0 0 0.65 0 0 0
33 NFA 0 0 10.7 1 1 1
34 Aero 0 0 3.9 0 0 0
35 TSH 1 1800 1.7 1 0 1
36 NFA 1 80 1.0 0 0 0
37 TSH 0 0.5 0 0 0
38 Prl 1 166 0.4 0 0 0
39 Aero 1 2160 0.9 0 1 0
40 Aero 1 3320 2.6 0 0 0
41 NFA 1 400 1.2 0 0 0
42 Cushings 1 240 0.1 0 0 0
43 Cushings 1 360 0.2 0 0 0
44 NFA 1 90 3.2 1 1 1
45 Prl 1 192 2.7 0 0 0
46 Prl 1 848 0.1 0 0 0
47 Prl 1 1476 0.1 0 0 0
48 Prl 1 656 0.1 0 0 0
49 NFA 0 5.1 0 1 0
50 Prl 1 2 9.4 1 I 1
51 Aero 1 180 4.6 0 0 0
52 Prl 1 1440 0.1 0 0 0
53 NFA 1 1104 8.7 1 0 1
54 Aero 1 360 0.1 0 0 0
55 Aero 0 0.23 0 0 0
56 NFA 1 264 9.0 0 0 0
57 Aero 1 2880 0.1 1 1 0
58 Prl 1 60 1.5 0 0 0
59 Cranio 1 216 0.7 0 0 0
60 Cranio 0 0 3.6 0 0 0
61 Aero 0 0 0.3 1 0 1
62 TSH 0 0 7.7 0 0 0
63 NFA 1 160 6.5 0 0 0
NFA non-functioning adenoma, Prl prolactinoma Aero acromegaly, Cranio craniopharyngioma TSH TSHoma
82Table 13. Headache scores for each tumour sub-type
Tumour sub-type u Mean score
Growth hormone secreting tumour 12 758
Prolactinoma 17 659
TSHoma 3 600
Craniopharyngioma 5 362
Non functioning adenoma 20 194
ACTH secreting tumour 6 200
Table 14. Association between cavernous sinus invasion, family headache history and headache
Cavernous Sinus Invasion X* test Significance
Superior 0.17 NS
Inferior 0.17 NS
Lateral 1.08 NS
Family History 8.36 P =  0.004*
NS P  > 0.05
* statistically significant association
83Figure 9. Validation of retrospective headache score
Clinic Headache Score vs Prospective Headache Diary Score
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842.1.5  Discussion
The close correlation between the retrospective clinic headache scores and the 
prospective headache diaries validates the semi-quantitative assessment of headache 
in these patients. The clinic headache score is a modification of a well-recognised 
assessment of headache morbidity (Stewart et al., 2000) and the high scores confirms 
the clinical impression that patients with pituitary tumours have a significant 
headache problem.
No positive correlation between headache and tumour volume was found, which 
would have been expected if the stretching of adjacent dural structures, such as the 
wall of the cavernous sinus or diaphragma sellae were an important mechanism of 
pituitary-associated headache. Headache also did not correlate with cavernous sinus 
invasion or carotid encasement. There was in particular no association between 
headache and invasion of the lateral compartment of the cavernous sinus (% 2   = 1.08), 
which contains the ophthalmic and maxillary divisions of the trigeminal nerve. The 
lack of association between cavernous sinus invasion and headache is in agreement 
with a previous study (Abe et al., 1998). Headache was also unrelated to the degree of 
carotid encasement, a potential indicator of tumour interference with the sympathetic 
plexus surrounding the internal carotid.
The 70% prevalence of headache in patients with pituitary tumours is significantly 
higher than the prevalence of headache in the general population (Rasmussen and 
Olesen, 1992; Lipton et al., 2002) confirming that there is a pro-nociceptive quality 
attached to pituitary tumours. Mean headache scores were high in the acromegaly and 
prolactinoma group, although larger numbers are required for a true comparison 
between tumour sub-types.
The significant association between a family headache history and pituitary- 
associated headache suggests that genetic factors are important in predicting whether 
a patient with a pituitary tumour will develop headache as part of the presentation. As 
discussed in Section 1.4, it is known that first-degree relatives of migraine sufferers 
are also predisposed to migraine (Gervil et al., 2001). The presence of a pituitary
85tumour may simply be the trigger in a patient who is already pre-disposed to 
headache.
Clearly functional imaging and animal studies suggest that the hypothalamo-pituitary 
axis plays an important role in the pathophysiology of primary headache syndromes 
such as migraine and the TACs, particularly cluster headache. As outlined in Section 
1.4, in migraine there is evidence of hypothalamic dysfunction (Peres et al., 2001) and 
the presence of polyphagia, polyuria and polydipsia as part of the premonitory phase 
of migraine further implicates the hypothalamus (Gififin et al., 2003). The striking 
relationship between the menstrual cycle and migraine in women suggests that 
changes in the hypothalamo-pituitary axis can profoundly alter the expression of 
migraine (Silberstein, 2000a).  That functional alterations in the hypothalamus may be 
relevant to headache has also been reviewed earlier in reference to cluster headache 
(May et al., 1998a; Goadsby and May, 1999) and SUNCT (May et al., 1999b) where 
there is evidence of hypothalamic activation during a bout (Section 1.5). The 
elucidation of the trigemino-hypothalamic tract (Malick et al., 2000) provides 
anatomical evidence for a direct neuronal interaction between the hypothalamo- 
pituitary axis and the trigeminal nucleus.
Although there was no significant association between cavernous sinus invasion and 
headache for the whole group, headache was ipsilateral to the side of cavernous sinus 
invasion in four cases. This appears to be in keeping with the clinical observation that 
there may be sub-set of patients with pituitary disease who have headache ipsilateral 
to the side of cavernous invasion (de Groot & Jameson, 2000). If this clinical 
impression is correct, it is unclear why cavernous sinus invasion should only cause 
headache in a select proportion of patients, and may suggest that headache associated 
with cavernous sinus invasion requires other factors in addition in order to give rise to 
headache.
This was an improvement on the previous study (Abe et al., 1998) because tumour 
volume rather than tumour diameter was measured, cavernous sinus invasion was 
classified by previously validated criteria, and a quantitative estimate of headache was 
calculated and correlated with tumour size. However, although there was a close 
statistical correlation between the prospective diary scores and the retrospective
86headache scores, the quantification of headache is likely to have produced the most 
inaccuracies, as the latter necessarily has a subjective component on behalf of the 
patient. A further possible confounding variable in this study arises from the 
potentially incorrect assumption that all patients experienced headache directly as a 
result of pituitary disease. Although all patients reported headache onset coincident 
with other classical pituitary tumour symptoms, it is possible that there were 
undetected aetiological causes for headache in certain cases. A larger series is 
required to allow for these potential confounders.
In summary, I found no association between pituitary size and headache, nor was 
there an association between cavernous sinus invasion and headache. This study may 
be important in dispelling the currently accepted view that headache in pituitary 
tumours is primarily a structural problem. Further studies are required to determine 
the pathophysiology of pituitary tumour-associated headache, such as the importance 
of biochemical properties of the tumour, which is now investigated.
87Pituitary tumours and headache! biochemical factors3.1  Study 2: the association between calcitonin gene related peptide, 
substance P and headache in pituitary tumours
Levy MJ, Classey J, Maneesi S, Powell M, Meeran K, Goadsby PJ 
Abstract ref: Cephalalgia 2003; 23: 687
3.1.1  Abstract
Objectives: To determine if the differential expression of Calcitonin Gene Related 
Peptide (CGRP) or substance P (SP) in a range of pituitary tumours was related to the 
presence or absence of headache.
Methods: Using recognised immunohistochemical techniques, twenty-six consecutive 
pituitary adenoma specimens were examined for the presence of CGRP and SP. One 
normal post mortem pituitary specimen was included for comparison. A separate 
observer divided the patients into two groups: headache and non-headache. The 
association between the presence of CGRP, SP and headache was observed.
Results: CGRP was observed in seven specimens (27%) and SP in six tumour 
specimens (23%), with cytoplasmic staining being the predominant morphological 
picture. CGRP and SP were co-expressed in the same tumour specimen in five cases. 
There was no significant association between the presence of CGRP and headache {%
0.86; P = 0.35). CGRP and SP were not observed in the control specimen. There was 
no correlation between tumour subtype and the presence of CGRP or SP. 
Conclusions: The mechanism of pituitary tumour-associated headache remains 
undetermined. The significance of the presence of CGRP and SP in pituitary tumours 
is unknown but does not appear to be related to headache or endocrine activity of the 
tumour.
893.1.2  Introduction
Study 1  demonstrated that the physical properties of pituitary tumours are not 
associated with headache in the majority of patients. Given the involvement of 
neuropeptides in primary headache (Edvinsson and Goadsby, 1995), and the 
observation that headache appears to be particularly prevalent in acromegaly (Ezzat et 
al.,  1994; Couch,  1986) and prolactinoma (Abe et al.,  1998), a biochemical 
explanation for headache is possible. The previous suggestion by several groups that 
pituitary tumour-associated headache may be due to the production of a pro­
nociceptive peptide (Williams et al.,  1986; Pascual, 2000) has been partly driven by 
the observation that somatostatin analogues can have an immediate and dramatic 
analgesic effect on the headache associated with acromegaly (Pascual et al., 1991; 
Newman et al.,  1998) and prolactinoma (Williams et al., 1987). Moreover, the 
uncoupling of the growth hormone from headache in acromegaly (Webb et al., 1989; 
Levy et al., 2003b) suggests that biochemical factors other than growth hormone may 
be involved in the headache associated with certain pituitary tumours.
As has been discussed in the general introduction, advances in the understanding of 
primary headache pathophysiology have pointed towards certain peptides as being 
important in the transmission of cranial nociceptive information (Goadsby and 
Edvinsson, 1993). Calcitonin gene-related peptide (CGRP), which rises during 
migraine (Goadsby et al., 1990; Gallai et al., 1995) and cluster headache (Goadsby 
and Edvinsson,  1994; Fanciullacci et al., 2000), could theoretically give rise to 
headache in pituitary tumours by acting on CGRP-containing sensory fibres present 
within the cavernous sinuses (Keller and Marfurt,  1991) and cerebral arteries 
(Uddman et al.,  1985). Although substance P (SP) levels do not rise during migraine 
(Goadsby et al.,  1990; Gallai et al.,  1995) or cluster headache (Goadsby and 
Edvinsson,  1994; Fanciullacci et al., 2000), SP-immunoreactive fibres richly 
innervate the dura mater in the cavernous sinus (Keller and Marfurt, 1991) and are 
present in the dorsal horn of the trigeminal nucleus (Ribeiro-da-Silva and Hokfelt, 
2000) suggesting it may have a role in headache. Sumatriptan, an agent that is useful 
in migraine and cluster headache (Ferrari et al., 2001), is also effective in the 
headache associated with pituitary tumours, possibly by the inhibition of vasoactive 
peptides, such as CGRP and SP, which may be theoretically produced by the tumour
90(Pascual, 2000). The review in Section 1.10 has presented the evidence that CGRP 
(Steel et al., 1992) and SP (Jessop et al., 1992) have paracrine roles within the 
hypothalamo-pituitary axis, and have been isolated in tumorous and non-tumorous 
human pituitary tissue (Roth and Krause, 1990; Wimalawansa, 1994). In the current 
study, I examined the expression of CGRP and SP within pituitary tumours, 
hypothesising that it may predict headache.
3.13  Subjects and Methods
Patient demographics
Twenty-six consecutive patients with pituitary tumours presenting to the single 
dedicated pituitary neuro-surgical unit, in which this thesis was based (QS), were 
included in the study (18 female, 9 male; mean age 51.9 ± 2.9). The diagnoses of the 
patients entering the study included acromegaly (n = 7), Cushing’s disease (n = 4), 
prolactinoma (n = 2 ) and non-functioning adenoma (n = 13).
Radiological characteristics
All patients had pre-operative MRI scans that showed evidence of pituitary lesions. 
Macro-adenomas were present in 20 cases, the remainder having micro-adenomas (n 
= 6 ). Cavernous sinus invasion was present in 6  tumours.
Study protocol
All patients were interviewed pre-operatively and the presence or absence of 
headache was documented. A headache history was obtained and a phenotypic 
description was given according to International Headache Society (I.H.S) diagnostic 
criteria (2004). Pituitary tissue was obtained at surgery and immediately fixed in 4% 
paraformaldehyde and stored at 4 ° C. Local ethical committee approval of the 
protocol was obtained, and tissue was anonymised for immunohistochemical study. 
One post mortem pituitary specimen was available as control tissue (kindly provided 
by Professor F. Scarivelli, Institute of Neurology).
Immunohistochemistry 
Tissue collection and preparation
91Pituitary tissue was obtained at operation from consecutive patients undergoing 
transphenoidal surgery. Tumour specimens were kindly provided by the lead pituitary 
surgeon in the hospital (Mr M Powell) and the tissue was given an anonymous code. 
Perioperatively, the specimens were immediately transferred into 4% 
paraformaldehyde fixative and refrigerated for 24 hours at 4°C. The tissue was 
subsequently transferred to Vi paraformaldehyde/ V 4  30% sucrose for 48 hours and 
then stored in 30% sucrose alone at 4°C prior to immunostaining.
Immunostaining method
1. Xylene Removal of Paraffin and rehydration
After collection and storage, the pituitary tissue was paraffin-embedded, and sections 
were cut and slide-mounted ( 6  pm). Paraffin was removed from the sections by the 
addition of xylene followed by rehydration. The selected slides, containing 2 sections 
of pituitary tissue, were placed in plastic racks with handles through a series of  2 x 
xylene, and subsequently treated with successively lower-graded alcohols ( 2  x 1 0 0 , 2  
x 95%, 1  x 80% and 1  x 50%). Slides were then placed in tap water and rinsed to 
remove the alcohol. This was followed by immersion in distilled water and then 3x5 
minute rinses in 0.01 M phosphate-buffered saline (PBS).
2. Removal of Endogenous Peroxidases
Following paraffin removal and rehydration, endogenous peroxidases were removed 
by oxidation. Slides were incubated in 0.6% hydrogen peroxide for 30 minutes and 
washed in PBS for 3 x 5 minutes.
3. Antigen Retrieval
Heat treated antigen retrieval was performed to remove paraffin bonds and increase 
the sensitivity of the immunoreaction (Cattoretti et al., 1993). Slides were placed in 
covered containers filled with citrate buffer (pH =7.4) and heated in the microwave 
for 10 minutes at full power, in two 5 min bouts. Further buffer was added after the 
first heating bout, in order to avoid dehydration of the sections. Sections were then 
cooled safely through heat exchange, by running cold water into the containers 
without exposing the slides to the air.
924. Formation of water-resistant barrier
The slide-bound sections were re-washed for 3x5 minutes in PBS and placed into an 
incubation-box, whose absorbent base had been soaked with distilled water. Both 
sections on each slide were circled with a peroxidase-anti-peroxidase pen to prevent 
the reagents from spreading over the slide and to avoid unnecessary wastage of 
reagents.
5. Addition of blocking agent
Sections were incubated with a blocking-agent in order to increase the specificity of 
the immunoreaction (Polak and Van Noorden, 1987). Blocking agent involves the use 
of phosphate buffered serum derived from a species different from that in which the 
primary antibody was raised, to avoid non-specific binding to the primary antibody. In 
both the CGRP and SP reactions, phosphate-buffered goat serum, derived from 
diluting normal goat serum in phosphate buffered saline, was used as the blocking 
agent as both primary antibodies were raised in rabbit. Blocking agent was made up at 
a dilution of 1:20 (1 ml of reconstituted frozen serum was added to 19 ml of 
phosphate buffered saline) and added to each section (1 ml). A box containing the 
slides was covered with its lid and left at room temperature for  1‘ hour.
6 . Removal of blocking agent
Blocking agent was tipped off into a waste-col lection beaker for separate disposal, as 
well as any excess of the sodium azide-containing normal serum.
7. Addition of Primaiy Antibody
Because I was interested in the level of CGRP and SP peptide secretion, the presence 
of peptide rather than receptor was examined. Primary antibody was made-up at the 
appropriate dilution in phosphate buffered serum. Several dilutions were attempted 
for each antibody until the optimum dilution was found to compromise between 
background and specific staining. Anti-rat CGRP polyclonal antibody raised in rabbit 
(Amersham Biosciences, UK) was diluted to an optimal dilution of 1:1000. 
Antihuman SP polyclonal antibody raised in rabbit (Biogenesis Ltd, UK) was diluted 
to an optimal dilution of 1:400. Primary antibody (200 pi) was added to each slide
93and the incubation box covered with its lid and incubated overnight in the refrigerator 
at 4°C.
8 . Addition of Secondary Antibody
Biotinylated secondary antibody was made up to a dilution of 1:30, i.e 10 pi of 
secondary antibody in 2 ml of phosphate buffered serum and added to the slide. The 
sections were left to incubate for  1 hour in a covered box at room temperature.
9. Addition of Tertiary Antibody
Secondary antibody was washed off with 3x5 minute rinses with phosphate buffered 
saline. The avidin-biotin complex (ABC) as the tertiary antibody was used (Boenish, 
1989). In this method, ABC is added to the secondary antibody, where open avidin 
sites bind to the biotin component of the secondary antibody. Because a large number 
of biotin molecules can be attached to a single antibody, this method amplifies the 
signal of the antigen-primary antibody-secondary antibody complex, allowing for 
increased sensitivity of the immunostain (Polak and Van Noorden, 1987). The ABC 
reagent was constituted 30 minutes prior to addition to the section, in which 2 drops 
of solution A were added to 2 drops of solution B from the Standard Elite Vector 
ABC kit, in 5 ml phosphate buffered saline. The ABC reagent was added each slide 
(2 0 0 pl), and the sections covered with a lid and left to incubate at room temperature 
for 1   hour. After the reaction, the ABC solution was washed off with 3x5 minute 
rinses of phosphate buffered saline.
10. Diaminobenzidine Reaction
The diaminobenzidine (DAB) reaction causes colour change and allows the antigen- 
antibody complex to be visualised. In this reaction, hydrogen peroxide is used as the 
substrate and DAB as the chromogen (Polak and Van Noorden, 1987).The oxidised 
DAB polymerises and forms an insoluble dark brown precipitate at the site of the 
reaction. In certain situations, the brown colouration may not be sufficiently 
visualised, in which case nickel (Ni2+) may be added to the incubation medium to 
produce a black product (Polak and Van Noorden, 1987).
94Ni2+-enhanced or non- Ni2+-enhanced half-strength DAB solution was made up 
immediately prior to adding to the sections, using a standard Vector DAB kit. This 
consisted of 5 ml of distilled H2O  + 2 drops of buffer stock solution (mix) + 2 drops of 
DAB stock solution (mix) +  1 drop of H2O 2 (mix) + 1  drop of Ni2+ solution (mix). For 
the SP reaction, chromagen nickel-enhanced half-strength DAB solution was used, 
and for CGRP, the DAB reaction was not nickel-enhanced. The reaction was timed 
after the addition of DAB solution (200 pi) to each slide until an appropriate level of 
differentiation was seen, as black / grey reaction product in Ni2+-enhanced chromagen 
and brown in non- Ni2+-enhanced chromagen. The reaction was aborted by placing 
the sections in deionised H2O. On average, sections were reacted with DAB for 
between 5-10 minutes. A schematic diagram of the avidin-biotin complex binding to 
the primary and secondary antibody complex is shown in Figure 11.
11.  Rehydration and Cover Slipping of Sections 
The sections were dehydrated by placing them through increasing 
concentrations of alcohol (50%, 80%, 2 x 95%, 2 x 100%) and then 2 x xylene (the 
reverse of step 1). The sections were finally cover slipped using DPX mountant and 
left to dry before inspection.
Control sections were prepared using the same method as above with the omission of 
primary antibody. All control sections showed no background staining. The 
specificity of CGRP and SP anti-bodies was confirmed using human spinal cord 
dorsal hom as a positive control (Figure 12).
95Figure 11. Schematic diagram of avidin-biotin complex
Antibody specificity
In accordance with Burry (2000), antibody specificity was confirmed by replacing the 
primary antibody with normal goat serum, and using positive control tissue. Human 
post-mortem spinal cord, which is known to contain CGRP and SP, was used as the 
positive control, and was reacted with primary antibody. No background staining was 
observed in any specimens in the absence of primary antibody, and specificity for 
CGRP and SP was confirmed by the observation of axonal and dendritic staining in 
human spinal cord (Figure 12).
Identification of CGRP / SP positive cells
Analysis of the tissue was performed by two independent observers who were blinded 
to headache status (the candidate and Dr S Maneesri) to exclude inter-observer 
variation. The presence or absence of immuno-positivity was documented for each 
specimen and a comment made about the morphology and distribution of the staining. 
After the data was locked, the association between the presence of peptide and the 
presence of headache was studied.
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Antibody specificity
In accordance with Burry (2000), antibody specificity was confirmed by replacing the 
primary antibody with normal goat serum, and using positive control tissue. Human 
post-mortem spinal cord, which is known to contain CGRP and SP, was used as the 
positive control, and was reacted with primary antibody. No background staining was 
observed in any specimens in the absence of primary antibody, and specificity for 
CGRP and SP was confirmed by the observation of axonal and dendritic staining in 
human spinal cord (Figure 12).
Identification of  CGRP /  SP positive cells
Analysis of the tissue was performed by two independent observers who were blinded 
to headache status (the candidate and Dr S Maneesri) to exclude inter-observer 
variation. The presence or absence of immuno-positivity was documented for each 
specimen and a comment made about the morphology and distribution of the staining. 
After the data was locked, the association between the presence of peptide and the 
presence of headache was studied.
StatisticsThe presence of headache and CGRP/ SP immunopositivity were recorded and treated 
as binary, x2 tests were used to look for an association between the presence of 
candidate peptide and headache (SPSS Version 10 Chicago IL). Statistical 
significance was set to the P < 0.05 value. Assuming a greater than chance association 
of headache and either CGRP or SP, and a headache frequency of 50% based on 
previous work (Abe et al., 1998) we sought a 30% or greater association. It was 
calculated that 2 0  tumours were needed for an 80% power of detecting a difference at 
the 5% level. I stopped the study at 26 tumours.
97Figure 12. Specificity of CGRP and substance P antibody in dorsal horn of human spinal cord
Figure 12a. CGRP immuno-staining in dorsal column of human spinal cord
Figure 12b. SP immuno-staining in dorsal column of human spinal cord
QR3.1.4  Results
Immunohistochemistry
Cushings disease: ACTH immuno-staining was confirmed in all 4 specimens. 3 
tumours elicited immuno-staining exclusively for ACTH, whilst one also contained 
scattered somatotrophs and lactotrophs. CGRP and SP immuno-staining cells were 
identified in one ACTH-positive specimen.
Acromegaly: GH immuno-staining was confirmed in all 7 specimens, of which 5 were 
exclusively somatotroph tumours, and 2 were somato-mammotrophs. CGRP and SP 
immuno-staining cells were identified in 2 somatotroph tumours.
Prolactinomas: Both specimens displayed dense immuno-staining for lactotrophs. 
CGRP and SP immuno-staining cells were identified in one specimen. 
Non-functioning adenomas: Of the 13 patients with non-hormone secreting tumours,
11 did not stain for any hormones and 2 were found to contain thyrotrophs. SP 
immuno-reactive cells were identified in both thyrotroph-containing tumours, whilst 
CGRP was identified in one of these. In the remaining tumours that did not stain for 
any hormones, CGRP immuno-reactivity was identified in 2 specimens.
CGRP-containing cells were characterised morphologically by predominantly 
cytoplasmic staining (Figure 13), and the SP-containing cells appeared as a 
combination of nuclear and cytoplasmic staining (Figure 14). In both cases, the 
immuno-positive cells were distributed evenly throughout the tumour tissue.
Headache
For the whole group, headache was present in 11 patients (42%). Headache 
prevalence was highest in prolactinoma (100%) and acromegaly (43%) but was seen 
in all tumour types (Table 1). The commonest headache phenotype was migraine (n= 
10). One patient presented with an I.H.S diagnosis of Short lasting headache 
Unilateral Neuralgiform headache attacks Conjunctival congestion and Tearing 
(SUNCT). There was no association between the presence of cavernous sinus 
invasion and headache.
99Relationship between CGRP, SP and headache
There was no significant association between the presence of CGRP and headache (x2 
= 0.86 P = 0.35), nor was there an association between the presence of SP and 
headache (x2 = 0.19; P = 0.67).
100Table 15. Tumour, headache and immuno-staining characteristics
IM M U N O SEX T U M O U R
SIZ E
IN V A SIO N H E A D A C H E PH EN O T Y PE C G R P SP
ACTH F MACRO - - - + +
GH F MICRO - - - - -
NFA F MACRO + + MIGRAINE - -
NFA F MACRO + + MIGRAINE - -
NFA M MACRO - - - - -
TSH F MACRO - + MIGRAINE + +
NFA M MACRO - - - - -
GH/PRL M MICRO - - - - -
NFA F MACRO - - - - -
GH M MICRO - + MIGRAINE + +
PRL F MACRO - + MIGRAINE - -
NFA F MACRO - - - + -
NFA F MACRO - - - - -
NFA F MACRO - - - - -
NFA M MACRO + - - - -
PRL M MACRO - + MIGRAINE + +
GH F MICRO + - - + +
NFA F MACRO - + MIGRAINE + -
ACTH F MACRO - + MIGRAINE - -
GH/PRL F MACRO + + MIGRAINE - -
ACTH M MICRO - - - - -
GH F MACRO - + MIGRAINE - -
ACTH F MICRO - - - - -
TSH F MACRO + - - - +
NFA M MACRO - + SUNCT - -
GH F MACRO - - - - -
NFA= non functioning adenoma, GH = growth hormone secreting tumour, PRL = prolactinoma, GH/ 
PRL = mixed growth hormone/ prolactin secreting (somatomammotroph), TSH = thyrotroph 
containing, SUNCT = Short lasting Unilateral Neuralgiform attacks with Conjunctival congestion and 
Tearing.
Table 16. Headache and immunopositivty within each tumour sub-type
Tumour sub-type Total no. Headache +ve CGRP +ve SP+ve
ACTH 4 1 1 1
GH 5 2 2 2
GH/PRL 2 1 0 0
PRL 2 2 1 1
TSH 2 1 1 2
NFA 11 4 2 0
Total 26 11 7 6
NFA= non functioning adenoma, GH = growth hormone secreting tumour, PRL = prolactinoma, GH/ PRL = mixed growth 
hormone/ prolactin secreting (somatomammotroph
101Figure 13. CGRP  immuno-staining appearances
Figure 13a Non-functioning adenoma (x20)
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Figure 13b. Non-functioning adenoma (x40)
10?Figure 14. Substance P immuno-staining appearances
4
Figure 14a. Non-functioning adenoma (x20)
t
Figure 14b. Non-functioning adenoma (x40)3.1.5  Discussion
The results of this study do not demonstrate a relationship between the presence of 
CGRP or SP with headache. Although the tumour numbers in this study were 
relatively small, the study was powered for an association that would be robust, so the 
findings show that headache can be present without any demonstration of CGRP or 
SP and vice versa. I did not find any association between CGRP or SP with tumour 
activity, although the presence of SP in association with thyrotrophs has been reported 
by other groups (Roth et al., 1994; Arita et al., 1994). The co-localisation of CGRP 
and SP in 5 out of 9 immuno-positive tumours is in keeping with previous 
observations that CGRP and SP have a tendency to co-localise (Ribeiro-da-Silva et 
al., 2000), although this has not been previously described in relation to the anterior 
pituitary gland.
The aim of the study was to determine whether the presence of CGRP and SP could 
predict pituitary tumour-associated headache. The result was negative and this must 
raise study design issues. An underlying assumption of this, and similar studies that 
seek associations with headache, is that the headache is a direct result of the pituitary 
tumour. It is possible other variables impinged on that likelihood to manifest 
headache. For example, a genetic predisposition to primary headache and the presence 
of environmental trigger factors was not documented, which may have been important 
in individual cases (Goadsby et al., 2002). Migraine is more commonly seen in 
women (Goadsby et al., 2002), and the fact that the ratio of women to men in the 
study group was greater than 2:1 may have biased the results. Also, I did not take into 
consideration the possibility that endocrine deficiency could have been a confounding 
variable, although no patients exhibited typical features of cortisol deficiency 
headache.
Headache was simplistically treated as a binary variable (present or absent), whereas a 
clinical sub-categorisation of headache phenotypes may have been more meaningful. 
This would require a much larger study to attempt to associate CGRP or SP with a 
particular type of headache. Although headache classification was not the primary 
focus of the study, being fully investigated in Chapter 4 of this thesis, migraine was
104the commonest headache phenotype observed in this study. The other case presenting 
with headache had a diagnosis of SUNCT. If pituitary tumour-associated headache is 
a heterogenous rather than a homogenous clinical entity, much higher numbers would 
be required to comment on the relative prevalence of each phenotype within particular 
tumour sub-groups.
The presence of peptide rather than receptor status within the tumour tissue was 
studied because the hypothesis generated was that pituitary tumour-associated 
headache is caused by active peptide secretion. Although the importance of 
immunoblotting as an antibody purity determinant is acknowledged, antibody 
specificity was demonstrated by the use of a both a negative and positive control 
(Burry, 2000). However, molecular techniques such as in situ hybridisation may have 
provided more sensitivity to this study. It is possible that the immunohistochemical 
method used was insufficiently sensitive to demonstrate small quantities of CGRP and 
SP that may have been present in some of the apparently negative tumour specimens. 
Further studies looking at mRNA rather than presence of peptide may be necessary if 
the nociceptive peptide hypothesis is to be definitively refuted.
Finally, if pituitary tumour-associated headache is indeed due to the production of a 
locally active nociceptive peptide, it is possible that CGRP and SP are the wrong 
candidate peptides. As mentioned in the general introduction, other neuropeptides that 
have been implicated in headache pathophysiology, and also play a role in paracrine 
activity of the hypothalamo-pituitary axis, including neuropeptide Y and vasoactive 
intestinal polypeptide (Jansen et al., 1994; Grouzmann et al., 1998; Hsu et al., 1989). 
Further studies are required to see if there is an association between these alternative 
peptides and headache in pituitary tumours.
In conclusion, although headache appears to be a significant cause of morbidity in 
patients presenting with pituitary tumours (Abe et al., 1998), particularly acromegaly 
and prolactinoma (Abe et al.,  1998; Ezzat et al.,  1994; Couch, 1986) there have been 
few studies regarding the mechanisms of headache. It has been discussed that severe 
headache may occur in patients with small functionally active tumours and Study 1  
showed no relationship between tumour size and invasion with headache (Abe et al., 
1998; Levy et al., 2004a). This has led to the hypothesis that headache may be caused
105by the secretion of nociceptive peptides. This study suggests that CGRP and SP do 
not represent such peptides, although larger studies using molecular techniques may 
be required to confirm or refute these findings.
106Pituitary tumours and headache: clinical characteristics4.1  Study 3: phenotypic characteristics of pituitary tumour related 
headache
Levy MJ, Matharu MS, Powell MP, Meeran K, Goadsby PJ 
Abstract ref: Cephalalgia 2003; 23: 261
4.1.1  Abstract
Background: Pituitary tumours may be associated with a variety of headache 
syndromes, although there are few prospective studies regarding the range of 
phenotypes observed.
Methods: Eighty-four patients with pituitary tumour related headache underwent a 
detailed interview regarding the clinical characteristics, associated features and 
response to treatment. The information was entered prospectively onto an electronic 
data base.
Results: The commonest phenotypic presentations were chronic (46%) and episodic 
(30%) migraine. Other headache syndromes included SUNCT (5%), cluster headache 
(4%), hemicrania continua (1%) and primary stabbing headache (27%). It was not 
possible to classify the headache according to International Headache Society 
diagnostic criteria in 6 cases (7%). Cavernous sinus invasion was present in the 
minority of presentations (21%), but was present in two of three patients with cluster 
headache. SUNCT-like headache was only seen in patients with acromegaly (n=2) 
and prolactinoma (n=2). Hypophysectomy improved headache in 49% and 
exacerbated headache in 15% of cases. Somatostatin analogues improved acromegaly- 
associated headache in 64% of cases, although rebound headache was described in 
three patients. Dopamine agonists improved headache in 25% and exacerbated 
headache in 21 % of cases. In certain cases, severe exacerbations in headache were 
observed with dopamine agonists.
Conclusion: Headache appears to be a significant problem in pituitary disease and is 
associated with a range of phenotypes. The presenting phenotype is likely to be 
governed by a combination of factors including tumour activity, relationship to the 
cavernous sinus and patient predisposition to headache. A proposed modification of 
the current classification of pituitary-associated headache is given.
1084.1.2  Introduction
The clinical presentation of pituitary adenomas is dependent upon both structural and 
functional properties of the tumour (De Groot and Jameson, 2000). As discussed in 
Chapters 2 and 3, it is unclear whether headache, a common symptom of pituitary 
disease (Abe et al.,  1998), is a structural or functional consequence of pituitary 
tumours. The presentation and mechanisms of headache in pituitary disease have not 
been widely investigated. Abe et al. (1998) described the headache characteristics in 
19 patients with pituitary tumours, reporting generalised and predominantly bilateral 
frontal headache. However, with the advent of a systematic classification of headache 
(1988) and its subsequent revision (2004), the opportunity exists to carefully 
phenotype the headache seen with pituitary tumours. This effort allows the prospect 
of providing clinical information with which to manage such patients and may 
provide some insights into the primary headaches that are seen in pituitary disease. 
The aim of this study was to describe prospectively the phenotypic characteristics of 
pituitary tumour related headache in a large series of patients.
4.13  Subjects and Methods
Eighty-four consecutive patients presenting with pituitary tumour related headache 
were studied between February 2001 and August 2003. An interview was conducted 
by a physician trained in headache (the candidate), during which a questionnaire was 
completed that required detailed documentation of headache characteristics and 
response to treatment. The information was entered prospectively onto an electronic 
data-base (Microsoft Access 2003).
Headache
Headache characteristics collected were laterality, site, severity, quality of pain, attack 
duration, frequency, and associated symptoms as well as triggers. I recorded response 
of the headache to surgery, radiotherapy and medical treatment. In each case, an 
attempt was made to classify the headache in line with the International Headache 
Society Diagnostic Criteria (1988), taking account ultimately of the revised second 
edition (2004).
109Tumour
Tumour size and the presence or absence of cavernous sinus invasion was also 
documented. Tumour size was classified according to maximum tumour diameter into 
the categories of micro-adenoma (< 1cm) and macro-adenoma (> 1cm). Cavernous 
sinus invasion was diagnosed on the basis on radiological appearance and treated as 
present or absent, and the laterality of cavernous sinus invasion was documented 
using standard radiological criteria (Cottier et al., 2000).
Disability
Headache-related disability was assessed using a MIDAS questionnaire (Stewart et 
al., 2000).
4.1.4  Results
Patient Demographics
Of the 84 subjects interviewed, 60 were female (71%) and 24 male (29%). The mean 
age was 44 ± 1.4 years (Table 17). The commonest tumour associated with headache 
was prolactinoma {n = 31; 37%), followed by acromegaly (n = 28; 33%), non­
functioning adenoma (n = 20; 24%), Cushings disease (n = 4; 5%) and TSHoma (n = 
1;  1%). Full details are shown in Table 17.
Tumour characteristics
For the whole group, 55 tumours were macro-adenomas (65%) and 29 were micro­
adenomas (35%). Eighteen tumours (21%) were associated with cavernous sinus 
invasion. Macro-adenomas were commoner in the non-functioning adenoma (100%) 
and acromegaly groups (68%), whilst micro-adenomas were commoner in the 
Cushings (100%) and prolactinoma (52%) groups (Table 18).
110Table 17. Patient demographics and tumour characteristics
Characteristic  Patients n (%)
Sex (n, %)
Female  60  (71)
Male  24  (29)
Age (mean ± SD)  44  ± 1.4
Tumour type (n, %)
Prolactinoma  31  (37)
Acromegaly  28  (33)
Non-functioning adenoma  20  (24)
Cushings disease  4  (5)
TSHoma  1   (1)
Tumour characteristics
Macro-adenoma  55  (65)
Micro-adenoma  29  (35)
Cavernous sinus invasion  18  (21)
111Table 18. Tumour characteristics for each sub-type
Macro-adenoma
(*)
Micro-adenoma
(*>
Cavenoas sins invasion 
(if)
Acroncfily 
(*-28)
19 9 7
Prolactinoma 
(*-31)  -
15 16 6
NFA
(#1-20)
20 0 4
Cashings
(*-4)
0 4 0
TSHoma
(it-1)
1 0 1
Total
(*-*41
55 29 18
112Headache Characteristics
Laterality
Sixty patients (71%) had unilateral headache, which was side-locked in 53 (88%), 
while it was side variable in seven (12%; Table 19). Seventeen patients (20%) 
reported both bilateral and unilateral headache, whilst seven (12%) described 
exclusively bilateral symptoms. Of the 18 patients with cavernous sinus invasion, ten 
subjects (56%) experienced headache ipsilateral to the side of invasion.
Site
The commonest location of headache was the orbital / retro-orbital (79%) and frontal 
(64%) region. Twenty-nine percent of patients had headache involving non-trigeminal 
territory and in 71% the trigeminal territory was exclusively involved. The full 
distribution of headache location is shown in Table 19.
Severity
Ten patients (12%) graded their headache as moderate, 55 (65%) severe, 17 (20%) 
very severe, and 2 (2%) graded the pain excruciating. No patients graded their 
headache mild (Table 20).
Quality
The range of pain quality is shown in Table 20. The commonest quality of pain was 
described as throbbing (63%).
Duration and frequency
The median duration of headache exacerbation was seven hours (range 15 seconds - 
96 hours; Table 21). The median attack frequency was 20 per month (range 1  - 30). 
Using the definition of Chronic Daily Headache as greater than 15 headache days per 
month (Welch and Goadsby, 2002) the frequency of chronic daily headache was 53%. 
Twenty-five patients (30%) used paracetamol (acetaminophen) - or codeine- 
containing agents on greater than  10 occasions per month, and were defined as having 
medication overuse.
Associated Symptoms
113The frequency and distribution of associated symptoms are shown in Table 21. The 
commonest associated symptoms were photophobia (71%) and nausea (58%). During 
an exacerbation, 64 patients (76%) preferred to lie still during an attack, 12 (14%) felt 
restless and preferred to move around, whilst 8 (10%) had no preference (Table 21).
Forty-two patients (50%) reported one or more cranial autonomic features in 
association with headache exacerbations (Table 21), the commonest of which were 
lacrimation (35%) and conjunctival injection (26%).
114Table 19. Headache laterality and site
Characteristic  Patients n (%)
Laterality; n (%)
Strictly unilateral  60  (71)
Side-locked  53  (63)
Side-variable  7  (8)
Bilateral and unilateral  17  (20)
Strictly bilateral  7  (8)
Site; n (%)
Orbital / retro-orbital  66  (79)
Frontal  54  (64)
Temple  30  (36)
Parietal  19  (23)
Vertex  26  (31)
Occiput  24  (29)
Nasal  4  (5)
Cheek  4  (5)
Teeth  4  (5)
Jaw  3  (4)
Ear  3  (4)
Neck  4  (5)
115Table 20. Headache severity and quality
Characteristic  Patients n (%)
Severity; n (%)
Mild  0  (0)
Moderate  10  (12)
Severe  55  (65)
Very Severe  17  (20)
Excruciating  2  (2)
Quality; n (%)
Throbbing  53  (63)
Sharp  29  (35)
Dull  21  (25)
Pressure  19  (23)
Stabbing  15  (18)
Tightening  13  (15)
Boring  6  (7)
Burning  3  (4)
Aching  3  (4)
116Table 21. Headache duration, frequency and associated features
Characteristic  Patients n (%)
Median Duration (range) 7 (15 sec -  96 hrs)
Median attack  frequency per month  (range) 20 (1-30)
Chronic daily headache; n (%) 45 (53)
Analgesia overuse; n (%) 25 (30)
Associated symptoms
Nausea 49 (58)
Vomiting 18 (21)
Photophobia 60 (71)
Osmophobia 20 (24)
Restlessness 12 (14)
Aggravation with movement 64 (76)
Cranial autonomic symptoms; n (%)
Ptosis 16 (19)
Eyelid oedema 10 (12)
Conjunctival injection 22 (26)
Lacrimation 29 (35)
Nasal blockage 10 (12)
Rhinorrhoea 6 (7)
Facial sweating 6 (7)
Facial flushing 2 (2)
117Triggers
The frequency and distribution of headache triggers are shown in Table 22.
Family history
Forty-one patients (49%) reported a family history of a headache disorder (Table 22).
118Table 22. Headache triggers and family history
Characteristic  Patients n (%)
Triggers; n < % )
Stress 54 (64)
Exertion 22 (26)
Hunger 34 (40)
Alcohol 22 (26)
Bright lights 15 (18)
Family history of headache disorder; n (%)  41  (49)
119International Headache Society (I.H.S) Classification (Headache Classification 
Committee of The International Headache Society, 2004)
There were broadly two groups of patient diagnoses: those with phenotypes that 
mapped well onto accepted primary IHS diagnoses (n = 73) and those that did not («
=  11).
Of the former group, the commonest diagnosis was chronic migraine (n = 39), 
followed by episodic migraine (« = 25). Other headache diagnoses included Short- 
lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and 
Tearing (SUNCT; n = 4), cluster headache (n = 3), hemicrania continua (n = 1) and 
isolated primary stabbing headache (w = 1). Twenty-two patients (26%) had primary 
stabbing headache as a second headache diagnosis (Table 23). The IHS  headache 
diagnoses within each tumour sub-type are shown in Table 24. SUNCT syndrome was 
only seen in patients with prolactin- and growth hormone- secreting tumours, and 
primary stabbing headache was also more common in these two groups (87%).
Of those that did not map well onto an accepted primary IHS headache diagnosis, 
three patients were compatible with the current criteria for headache attributed to 
pituitary disease (IHS 7.4.4; Table 25). Of the remaining eight patients, two patients 
experienced featureless headache, which did not fit with tension-type headache or IHS
7.4.4  because the severity interfered with daily activities and the timing of headache 
was associated with the onset of pituitary disease but the treatment of the tumour did 
not absolutely resolve the headache (Criteria D; see Table 27). In 6 patients, it was not 
possible to classify the headache phenotype in accordance with the IHS criteria (Table 
25). These patients had a mixture of migrainous
(throbbing/nausea/photophobia/phonophobia) or cranial autonomic symptoms. These 
patients stood out in our groups experience with the particular mixture of symptoms 
and may represent a unique headache type seen in association with pituitary tumours.
120Table 23. Headache characteristics
Characteristic  Patients n (%)
IHS Classification
Chronic migraine 39 (46)
Episodic migraine 25 (30)
SUNCT 4 (5)
Cluster headache 3 (4)
Hemicrania continua 1 (1)
Primary stabbing headachet 23 (27)
Other t t 11 (13)
t  Lone diagnosis in one patient
t t   Not definable by IHS criteria (2004), see Table 24
SUNCT  Short-lasting Unilateral Neuralgiform headache, Conjunctival injection
and Tearing
121Table 24. International Headache Society (I.H.S) Classification (2004) diagnoses for each tumour
subtype
CM EM SUNCT CH HC PSH Otkert
Acromegaly
(it -  28)
15 6 2 0 0 8 3
ProiactiBOMa
(*-31)
11 13 2 1 1 12 4
NFA
(* -2 » )
12 4 0 2 0 3 3
Cashlags
(*-4)
1 3 0 0 0 0 1
TSHoma
(n-1)
1 0 0 0 0 0 0
Total
(* -« >
40 26 4 3 1 23 11
CM Chronic migraine
EM Episodic migraine
SUNCT See Table 7
CH Cluster headache
HC Hemicrania continua
PSH Primary Stabbing Headache
NFA Non-functioning adenoma
t  Not definable by IHS criteria
122Table 25 Patients with potentially secondary headache phenotypes (Headache Classification Committee of The International Headache Society, 2004)
Case Age/
Sex
Effect
of
surgery
Tumour Characteristics Headache Characteristics
Histology Size
Cavernous
sinus
invasion
Site Quality Severity Mvt Nausea Photo Phono Cranial
autonomic
Featureless Headache phenotypes
GS 74/M Better NFA Macro - Orbital/retro-
orbital
Continuous
Dull
Moderate - - • •
GW 84/F Better NFA Macro - Retro-
orbital/vertex
Continuous
Pressure
Moderate - • - • “
PC 65/M Medical 
Rx only 
better
Prolactin Macro Right Strict right Orbital/ 
parietal/ vertex 
Tight/sharp 
2 hr stabbing 
exacerbations
Severe
NE 31/F Worse Prolactin Macro Frontal Episodic 
3 hours 
Dull
Moderate
MN 37/F Worse Aero Macro Left Strict left 
retro-orbital
Continuous 
dull ache
Severe - " - “
Headaches with mixed migraine/trigeminal autonomic cephalalgia phenotypes
LD 29/F Better Aero Macro Left Strict left 
retro- 
orbital/frontal
Continuous 
pressure plus 
stabs
Severe + + + Lacrimation
IT 50/M Better Aero Macro Uni/Bilateral
Temporal/
vertex
Ache/boring/
dull
Very
severe
+ + + Lacrimation
SB 38/M Better Prolactin Macro Left Strict left Continuous Severe R - + - Lacrimation
123Orbital/retro-
orbital
boring/dull
30-60
exacerbations
ptosis
PT 52/F Better NFA Macro Bilateral
frontal
Continuous 
dull/throbbing 
60 min 
exacerbations 
± visual aura
Severe R Lacrimation
CW 51/F Better Cushings Micro Bilateral
generalised
Episodic 
(4-48 hrs) 
pressure
Severe +
BP 73/M Worse Prolactin Macro Left Strict Left 
Orbital/maxilla 
/jaw
Continuous 
Sharp 
Plus stabs
Very
severe
+ + Nasal block 
ptosis
124Treatment characteristics 
Surgery
Fifty-five patients (65%) underwent hypophysectomy, of which 50 had 
transphenoidal, and 5 trans-cranial approaches. Twenty-seven patients (49%) reported 
an improvement in headache following surgery, 20 (36%) experienced no change in 
symptoms, and 8 (15%) reported worsening of headache (Table 26).
Radiotherapy
Sixteen patients underwent radiotherapy, of which one experienced an improvement 
in headache, the remainder reporting no change in symptoms (Table 26). The median 
time to follow up from radiotherapy was 5 years (range 2-13 years).
Somatostatin analogues 
Octreotide
Twelve patients received octreotide lOOpg, of which seven reported a reduction in 
headache frequency and severity (Table 26). Of those that experienced improvement 
in headache, four experienced improved migraine, two reported an improvement in 
featureless headache, and one reported a reduction in the frequency and severity of 
SUNCT-like attacks. After several months of octreotide administration, three patients 
experienced rebound headache. One patient developed a dependency syndrome, 
requiring twelve injections per day. Four patients received both octreotide and 
lanreotide during treatment, three of who reported a preferential response to octreotide 
in terms of headache.
Octreotide LAR
Six patients received octreotide LAR 20mg per month, of which four reported a 
reduction in headache frequency and severity (Table 26). Two patients reported 
headache recurrence one week prior to the following injection. No patient on 
octreotide LAR developed tachyphylaxis or a dependency syndrome.
Lanreotide
125Four patients received lanreotide 30mg every two weeks. One patient experienced 
reduction in headache frequency and severity on lanreotide, the remaining three 
reporting no change in symptoms (Table 26). The single patient who experienced 
improvement in headache on lanreotide did not experience benefit from octreotide.
Dopamine agonists 
Cagergoline
Cabergoline (dose range 0.25 -  4mg per week) was prescribed in 23 patients. Nine 
patients reported a reduction in headache severity and frequency on cabergoline, 11 
experienced no change, and 3 reported an exacerbation in symptoms (Table 26). Of 
the 3 patients who reported an exacerbation in symptoms, one experienced a change 
from episodic to chronic migraine, one underwent a change from episodic migraine to 
persistent unilateral indomethacin-responsive headache, classified as hemicrania 
continua, and one experienced a severe and reproducible exacerbation of SUNCT-like 
syndrome that lasted for 12 hours.
Bromocriptine
Twenty-two patients received bromocriptine (dose range 2.5 -  22.5 mg per day). Of 
these, three patients experienced a reduction in headache frequency and severity, 13 
reported no change, and six reported headache exacerbation (Table 26). Of the six 
patients that reported headache exacerbation, five experienced worsening migraine, 
and one experienced severe exacerbation of SUNCT lasting 12 hours.
Quinagolide
Two patients received quinagolide therapy. One experienced worsening migraine 
whilst the other reported an exacerbation in SUNCT identical to the cabergoline and 
bromocriptine responses described above (Table 26).
126Table 26 Response of headache to treatment of pituitary disease
Improvement Exacerbation No change
Snrgeiy
Transphenoidal 23 8 19
Transcranial 4 0 1
Radiotherapy 1 0 15
Somatostatin analoene
Sandostatin 7 0 5
Octreotide LAR 4 0 2
Lanreotide 1 0 3
Dopamine agonist
Cabergoline 9 3 11
Bromocriptine 3 6 13
Quinagolide 0 2 0
127Quality of life
MIDAS questionnaires were completed in 69 patients. The highest MIDAS scores 
were seen in the acromegaly and prolactinoma groups (Figure 15). The mean MIDAS 
score for the whole group was 27 ± 24 days. Forty-eight percent of patients with 
pituitary tumour associated headache had severe levels of disability (Figure 16)
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Figure 16 Distribution of MIDAS scores by conventional grading cut-offs in patients with pituitary tumour and headache. The distribution is right-shifted in 
comparison to primary headache.
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1304.1.5  Discussion
Headache is a common and disabling aspect of pituitary disease. The cohort most 
often reported migraine, but cluster headache, Short-lasting Unilateral Neuralgiform 
headache attacks with Conjunctival injection and Tearing (SUNCT) and hemicrania 
continua was also observed. Some patients had unclassifiable headaches, which may 
be new forms of secondary headache specific to pituitary tumours that have not 
hitherto been recognised. No particular tumour type produced a specific headache 
syndrome. The observation that 48% of patients had MIDAS scores within the severe 
range suggests that disability due to pituitaiy headache is considerable (Lipton et al., 
2001). Pituitary tumour-related headache is an important, common issue that requires 
careful history to facilitate correct diagnosis and thus specific management of those 
afflicted.
The improvement in headache following surgery in 49% of cases implies a causal link 
between the tumour and presence of headache, although it is difficult to control for 
the confounding variables of the anaesthetic, or indeed natural history. Furthermore, 
the abolition of headache in 64% of acromegalics who were prescribed somatostatin 
analogues suggests a link between tumour activity and headache. Octreotide appeared 
to be more beneficial than lanreotide for headache, although one patient responded 
preferentially to lanreotide. As discussed in Section 1.15.2, it is possible that the 
somatostatin receptor status of the tumour is important in predicting headache 
response. Some patients in the cohort who had migraine headache reported a useful 
therapeutic effect with octreotide, and an interesting question is whether this drug is 
useful in non-pituitary tumour headache, which is investigated in Chapter 6. 
Octreotide dependency has been previously reported (Popovic et al., 1988, May et al., 
1994) and this was observed in the cohort as a potential complication in the 
management of pituitary-related headache.
Dopamine agonists both alleviated and exacerbated headache, which has previously 
been observed (Ferrari et al.,  1988, Massiou et al., 2002) and decribed in the 
Appendix (Cases 1, 2 and 4). This paradoxical observation may be related to a 
complex interplay of the physical effects on the tumour and the central actions of 
dopamine agonists. The reduction of tumour size in large prolactinomas may improve
131headache via structural changes, although the data from Study 1  and others (Abe et 
al., 1998) suggests that tumour size does not correlate with headache. Alternatively, or 
in addition, the effects of dopamine agonists on the trigeminovascular system may 
have deleterious effects on headache. Dopamine agonists share properties with ergot 
alkaloids (Trabucchi et al., 1978), and ergot alkaloids are known to alter the activity 
of the trigeminovascular system (Hoskin et al.,  1996). As discussed in Sections 1.4 
and 1.5, it has also been suggested that the dopamine-prolactin axis plays an 
important role in some forms of primary headache, notably migraine (Peroutka et al., 
1997; Peres et al., 2001) and cluster headache (Goadsby, 2002). This may, in part, 
explain the unpredictable headache responses observed with dopamine agonists. The 
exacerbation of headache was dramatic in certain cases, an observation that has been 
described in Appendix Cases 1  and 2, and previously observed in association with 
SUNCT (Ferrari et al., 1988, Massiou et al., 2002).
In addition to tumour-related factors, the type of headache in pituitary disease is likely 
to be a result of patient-dependent factors. The finding that 49% of the study group 
had a family history of headache suggests that they were more predisposed to the 
primary headaches than the general population (Steiner et al, 2003). As discussed in 
Section 1.4, migraine is known to have a familial aggregation (Ferrari, 1998) and the 
development of pituitary tumour-associated migraine, accounting for 75% of 
presentations in this study, may have been a result of genetic predisposition to 
migraine in affected patients rather than specific tumour-related factors. As 
migraineurs have an increased sensitivity to any external changes in the internal or 
external milieu compared to controls (Goadsby et al., 2002) it may be that the 
development of the pituitary tumour simply lowered the threshold for attacks in 
predisposed migraineurs. The presence of a higher proportion of migraine in 
prolactinomas and growth hormone-secreting tumours suggests that functional 
activity may be an important trigger.
Cluster headache and SUNCT are relatively rare headache syndromes and the 
observation of three cases of cluster headache and four cases of SUNCT in this 
relatively small cohort of 84 patients suggests that these phenotypes may be over­
represented in pituitary disease. While it is possible that this is in part referral bias 
with regard to the unit’s headache interest where 1  conducted the thesis (QS), this was
132minimised by studying consecutive referrals to the neurosurgery unit, which is 
unlikely to have this headache-related bias. Cavernous sinus invasion was present in 
two of the three cluster cases which may suggest that invasion of local structures is 
relevant to this headache syndrome. Although Study 1  showed that the cavernous 
sinus invasion is not predictive of headache in pituitary tumours, per se (Abe et al., 
1998; Levy et al., 2004a), the sinus does contain pain-producing structures, such as 
the internal carotid artery and trigeminal nerve and ganglion, invasion of which might 
be expected to cause pain. As discussed in Section 1.8.3, there have been several 
reports of pituitary-associated cluster headache presenting with ipsilateral cavernous 
sinus tumour invasion (Tfelt-Hansen et al.,  1982; Greve a& Mai,  1988; Milos et al., 
1996; Porta-Etessam et al., 2001). The cavernous sinus has been previously 
implicated in the pathophysiology of cluster headache (Moskowitz, 1988; Harbedo, 
1994), although functional imaging data suggests that ipsilateral hypothalamic 
activation may be more important (May et al., 1998a, May et al., 2000; Sprenger et 
al., 2004). Of the four SUNCT cases, two were prolactinomas and two were growth 
hormone-secreting tumours, suggesting that tumour activity may be important in 
pituitary-related SUNCT, although our sample size is small. The dramatic 
exacerbation of SUNCT with dopamine agonists observed in certain cases further 
suggests that perturbations in the dopamine-prolactin axis may be important in this 
headache syndrome. As described in Section 1.5.2, ipsilateral hypothalamic activation 
has been demonstrated in primary SUNCT (May et al, 1999) and it is conceivable that 
specific neuroendocrine pathways involving the dopamine-prolactin and growth 
hormone axis are capable of activating SUNCT pathophysiology.
The aim of this study was to document the clinical spectrum of pituitary tumour- 
associated headache. No attempt was made to determine the prevalence of headache 
in pituitary disease, which would have required recruitment of larger numbers of 
patients from both the surgical and non-surgical setting in a prospective and 
consecutive fashion. Because the study was based in a neurosurgical centre, the 
patient population is likely to have contained relatively larger numbers of 
macroadenomas compared to a non-surgical centre. This may have given a biased 
impression of the frequency and quality of headache found in our study, and further 
work is required to determine the validity of the findings in the generality of patients 
with pituitary tumours. 1  observed a significant number of patients who experienced
133residual headache after treatment of their pituitary tumour and found these patients to 
present a difficult management problem. Although treatment response was not 
formally part of the study design, a large number of this cohort was managed in a 
dedicated clinic. I observed that phenotype-driven medical management markedly 
improved the patients’ disability. There are previous reports that pituitary tumour- 
associated with headache may respond to serotonin-5-HTie/iD receptor agonists, 
triptans (Shah & Frei, 1999; Pascual 2000). I found that both acute and preventive 
phenotype-driven treatment was helpful for many patients. Patients with residual 
ipsilateral cavernous sinus invasion were particularly refractory to medical therapy. 
Prospective blinded placebo-controlled studies are required to determine the optimum 
management of the pituitary tumour-associated headache, although in their absence 
placebo-controlled studies from the underlying primary headache types manifest by 
these patients seem a very useful guide to their management.
Lastly, based on the relatively large, prospective study with tissue verification of the 
diagnosis, it may be possible to make some new suggestions as to the classification of 
headache in patients with pituitary disease (Table 27). Currently the International 
Headache Society classifies pituitary and hypothalamic headaches together (Headache 
Classification Committee of The International Headache Society, 2004). However, 
because pituitary adenomas are clinically distinct from hypothalamic syndromes, it 
seems reasonable to split these into separate entities. Despite the negative correlation 
between cavernous sinus invasion and headache found in Study 1, the implications of 
local involvement of the cavernous sinus from both a local treatment and headache 
presentation, suggest that it is sensible to specify the presence or absence of cavernous 
sinus invasion for research and characterisation (Table 27). It is suggested that 
requirement C (Table 27) is insufficient to deal with non-functioning adenomas, 
which made up nearly one quarter of the cohort, as it fails to demonstrate that the 
majority of these tumours present with a non-endocrine manifestation of the tumour, 
such as visual impairment. For requirement D (Table 27) the requirement of complete 
resolution of headache after surgical or endocrine management is not uniformly 
useful, as many patients were observed to have improvement in headache rather than 
complete resolution post-treatment. Therefore it seems appropriate that amelioration 
of headache after tumour treatment, rather than resolution more completely captures 
the outcome, thus it is suggested that section D is altered. With publication of this
134study, it is hoped that other centres will consider these proposals and test them prior to 
the next edition of the headache classification.
135Table 27 Proposals for modifications to the I.H.S criteria 
Current classification
7.4.4  Headache attributed to hypothalamic or pituitary hyper- or hyposecretion 
Diagnostic criteria:
A.  Bilateral, frontotemporal and/or retro-orbital headache fulfilling criteria C and D
B.  At least one of the following:
1.  prolactin, growth hormone (GH) and adrenocorticotropic hormone 
(ACTH) hypersecretion associated with microadenomas <10 mm in 
diameter
2.  disorder of temperature regulation, abnormal emotional state, altered 
thirst and appetite and change in level of consciousness associated with 
hypothalamic tumour
C.  Headache develops during endocrine abnormality
D.  Headache resolves within 3 months after surgical resection or specific and 
effective medical therapy
New proposal
7.4.4  Headache attributed to hypothalamic dysfunction 
Diagnostic criteria:
A.  Bilateral, ftontotemporal and/or retro-orbital headache fulfilling criteria C and D.
B.  Disorder of temperature regulation, abnormal emotional state, altered thirst and 
appetite and change in level of consciousness associated with hypothalamic 
tumour
C.  Headache develops when hypothalamic pathology is manifest
D.  Headache resolves within 3 months after specific and effective  medical therapy
7.4.5  Headache attributed to pituitary disease 
Diagnostic criteria:
A.  Bilateral or unilateral frontotemporal and/or retro-orbital headache fulfilling 
criteria C and D
B.  Either a functioning or non-functioning pituitary tumour is identified by 
biochemical testing or appropriate brain imaging
a. with cavernous sinus involvement
b. without cavernous sinus involvement
C.  Headache develops in close temporal proximity to endocrine abnormality or with 
structural symptoms attributable to pituitary disease, such as visual loss
D.  Headache resolves, or there is marked improvement, within 3 months after 
surgical resection, or specific and effective medical therapy
136In summary, I have described the headache characteristics observed in 84 patients 
with pituitary tumour-associated headache. Functioning tumours presented with the 
most headache-related disability, and the dopamine-prolactin and growth hormone 
axes were exclusively associated with SUNCT. The majority of cases of pituitary- 
associated headache presented with migraine, although a wide spectrum of headache 
presentations was observed. The current classification system is useful but 
suggestions for revision have been suggested based on the data. From a clinical 
perspective, pituitary-associated headache appears to be a management problem both 
pre-and post-treatment of the pituitary tumour and warrants further study to optimise 
outcome.
137Somatostatin withdrawal and headache5.1.  Study 4: Somatostatin infusion withdrawal: a study of patients with 
migraine, cluster headache and healthy volunteers
Levy MJ, Matharu MS, Lightman SL, Goadsby PJ 
Paper ref: Pain 2003; 102 (32): 237-242
5.1.2  Abstract
Background'. Migraine and cluster headache are the most common disabling primary 
headache syndromes and are typically episodic. A reliable method of triggering such 
headache attacks facilitates the study and treatment of these disorders. There is 
sufficient clinical and laboratory evidence to suggest that somatostatin withdrawal 
may be a useful way of triggering headache.
Methods:  15 subjects were studied; 8 migraineurs, 4 cluster headache sufferers and 3 
healthy controls. Each subject had a standard somatostatin infusion, 250pg/h for 3.5 
hrs.  Subjects were followed for 24 hours post-infusion to observe headache response 
following cessation of infusion.
Results'. Growth hormone was suppressed in each subject demonstrating a biologically 
active infusion of somatostatin.  None of the non-headache sufferers had pain. Seven 
of eight migraine sufferers had no immediate headache and no delayed headache. One 
migraineur experienced short lasting headache with no migrainous features. Three of 
four patients with cluster headache had no significant pain with the infusion, while 
one had pain after one hour.
Conclusion: The results suggest that somatostatin infusion is not a reliable way to 
produce headache in experimental settings in either migraine or cluster headache. The 
data do not exclude a role for somatostatinergic mechanisms in primary headache.
1395.1.3  Introduction
This chapter utilises the observations that somatostatinergic mechanisms may be 
important in headache. It has been observed in the previous chaper that overuse of 
octreotide in patients with pituitary tumours may give rise to increased headache. An 
interesting question is whether over-exposure to somatostatin may trigger headache in 
patients with primary headache. Migraine and cluster headache are the most common 
disabling primary headache syndromes. In their typical form a key feature of both 
disorders is episodicity (Headache Classification Committee of The International 
Headache Society, 1988). This feature makes the study of these conditions 
particularly challenging. A reliable method of triggering either condition would be, at 
least, extremely useful and may provide insight into the disorder in terms of 
development of new acute attack or preventative treatment strategies.
Nitroglycerin (Thomsen et al., 1994) and histamine (Krabbe et al., 1980; Lassen et al., 
1995) have both been used to induce migraine and cluster headache attacks (Ekbom et 
al., 1968). Patients with migraine develop symptoms usually several hours after 
exposure to nitroglycerin (Iversen, 2001) whilst cluster patients (during a cluster 
period) may have an attack within minutes (Ekbom et al., 1968). A problem with 
these existing models is that the most reliable and best studied model, that of 
nitroglycerin-triggering, is directly associated with vasodilatation (Thomsen et al.,
1994) and thus dissecting the non-vascular mechanisms in these headache types is a 
considerable challenge. It would thus be desirable to have a non-vasoactive method 
for triggering migraine or cluster headache, or both.
The evidence that somatostatin plays an important role in pain modulation has been 
reviewed in the introduction to the thesis. It has been observed that somatostatin, after 
repeated or prolonged exposure, may be pro-nociceptive (Popovic et al., 1988) while 
repeated exposure to somatostatin analogues may lead to a dependency syndrome, 
which is characterised by headache induction and rebound headache (May et al., 
1994). Similarly, cluster headache has been reported to be induced by a somatostatin 
analogue (Otsuka et al., 1998). The administration of native somatostatin to healthy 
individuals causes suppression of growth hormone, which rebounds when it is 
discontinued. Endocrinologists have observed that patients may experience headache
140after somatostatin withdrawal during metabolic studies (S Lightman, unpublished 
observations). I aimed to study systematically the effect of somatostatin withdrawal 
after prolonged intravenous exposure in patients with migraine, cluster headache and 
healthy controls. Headache scores were recorded before, during and after somatostatin 
infusion, in order to determine any correlation between headache and serum growth 
hormone, in an attempt to characterise a new model for triggering primary 
neurovascular headache.
5.1.4  Subjects and Methods
Patients
Fifteen subjects were studied (8 migraine, 4 cluster headache and 3 healthy controls). 
Headache diagnoses were based on International Headache Society Diagnostic 
Criteria (Headache Classification Committee of The International Headache Society, 
2004).  Patients with cluster headache were recruited from the headache clinic (QS). 
Migraineurs and healthy controls were recruited both from the headache clinic and via 
local advertisements The episodic cluster headache patients included in the study 
were in the middle of their bout. All had attacks in the weeks following the trial 
confirming that they were still in the bout at the time of the infusion. None of the 
patients were on preventative medication. Exclusion criteria included diabetes 
mellitus and ischaemic heart disease. The study was approved by the local ethics 
committee (Study Ref: 01 / N062).
Study Design
Patients arrived fasted and an intravenous cannula was inserted in the antecubital vein 
of each forearm. Native somatostatin (Stilamin ®, Serono) was infused at a rate of 
250pg/h for 3 Vz hours, according to previously published protocols (Villaume et al.,
1986). Subjects remained awake and supine throughout the procedure. Serum glucose 
was monitored at 10-minute intervals for the first 30 minutes of the study. No 
hypoglycaemic episodes were recorded and no adverse effects were observed during 
or after somatostatin infusion. A headache visual analogue (VAS) score was taken at 
15-minute intervals throughout the study. Serum growth hormone (GH) was assayed 
at 0, 60, 120 and 180 minutes. After somatostatin infusion withdrawal, the VAS score 
was taken at 5 minute intervals and serum GH taken at 5, 15 and 30 minutes post-
141infusion. Subjects subsequently kept a headache diary for 24 hours and were followed 
up to see if headache occurred after discharge from hospital.
Statistical considerations
The study was designed as a pilot one to consider the utility of somatostatin infusion 
withdrawal in triggering migraine or cluster headache. As such the study was powered 
based on the most reliable method of triggering migraine and cluster headache, which 
is by administration of a nitric oxide donor. The nitroglycerin migraine model 
produces migraine attacks in 90% of patients (Iversen, 2001) while histamine 
infusion, which also acts as an NO donor, produces headache in 100% of patients 
(Lassen et al.,  1995). It was considered that any new model would need to trigger 
attacks in at least 80% of patients to be worth further characterisation. It was thus 
calculated that for 8 patients the study would have an 80% power to detect a 
difference from the NO trigger if  just one were to have migraine with a P < 0.05, 
using a chi-square test. For cluster headache, nitroglycerine has long been known to 
be a very reliable trigger (Ekbom, 1968). It has been shown to trigger 85% of patients 
in their bout to have headache (Matharu and Goadsby, unpublished data). It was 
considered that any new model system that consecutively failed in four patients was 
unlikely to be helpful.
5.1.5  Results
Each subject completed the acute phase of the study and was followed up for at least 
24 hours to determine if any delayed headache had been triggered. The patient 
demographics and headache responses are outlined in Table 28.  Demonstrating that a 
biologically active infusion of somatostatin had been employed, growth hormone was 
appropriately suppressed in all subject groups (Table 29, Figures 17 -  20). There was 
no difference in growth hormone response in all three groups (Figure 20).
Control Group
The control group, volunteers without headache (n = 3) did not develop any 
significant headache symptoms before or after the somatostatin infusion (Figure 21).
Migraine Group
142In the migraine group, 7 of 8 patients had neither an acute headache nor did they 
experience any form of delayed headache. One patient in the migraine group 
developed a mild/ moderate unilateral headache during the infusion that remained 
mild for three hours after the infusion was withdrawn and subsequently subsided 
(Figure 22). This headache had no migrainous features.
Cluster Headache Group
Of the cluster headache patients, 3 of 4 patients had no immediate nor any delayed 
attacks after the somatostatin infusion. One patient in the cluster group developed an 
attack during the first hour of the infusion (Figure 23). This was aborted with 100% 
oxygen within ten minutes and did not return. One patient had an attack at 2am, 17 
hours after the infusion that was in keeping with his typical attack periodicity.
There was no correlation between headache score and growth hormone for all three 
groups (Pearson correlation 0.91; p=0.357: Figure 24)
143Table 28. Patient demographics and headache response to somatostatin infusion
t a A * Hendnche Score (O-10) with somatostatin lafjrtw
Omin 60min 120min 180m  in +5min +15min +30min
Migraine with 
aura
M 40 0 2 1 0 0 0 0
F 29 0 0 0 0 0 0 0
Migraine without 
aura
M 24 0 1 0 0 1 0 0
F 41 0 0 0 1 0 0 0
F 37 0 0 0 0 0 0 0
F 37 0 0 1 0 0 0 0
M 44 2 4 5 5 5 5 5
F 39 0 1 0 0 1 0 0
Chronic cluster
M 53 0 7 0 0 0 0 0
Episodic cluster
M 47 2 3 3 4 4 0 0
M 36 0 0 0 0 0 0 0
M 33 0 0 0 0 0 0 0
Controls
M 32 0 0 0 0 0 0 0
M 33 0 0 0 0 0 0 1
M 54 0 0 0 0 0 0 0
•Clinical phenotype according to International Headache Society (1988)
144Table 29. GH response to somatostatin infusion
DtagpMMls* Growth HonuuNM response to iNMtoatdfai (mU/L)
0 min 60  min 120 min 180min +5min +15min +30min
Migraine with aura 8.3 0.5 0.1 0.1 0.1 0.1 0.1
0.2 0.1 0.2 0.2 0.2 0.3 0.3
Migraine without aura
0.6 0.1 0.1 0.1 0.3 0.3 0.3
11.9 0.6 0.4 0.3 0.3 4.0 5.4
0.6 0.1 0.1 0.1 0.1 0.2 0.2
21.6 1.0 0.4 0.3 0.4 1.4 9.6
2.1 2.1 1.0 0.1 0.1 0.2 0.2
22.9 1.1 0.5 0.3 0.3 1.0 1.2
Chronic cluster
0.8 0.4 0.2 0.1 0.1 0.1 0.1
Episodic cluster
0.2 0.9 0.2 0.1 0.1 0.2 0.2
0.2 0.1 0.1 0.1 0.1 0.6 1.2
11.9 0.4 0.1 0.1 0.1 0.2 0.2
Controls
3.1 0.1 0.1 0.1 0.1 0.1 0.1
0.6 0.6 0.3 0.2 0.2 0.8 0.9
0.2 0.1 0.1 0.1 0.1 0.2 0.2
"Clinical phenotype according to International Headache Society (1988)
145Figure 17. Effect of somatostatin on GH. Control Group
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Figure 18. Effect of somatostatin on GH. Migraine Group.
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Figure 19. Effect of somatostatin on GH. Cluster Group.
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Figure 20. Effect of somatostatin on GH. Group Data.
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149Figure 21. Effect of somoatostatin on headache. Control Group.
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Figure 22. Effect of somatostatin on headache. Migraine Group.
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1535.1.6  Discussion
This study demonstrated no significant headache triggering, either immediate or 
delayed, in patients with migraine or cluster headache, and no headache in control 
subjects. Significant growth hormone suppression confirmed biologically active 
somatostatin was infused and an appropriate physiological response obtained. 
Although one patient in the migraine group and one patient in the cluster headache 
group had acute pain this response rate is markedly less than that seen with 
nitroglycerine triggering (Iversen, 2001) and is therefore not considered to be a 
sufficiently robust response in comparison with nitroglycerin or histamine. Whether 
that small response represents chance or a biological effect, it is of no value in terms 
of studying either migraine or cluster headache. The data suggest that somatostatin is 
not a useful substance in trying to establish a non-vascular migraine-triggering model, 
although the results do not exclude a role for somatostatin in primary headache.
Somatostatin has a peripheral endocrine effect of lowering first glucagon, and then 
insulin, as well as its central effect on GH suppression. It is possible that previous 
observations of headache induction after somatostatin infusion were related to 
hypoglycemia and peripheral insulin levels rather than a mechanism related to GH 
secretion. Hypoglycaemia is a recognised trigger for migraine in clinical practice 
(Lance and Goadsby, 1998) and there has been interest in the relationship between 
insulin and migraine (Pearce, 1971). Recent evidence points to a genetically 
determined predisposition to hypoglycemia as a trigger factor for migraine with the 
identification of single-nucleotide polymorphism alleles in the insulin receptor in 
some patients with migraine (McCarthy et al., 2001). None of the patients in this 
study developed hypoglycaemia during the somatostatin infusions.
The observation of octreotide dependent headache suggests that up-regulation of 
somatostatin receptors is in some way pro-nociceptive (May et al., 1994) and the 
reciprocal relationship between somatostatin and growth hormone may suggest that 
GH, or some other signalling molecule related to its secretion, is important in the 
relationship between somatostatin and pain. Case 3 in the Appendix (Levy et al., 
2003b) describes a patient whose headache responded only to octreotide, despite GH 
reduction with both octretide and lanreotide, and indicates that the relationship
154between somatostatin and pain is not exclusively related to GH. The absence of a 
correlation between headache score and GH in this study further suggests that 
somatostatin and GH are not coupled in terms of analgesia.
This study demonstrates that somatostatin infusion-withdrawal alone is not a 
sufficiently robust stimulus to produce headache. Although I studied a relatively small 
number of patients the induction rate, particularly in migraine, could not be large 
enough to be experimentally useful. The role of somatostatin in headache remains to 
be elucidated, but the anatomical distribution of its receptors strongly supports a role 
for this peptide in headache. The following chapter investigates the possibility that the 
acute use of somatostain analogues may be effective in aborting primary headache.
1556.Octreotide and primary headache6.1.  Study 5a: Octreotide is not effective in the acute treatment of 
migraine attacks
Levy MJ, Matharu MS, Bhola R, Meeran K, Goadsby PJ 
Paper ref: Cephalalgia 2004; 24
6.1.1  Abstract
Objective: To determine whether subcutaneous octreotide is an effective treatment for 
acute migraine.
Methods: Patients with migraine with and without aura as determined by the 
International Headache Society were recruited to a double-blind placebo-controlled 
crossover study. Patients were instructed to treat two attacks of at least moderate pain 
severity, with at least a seven-day interval, using 100 pg octreotide or matching 
placebo. The primary endpoint was the headache response defined as: severe or 
moderate pain becomes mild or nil, at 2 hours. The primaiy endpoint was analysed 
using a Multilevel Analysis approach. Secondary end-points included associated 
symptoms and a four-point functional disability score. The study was powered to 
detect a 30% difference at an a of 0.05 and a p of 0.8.
Results'. A total of 51 patients were recruited, of whom 42 provided efficacy data on 
attacks treated with octreotide and 41 with placebo. Modelling the treatment outcome 
as binomial where response was determined by treatment, using the patient as the 
level 2 variable, and considering a possible period effect, and sex and migraine type 
as other variables of interest, the effect of subcutaneous octreotide was not 
significantly superior to placebo. The two hour headache response rates were 20% for 
placebo and 14% for octreotide, whilst the two hour pain free rates were 7% and 2%, 
respectively.
Conclusions: Subcutaneous octreotide 100 pg is not effective in the acute treatment of 
migraine when compared to placebo.
1576.1.2  Introduction
The data in Chapter 4 support the generally accepted view that octreotide has 
analgesic properties in pituitary tumours. This Chapter investigates the possibility that 
octreotide may be helpful in primary headache. The aim of Study 5a was to test the 
hypothesis that octreotide might be effective in the acute treatment of migraine. 
Although a large number of different triptans, serotonin 5-HTiB /iD-agonists, have 
become available since the discovery of sumatriptan (Ferrari et al., 2001) there is still 
a need for new classes of abortive agents for migraine. Triptans are contra-indicated 
in patients with vascular disease, and a group of patients experience universally 
unacceptable side effects on these agents (Nappi et al., 2003) necessitating the 
development of novel drugs for migraine. Moreover, many patients overuse 5- 
HTiB/iD-agonists (Silberstein and Liu, 2003) particularly those with long-lasting 
attacks and headache recurrence, and it is desirable to have more than one 
pharmacological approach to prevent overuse of a single class of drug.
The involvement of neuropeptides in migraine has been reviewed in Sections 1.11- 
1.14. The apparent efficacy of CGRP receptor antagonists as abortive agents for 
migraine (Moreno et al., 2002; Olesen et al., 2004) suggests that the inhibition of 
nociceptive peptides may be a useful therapeutic approach for migraine. Although 
substance-P receptor antagonists have proved ineffective in trials of both acute 
(Goldstein et al.,  1997; Diener, 2003; Shepheard et al., 1995; Connor et al., 1998; 
Norman et al., 1998) and preventive (Golstein et al., 2001) migraine management, 
inhibitory effects have been observed on animal models of trigeminal nociception 
(O'Shaughnessy and Connor, 1994; Polley et al., 1997). As discussed in Section 1.15, 
somatostatin is known to have inhibitory effects on a range of neuropeptides, 
including substance P (Ferrar et al., 1990), CGRP (Helyes et al., 2001) and VIP 
(Fassler et al.,  1990), and it has been proposed that somatostatin may be a potential 
pharmacological target for the acute treatment of migraine (Selmer et al., 2000). 
Because native somatostatin is an unstable compound, being broken down by 
endogenous peptidases within a few minutes (Harris, 1994), octreotide, which has a 
half-life of approximately 1.5 hours (Harris, 1994), is an attractive compound to study 
in patients with migraine. In a placebo controlled trial of 29 patients, Kapiciolgu et al. 
(1997) demonstrated that subcutaneous administration of 100 pg octreotide gave
158headache relief in 77%, compared to 25% of a parallel placebo-treated group. Despite 
these findings, no other group has investigated the potential use of somatostatin 
analogues in migraine. Sicuteri et al. (1984) and Geppetti et al. (1985) found 
intravenous infusion of somatostatin to be as effective as ergotamine in the acute 
treatment of cluster headache, although this again has not been systematically further 
studied and the trial was not sufficiently powered.
As has been reviewed in Section 1.15.2 and Study 4, the analgesic effect of octreotide 
in acromegaly is well recognised but there are few data regarding its role in primary 
headache. The onset of octreotide analgesia in acromegaly is more rapid than the 30 
minutes required for growth hormone suppression (Chanson et al., 1993), which 
suggests that octreotide may have a direct anti-nociceptive property. The distribution 
of sst2a within the central nervous system strongly suggests that this particular 
somatostatin receptor has a role in cranial nociception, being highly expressed in the 
trigeminal nucleus caudalis and periaqueductal gray (Schindler et al., 1998). 
Octreotide has particular affinity for the sst2a receptor, which may explain its apparent 
anti-nociceptive action (Schindler et al., 1998).
I sought to verify Kapigioglu et al.’s finding that octreotide is an effective agent for 
the acute treatment of migraine by studying a larger group of patients in a double­
blind placebo controlled cross-over study. I used the more broadly accepted end point 
of the 2-hour response rate since patients desire quick relief of symptoms (Davies et 
al., 2000).
6.1.3  Subjects and Methods
Men or women between 18 and 65 years of age were recruited for the study, the 
majority of patients responding to trial advertisements published in patient 
information newsletters (The Migraine Trust and Migraine Action Association). All 
patients interested in the study underwent an initial telephone interview, followed by a 
detailed face-to-face clinical interview, in order to confirm the diagnosis of migraine 
with or without aura as defined by the International Headache Society (Headache 
Classification Committee of the International Headache Society, 1988).
159Exclusion criteria included pregnancy and lactation; analgesia or triptan overuse; 
frequent tension-type headaches (> 10 days/ month); inability to distinguish between 
tension-type or migraine headache; diabetes mellitus; or a coexisting condition that 
might expose the patients to a disproportionately increased risk of a significant 
adverse event: ischaemic heart disease, peripheral vascular disease, cerebrovascular 
disease, uncontrolled hypertension (blood pressure > 160/95), epilepsy, use of 
cimetidine, dopamine agonists, cyclosporine or oral hypoglycaemic agents, renal or 
hepatic impairment. The study was performed in accordance with the ethical 
principles of the Declaration of Helsinki, and was given local ethical committee 
approval (Ref 00/N117), as well as Medicines Control Agency (MCA) approval for 
the administration of octreotide as part of a clinical trial.
Design
The design was a randomised, double-blind, placebo-controlled, single-centre two- 
attack crossover study, involving patients with acute migraine headache of moderate 
to severe intensity. Octreotide was kindly donated for the purposes of the trial by 
Novartis. Octreotide and placebo were packaged into identical pre-filled vials at The 
Royal Free Hospital pharmacy. All drugs were kept refrigerated in the National 
Hospital for Neurology and Neurosurgery (NHNN) pharmacy department for the 
duration of the trial. Normal saline was used as placebo and the dose of octreotide was
100 pg.
At the first visit, patient eligibility for the study was confirmed and a physical 
examination was performed. Patients who met the inclusion criteria and were willing 
to participate in the study signed consent agreements authorized by the local ethics 
committee (NHNN).
Study medication and placebo were provided in two identical pre-filled vials, each 
containing lmL of fluid. The vials were labelled Treatment 1  and Treatment 2 for 
self-administration during a first and second headache attack respectively, each attack 
being separated by a minimum of 7 days. The order of active treatment and placebo 
was randomised by NHNN pharmacy, and each participant was assigned a 
randomisation number. The code was held by the pharmacy until study completion
160and database locking.  All patients were counselled how to draw up the treatment with 
a lmL syringe and taught how to give a self-administered subcutaneous injection. 
Participants were given the opportunity to practice the injection in supervised 
conditions during this visit in order to build up confidence. A help line was provided 
to patients to ring if they experienced trouble during the trial.
Efficacy Assessments
Patients were asked to complete forms during both treatments at home and to report to 
the investigator (the candidate) within 48 hours of completing both treatments. 
Headache severity was measured on a 4-point scale (0 = no pain; 1  = mild pain; 2 = 
moderate pain; 3 = severe pain) at 0 minutes, 30 minutes, 1  hour, 2 hours, 4 hours and 
24 hours after study intake. The primary end points for clinical efficacy were the 
relief of headache, from grade 3 or 2 to grade 1  or 0, within 2 hours after injection for 
consistency with recent development programmes in acute migraine (Pilgrim, 1991). 
Additional efficacy measures included headache free rate, functional disability (4 - 
point scale) and the presence or absence of nausea, vomiting, photo- or phonophobia, 
all of which were monitored for 24 hours.  Rescue medication was permitted 2 hours 
after the intake of study medication if the headache still required treatment. Ergots 
and triptans were accepted as rescue medication. Adverse effects were documented on 
the forms provided after both injections.
Statistical Analysis
The primary efficacy analysis was based on the number of patients who obtained 
relief from grade 3 or 2 to grade 1  or 0 within 2 hours of treatment. Assuming a 
treatment difference between placebo and active of 30% based on subcutaneous 
sumatriptan and placebo response rates (Pilgrim, 1991) it was calculated that 42 
patients were needed for the trial to have an 80% power to detect a difference at an 
a of 0.05 (Sample Power SPSS Inc.).
The outcome data were to be treated as binary: headache response or none at 2 hours. 
Because the trial was a cross-over study, attacks 1  and 2 were not truly independent 
because the patients remained the same, a multivariate analysis approach was
161employed using the software that has been developed by the Multi-level Project, 
MlwiN (available at www.ioe.ac.uk/multilevel: Van Vliet et al., 2003).
6.1.4  Results
A total of 51 patients were recruited, 2 men and 49 women, with a mean age of 48 ± 
12 years (mean  ±  SD). Patient demographics are shown in Table 30.
Disposition of  patients
Of the 51 patients recruited, 8 withdrew before completion of the study; one was 
unable to co-ordinate self-injection during a migraine attack, and seven were lost to 
follow up; whether they treated or did not treat attacks is not clear. I have treated them 
as if they did not treat any attacks. One patient was excluded from the first arm of the 
trial, and two from the second arm because of protocol violation (Figure 25).
Clinical  features of  study cohort
Of the 43 patients that successfully completed the study, the frequency of attacks 
included 4-10 per month (35%),  1  - 3 per month (60%) and < 1  per month 
(5%). The mean duration of attack was 53 ± 4.3 hours. Of the group, 33 (77%) had 
migraine without aura and 10 (23%) had migraine with aura. Thirty-eight (88%) had 
previously used 5-HTiB/iD-agonists for treatment of acute attacks, of which 28 (74%) 
experienced meaningful response within 2 hours.
Overall Efficacy
The primary endpoint of the study was the combined, attack 1  and 2, headache 
response rate to octreotide at 2 hours compared to placebo. The Wald test was not 
significant for the overall regression, suggesting that there was no difference between 
octreotide and placebo even accounting for treatment order, sex, or migraine type.
Efficacy Results
In total, 42 attacks were treated with octreotide and 41 attacks with placebo. In the 
octreotide-treated attacks, 6 patients reported headache relief at 2 hours (14%), 
compared to 8 (20%) in the placebo group.
162One patient was rendered pain-free at 2 hours with octreotide (2. 4 %), whilst 3 
patients were rendered pain-free with placebo (7. 3 %).
The 2 hour- and pain-free response rates are shown in Table 31. Mean pain scores at 
each time interval are shown in Table 32.
Associated symptoms and  functional score
To evaluate the associated symptoms, only patients who had the symptoms during an 
attack were included in the analysis. Octreotide performed less well than placebo for 
nausea, photophobia, phonophobia and aggravation with movement (Figure 26). 
There was no difference in functional disability scores between either group at any of 
the time points post-treatment (Table 32).
Escape Medication
The frequency of the use of escape medication was no different in the octreotide- 
treated attacks compared to those treated with placebo: 35 (83%) vs 33 (80%) as 
shown in Table 33.
Tolerability
No serious adverse events were reported in either the octreotide- or placebo-treated 
attacks. Four patients experienced diarrhoea with octreotide, and one patient 
experienced increased sweating, and another excessive nausea with octreotide, in 
comparison with their normal attacks. With placebo, one patient reported diarrhoea, 
one patient experienced light-headedness, and two patients reported excessive 
tiredness after injection.
163Table 30. Demographic data and migraine characteristics
Characteristic Patients
n = 43 (%)
Age, years (mean ± SD) 48 ± 12
Gender n  (%)
Male 2(5)
Female 41 (95)
Type of migraine n (%)
MWOAt 33 (77)
MWAft 10(23)
Frequency of attack per month n (%)
Daily 0
4-10 15(35)
1-3 26 (60)
<1 2(5)
Mean duration of attack ± SD (hours) 53 ± 4.3
Previous 5-HTIB/|D -agonist use 38 (88)
Meaningful response to 5-HTie/iD-agonists 28(74)
t  MWOA : migraine withont aura
ft  MWA : migraine with aura
164Figure 25. Disposition of patients in study
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165Table 31. Two hour- and pain free- response rates
Groups Not inproved at 2 
boors (%)
Haadacbo Response of 
2 hoorst (%)
Pate-fr«tat2
bounft(%)
Total no. 
trestmrntu
Placebo 33 (81) 8(20) 3(7) 41 (49)
Octreotide 36 (86) 6(14) 1(2) 42 (51)
Total 69 (83) 14(17) 4(5) 83 (100)
t   Headache response: relief of headache from moderate / severe/ excruciating pain to nil or mild pain
t t   Pain free: relief of headache from moderate / severe/ excriciating pain to no pain
Table 32. Mean pain and functional disability scores (0-3)
Group 0 urinates 120 minutes 240nrinutes 24 boors
Pain Score
Placebo 2.3 ± 0.5 2.2 ± 1.0 2.0 ± 1.0 1.3 ± 1.2
Octreotide 2.3 ± 0.6 2.2 ± 0.8 2.0 ± 1.0 1.2 ± 1.1
Functional Score
Placebo 1.6 ± 1.0 1.9± 1.1 1.7 ± 1.2 1.0± 1.1
Octreotide 1.5 ±0.9 1.9 ± 1.0 1.7 ± 1.0 1.4 ± 1.2
166Table 33. Escape medication use
Octreotide
n (%)
Placebo
n (%)
Escape medication used 35 (83) 33 (80)
Escape medication not used 7(17) 8(20)
Total 42(100) 41 (100)
Figure 26: Percentage of patients reporting persistent associated symptoms at 2 hours
octreotide
nausea  photophobia  phonophobia  aggravation with
movement
Secondary end point at 2 hours6.1.5  Discussion
Contrary to previous reports, the results of this study do not show a difference 
between 1  OOpg octreotide and placebo in the acute treatment of migraine. I did not 
find octreotide to be superior to placebo for relief of headache, associated symptoms 
or functional disability scores.
It is not clear why these findings are so different to the previous study (Kapicioglu et 
al.,  1997). The placebo response rate of 20% is not different from the 25% placebo in 
the previous study (Kapicioglu et al., 1997) suggesting that there was little difference 
in the patient population group in terms of migraine characteristics. However, the 
relatively low placebo response rates in both studies suggest that there may have been 
a selection bias towards a group of patients with difficult migraine (Jhee et al., 1998). 
This seems likely given that patients who volunteered were willing to have an 
injection for their migraine attacks. The mean attack duration in the study group was 
2.2 days, which is longer than that seen in population studies (Koseoglu et al., 2003). 
Despite this, 74% of patients reported a useful response with 5-HTib/iD-agonists, 
suggesting that this study did not recruit a particularly pharmacologically refractory 
group of patients.
In the previous study (Kapicioglu et al., 1997) the primary efficacy end-point was 
response rate at 6-hours (76%), compared to the end-point of response rate at 2 hours 
in this study (14%). Although response rates at 2 hours were not provided by 
Kapiclioglu et al., a statistically significant difference in pain scores at 2 hours (1.5 v 
2.2; p < 0.01) was reported, suggesting an analgesic action at this earlier time point. 
Conversely, there was no difference between octreotide and placebo at 6 hours (Table 
33), suggesting that the superior response rates observed in the earlier study were not 
related to the difference in time-to-headache relief used in the two studies. It is 
generally considered that if an acute treatment for migraine is to be useful in clinical 
practice, it should have an effect within 2 hours (Geraud et al., 2000). For an 
injectable treatment this is considered slow, so my primary end point could be 
considered generous.
168The study by Kapigioglu et al. (1997) did not have a cross-over design, so it is 
possible that the excellent response rate they found in the treatment group was due to 
a difference in migraine characteristics from the placebo-treated group. My study had 
a cross-over design to avoid this possible confounder. The previous study (Kapicioglu 
et al.,  1997) did not give outcome data for the secondary end-points of associated 
symptoms or functional ability scores, although my findings were negative. The 
gastro-intestinal side effects observed in five patients in response to 100 pg octreotide 
in our study is in keeping with the reported experience of side effects on this dose 
(Plockinger et al., 1990). The same dose of octreotide was used as in the previous 
study (Kapicioglu et al., 1997) suggesting that the difference in observed response is 
not dose-related.
Although the findings were negative, the somatostatin receptor remains a theoretically 
attractive pharmacological approach to primary headache management. As discussed 
in Section 1.15.1, there are in vivo animal data to suggest that the central 
administration of somatostatin and its analogues results in anti-nociception, both in 
peripheral (Helmchen et al., 1995) and trigeminal (Bereiter, 1997) pain models. In 
conjunction with the localisation of somatostatin receptors (particularly sst2) in the 
trigeminal nucleus caudalis and periaqueductal gray (Schindler et al., 1996) these 
findings suggest that drugs acting on the somatostatin receptor remain realistic 
therapeutic options. It is possible that octreotide needs to cross the blood-brain barrier 
to have an effect in primary headache, whilst it may not need to do this to be analgesic 
in pituitary tumour-associated headache. If this is the case, octreotide may simply be 
the wrong compound due to its non-lipophilicity and apparent poor ability to cross the 
blood-brain barrier (Kitazawa et al., 1998; Schmidt et al., 1998). It is necessary to 
develop a somatostatin analogue with good brain access to test the somatostatin 
theory completely. Novel somatostatin analogues with differing receptor affinities are 
currently being developed for the treatment of functional pituitary adenomas (Shimon 
et al.,  1997). Some of these compounds are particularly avid for the sst2 receptor, 
making them potential targets for analgesic agents (Saveanu et al., 2002). The central 
nervous system permeability of these new agents has not yet been determined, 
although they present attractive compounds to study for future clinical and non- 
clinical trials as regards primary headache and requires further study.
1696.2.  Study 5b: subcutaneous octreotide is effective in the treatment of 
acute cluster headache
Matharu MS, Levy MJ, Meeran K, Goadsby PJ.
Abstract ref: Cephalalgia (2003) 23: 687. 6.4 
Paper ref: Annals of Neurology 2004 (in press)
6.2.1  Abstract
Objective: To determine whether subcutaneous octreotide is an effective treatment for 
acute cluster headache.
Methods:  Patients with episodic and chronic cluster headache, as defined by the 
International Headache Society, were recruited to a double-blind placebo-controlled 
crossover study. Patients were instructed to treat two attacks of at least moderate pain 
severity, with at least a 24 hour break, using subcutaneous octreotide lOOpg or 
matching placebo. The primary endpoint was the headache response defined as: very 
severe, severe or moderate pain becomes mild or nil, at 30 min. The primary endpoint 
was analysed using a Multilevel Analysis approach.
Results: A total of 57 patients were recruited of whom 46 provided efficacy data on 
attacks treated with octreotide and 45 with placebo. The headache response rate with 
subcutaneous octreotide was 52 % while that with placebo was 36 %. Modelling the 
treatment outcome as a binomial where response was determined by treatment, using 
the patient as the level 2 variable, and considering period effect, sex and cluster 
headache type as other variables of interest, the effect of subcutaneous octreotide 
1  OOpg was significantly superior to placebo (P < 0.05).
Conclusions: Subcutaneous octreotide 100 pg is effective in the acute treatment of 
cluster headache when compared to placebo.
1706.2.2  Introduction
The previous study (5a) found octreotide to be ineffective in the acute treatment of 
migraine. The current study investigates the possibility that octreotide may be helpful 
for the acute treatment of cluster headache (CH). As described in Section 1.5.1, CH is 
the most severe form of primary neurovascular headache. It is characterized by 
excruciating pain lasting 15 to 180 minutes (Headache Classifacation Committee of 
The International Headache Society, 2004). Controlled evidence exists to treat acute 
attacks of CH with oxygen inhalation (Fogan, 1985), intranasal (van Vliet et al., 2003) 
and injectable (Ekbom, 1991) sumatriptan, high dose oral zolmitriptan (Bahra et al., 
2000) and intranasal dihydroergotamine (Andersson & Jesperson, 1986). An 
unequivocally non-vasoconstrictor treatment for acute CH is not available. Ergots and 
triptans are contraindicated in patients with vascular disease and therefore caution 
must be exercised in patients with CH since the disorder predominates in middle-aged 
men, who often have risk factors for cardiovascular disease, particularly smoking 
(Manzoni et al.,  1983). There is, therefore, a compelling need to develop new 
pharmacological approaches to CH, particularly if possible approaches without 
vascular effects, in order to effectively and safely manage these patients. Moreover, 
the question of whether a non-vasoconstrictor approach might be effective would 
offer a fundamental insight into the more generic issue of whether CH is a vascular of 
central nervous system disorder.
As described in Sections 1.11 and 1.14, an acute cluster attack is associated with the 
release of calcitonin gene related peptide (CGRP) and vasoactive intestinal 
polypeptide (VIP), while triptans, serotonin 5-HT-ib/idagonists, attenuate the levels 
of these neuropeptides during successfully treated attacks, thereby implying that the 
inhibition of these neuropeptides is an important mechanism for aborting a cluster 
attack (Goadsby & Edvinsson, 1994; Fanciullacci et al., 1995). Therefore, octretotide 
is an attractive compound to investigate, for the same reasons as described in the 
previous migraine study.
Only two previous studies have been performed which have looked at the potential 
benefits of octretoide in CH. In the first study, intravenous somatostatin (25 pg/min 
for 20 minutes) was compared to treatment with ergotamine (250 pg intramuscularly),
171or placebo in a double-blind trial comprising 72 attacks in 8 patients (Sicuteri et al.,
1984).  Infusion of somatostatin reduced the maximal pain intensity and the duration 
of pain significantly compared to placebo, and to a degree comparable to 
intramuscular ergotamine. In another randomized, double-blind study subcutaneous 
somatostatin was compared with ergotamine (Geppetti et al., 1985).  Five patients 
were treated for three attacks by each of the drugs.  Subcutaneous somatostatin and 
ergotamine were equally beneficial as regards effects on maximal pain intensity and 
the pain area, but somatostatin was less effective in reducing the duration of pain. 
This limited evidence of the beneficial effect of somatostatin needs to be explored 
further in properly controlled and adequately powered studies.
The aim of the current study was determine whether octreotide is an effective abortive 
agent for the acute treatment of CH.
6.2.3  Subjects and Methods
Patients
Men or women between 18 and 65 years of age with an established diagnosis of CH, 
according to the International Headache Society (Headache Classification Committee 
of the International Headache Society, 2004), were recruited for this single centre 
study. Patients were required to have CH attacks of at least 45 minutes duration when 
untreated. The ethical considerations and exclusion criteria are the same as for the 
migraine study (Study 5a).
Design
This was a randomised, double-blind, two-attack, crossover study of 100 pg 
subcutaneous octreotide and matching placebo. The packaging and storage of 
octreotide and placebo, and patient education regarding self-injection was identical to 
the migraine study. Patients were asked to treat two attacks at least 24 hours apart 
with either octreotide or matching placebo in a randomised order. They were 
instructed to grade attacks on an ordinal categorical (five-point) scale of none, mild, 
moderate, severe or very severe (Pilgrim,  1991). Subsequent assessments were at 5, 
10,  15, 20, 30 and 60 minutes. Escape medication was allowed at 30 minutes post-
172dose, usually injectable or intranasal sumatriptan, oxygen or analgesic, but not an 
ergotamine derivative.
Efficacy Assessments
The primary outcome measure was headache severity at 30 minutes, a reduction in 
headache from moderate, severe, or very severe to nil or mild. Secondary outcome 
measures included the percentage of patients headache-free at 30 minutes, rate of 
relief of associated symptoms, time to initial relief and rate of meaningful relief. 
Associated symptoms, such as vomiting, nausea, photophobia, phonophobia, 
lacrimation, nasal congestion, and other autonomic features, were recorded 
immediately before treatment and at 30 minutes. Initial relief was defined as the time 
that a patient recorded any headache relief. Patients were asked if they considered the 
response at 30 minutes meaningful.
Statistical Analysis
Using the results of a crossover study of subcutaneous sumatriptan versus placebo, 
and assuming a treatment difference between placebo and active of 30%, it was 
calculated (using Sample Power) that 42 patients were needed for the study to have an 
80% power to detect a difference at an a of 5%. The outcome data were treated as 
binary: headache response or none at 30 minutes. As for study 5a, the effect of active 
treatment and attack order was examined, as well as other variables of interest, such 
as sex, site, and CH type. Considering that attacks 1  and 2 are not strictly independent 
because the patients remain the same, a multilevel multivariate analysis was employed 
using the software that has been developed by the Multilevel Project, MlwiN 
(available at www.ioe.ac.uk/mulitlevel: Van Vliet et al., 2003).
1736.2.4  Results
A total of 57 patients were recruited, 45 men and 12 women, with a mean age of 40 ± 
10 years (mean ± SD).
Disposition of  patients
Of the 57 patients recruited, six came to the end of the bout before completing the 
study; one of these treated the first attack. Two patients withdrew before treating any 
attacks, and two were lost to follow up; whether they treated or did not treat attacks 
was not clear, and they have been treated as if they did not treat any attacks. Two 
attacks of mild severity were treated, and prior to the treatment of two attacks the 
syringe malfunctioned hence the patients were unable to treat the attacks; these four 
attacks were excluded from the analysis. Use of escape medication before 30 minutes 
after treatment was reported in five attacks, which were scored as outcome failures 
(Figure 27).
Clinical  features of  study cohort
The mean duration of CH history was 14 ± 9 years (mean ± SD). Forty-one patients 
had episodic CH, fifteen had chronic CH, and one was unclassifiable because it was 
the first bout. The average bout length of the patients with episodic CH was 9 ± 5 
weeks (mean ± SD). The average attack duration at recruitment was reported by 
patients to be 107 ± 75 minutes (mean ± SD). Thirty-seven patients had previously 
used sumatriptan injection, of whom 36 were responsive; 25 had used intranasal 
sumatriptan, of whom  16 were responsive; 38 had used oral sumatriptan, of whom 12 
were responsive. In terms of previous use of oxygen, 15 had used high dose and high 
flow oxygen, of whom 9 were responsive; 9 used low dose or low flow rate oxygen, 
of whom 4 were responsive.
Overall efficacy
The primary endpoint of the study was the combined, attack 1  and 2, headache 
response rate at 30 minutes compared to placebo. The Wald test was significant for 
the overall regression (x2= 14.1, P = 0.007) with only the treatment term being
174significantly different from zero. There was no significant effect of treatment order, 
cluster headache type and gender.
Efficacy Results
In total, 46 attacks were treated with octreotide and 45 with placebo. In the octreotide- 
treated attacks, 24 patients reported headache relief at 30 minutes (52 %) compared to 
16 (36 %) patients who treated an attack with placebo (Table 35). Fifteen patients 
were pain-free at 30 minutes (33 %) when treated with octreotide, compared to 6 (13 
%) when the attack was treated with placebo (x2 = 9.8, P = 0.04; Figure 28).
Associated symptoms
To evaluate the associated symptoms, only patients who had the symptom 
immediately before treatment were included in the analysis. Conjunctival injection, 
lacrimation, nasal congestion, rhinorrhoea, ptosis, eyelid oedema and photophobia 
were the most frequently mentioned. In the attacks treated with octreotide, more 
patients experienced relief from associated symptoms at 30 minutes (Figure 29).
Time to Initial Relief
The mean time to initial relief in the octreotide-treated group was 18.3 ± 8.9 minutes, 
compared to 18.1 ± 7.0 minutes in the placebo-treated group.
Meaningful relief
Patients were asked if they thought the CH attack was adequately treated at 30 
minutes. Seventeen (37 %) patients who treated an attack with octreotide reported 
meaningful relief, compared to 13 (29 %) patients who had treated an attack with 
placebo.
Escape Medication
The frequency of use of escape medication was lower in octretide-treated attacks 
compared to those treated with placebo; 20 (44%) vs 25 (56%).
175Tolerability
No serious adverse effects were reported with either the octreotide- or placebo-treated 
attacks. Eight patients treated with octreotide (17 %) reported minor gastrointestinal 
disturbance, including nausea, abdominal bloating and diarrhoea, compared with 4 
patients (9 %) treated with placebo. The adverse events are shown in Table 36. All 
resolved spontaneously and were generally short-lived and mild in nature.
176Table 34. Demographic data and cluster headache characteristics
Characteristic Patients n = 57 (%)
Age, years (mean ± SD) 40 ± 10
Gender, n (%)
Male 45 (79)
Female 12 (21)
Type ofCH, n (%)
Episodic 41 (72)
Chronic 15 (26)
Unclassifiable 1 (2)
Mean attack duration ± SD (minutes) 107 ±75
45-60 21 (37)
61-90 14 (25)
91 -  180 16 (28)
> 180 6 (11)
Mean bout duration ± SD (weeks) 9 ±5
Length of  history ± SD (years) 14 ±9
177Figure 27. Disposition of patients in study
cross-over
Placebo
n=22
End of bout 
n=0
Octreotide
n=22
Octreotide
n=20
Placebo
n=21
Excluded protocol violator 
n=l
Octreotide
n=22
Excluded protocol violator 
n=2
End of bout 
n=l
Octreotide
n=26
Placebo
n=24
Placebo
n=25
Octreotide
n=26
Placebo
n=26
Excluded protocol violator 
n=l
Excluded protocol violator 
n=0
Total included 
n=57
Total treated first attack 
n=48
Excluded n=9 
(Withdrew 2; End of bout 5; Lost to follow-up 2)
178Table 35. Efficacy of octreotide and placebo
Groaps Not improved at 36 
minntes (%)
Headache Retpomet *t 
36 minntes (%)
Pata-fireett at 36 
minutes (%)
Total no. 
treatments
Placebo 29 (64) 16(36) 6(13) 45 (49)
Octreotide 22 (48) 24 (52) 15(33) 46 (51)
Total 51 (56) 40 (44) 21 (23) 91 (100)
t   Headache response: relief of headache from moderate / severe/ excruciating pain to nil or mild pain
t t   Pain free: relief of headache from moderate / severe/ excriciating pain to no pain
179Figure 28. Efficacy of octreotide versus placebo in cluster headache
70 1 
60  -
Headache Response  Pain Free
Efficacy:  headache  response  (a  reduction  of headache  intensity  from  very  severe, 
severe or moderate to mild or no pain) and pain-free rates (no pain) at 30 minutes 
after treatment with octreotide (■) versus placebo (■). ** P < 0.01; * P < 0.05.
180Table 36.  Advese events amongst patients treated with octreotide and placebo
Adverse Event Octreotide Placebo
Diarrhea, Abdominal bloating or Nausea 8 4
Dull background headache 3 1
Lethargy 2 1
Injection-site reaction 2 1
Dizziness 1 0
Loss of libido 1 0
Facial Flushing 1 0
181Figure 29. Percentage improvement in associated symptoms at 30 minutes
100  -
80  -
c«  60  -
B
.a
Conjunctival  Lacrimation  Ptosis  Eyelid  Nasal  Rhinorrhoea  Photophobia
injection  oedema  blockage
■ Octreotide
■ Placebo
* Only patients with symptoms at baseline were included. Because of multiple- 
comparison issues, no statistical analysis was performed.
1826.2.5  Discussion
This is the first placebo-controlled trial investigating the potential use of octreotide in 
the treatment of acute cluster headache attacks.  It demonstrates that octreotide is 
effective and well tolerated in cluster headache attacks that normally last longer than 
45 minutes. Headache response within 30 minutes was reported in 52% of the attacks 
that were treated with octreotide, compared to 36% of the attacks treated with 
placebo. Octreotide was also superior to placebo regarding pain-free rates, treatment 
of associated symptoms and meaningful relief. This study establishes a clear 
principle: that vasoconstrictor action is not necessaiy to abort acute cluster headache.
Octreotide was not compared with sumatriptan in this study, but given the results of 
studies of sumatriptan 6 mg by injection (Ekbom, 1991; Ekbom, 1993) and 20 mg by 
nasal spray (van Vliet et al., 2003), octreotide seems inferior to both of these 
formulations of sumatriptan in terms of the population response rate and time to initial 
relief. However, octreotide is not contra-indicated in ischemic heart disease, 
suggesting that it may have a role as an alternative therapeutic strategy to oxygen in 
patients who cannot take 5-HTib/ id receptor agonists. It is important to recall that the 
effect in responders is no less than the effect of injectable sumatriptan, since the 
response endpoint is identical, but that the study suggests the population of responders 
is smaller.
Octreotide was well-tolerated with no reports of serious side effects. The main side 
effect observed was gastrointestinal upset in eight patients treated with octreotide 
compared to four patients treated with placebo. All side effects resolved 
spontaneously and were generally short-lived and mild in nature. The side effects 
reported in this study were in keeping with the reported experience of side effects 
with this drug (Newman et al., 1995). The good tolerability data makes octreotide an 
attractive agent in a condition in which repeated doses will be required over a 
relatively short. Long-term octreotide therapy is commonly used in patients with 
acromegaly, and although there is a theoretical risk of gall stone development, this 
rarely poses a significant clinical problem compared to the burden of the disease itself 
(Lancranjan & Atkinson,  1999). Hence, the prolonged use of octreotide in CH, with
183its concomitant devastating morbidity from the excruciating pain, appears to be 
reasonable on clinical grounds.
As in the migraine study, the crossover approach was used. This design is particularly 
attractive in the study of CH because attacks are relatively stereotyped, and the attacks 
occur in rapid succession (van Vliet et al., 2003). Because treatment of two separate 
attacks in the same patient means that the attacks are not strictly independent, a 
multilevel multivariate statistical approach was used. The analysis showed no 
influence of the order in which the treatment was given. Moreover, the use of the 
multilevel multivariate approach permits consideration of all the relevant data in a 
single analysis. This analysis has been used in a randomized controlled trial of 
sumatriptan nasal spray in cluster headache (Van Vliet et al., 2003).
There are some limitations of this study that require consideration. First, patients were 
warned about about potential gastrointestinal side effects from octreotide when 
consenting patients for the study, in line with the requirements of the local ethics 
committee. This may have introduced an element of unblinding to the study in the 
patients who experienced these symptoms, which may have biased the results. This 
did not manifest as a significant ordering effect in the analysis. Secondly, this was a 
single dose study, and long-term studies would need to be performed to determine the 
long-term use of this medication, since cluster headache is a chronic condition. 
Thirdly, the study population consisted of 72% episodic cluster patients and 26% 
chronic patients. Although no difference in response was observed between the two, 
the study was not designed to dissect out the more common episodic from chronic 
cluster headache. A separate study of chronic cluster headache may reveal less robust 
results, which would, on the other hand, predict a better outcome in episodic cluster 
headache should a larger study in that sub-group be done. Lastly, this is a single 
centre study, although the unit in which this study was performed (QS) acts as a 
referral centre for the entire UK National Health Service, so the patient mix is taken 
from right across the UK.
As has been discussed in Section 1.5.1, functional imaging with positron emission 
tomography (PET; May et al., 1998a), structural imaging with voxel-based
184morphometry (May et al.,1999) and exciting results with deep brain stimulation 
(Leone et al., 2001) have identified the posterior hypothalamic gray matter as the key 
area for the basic defect in CH. Given that the hypothalamus is the chief source of 
somatostatin within the central nervous system (Swaab et al., 1993), the alteration in 
hypothalamic activity in CH may result in the disinhibition of descending 
somatostatinergic pathways to the trigeminal nucleus caudalis, either directly or via 
the periaqueductal gray. There is evidence that the periaqueductal gray and trigeminal 
nucleus caudalis are under tonic inhibition from the hypothalamus (Lumb, 2002). The 
disinhibition of descending input caused by hypothalamic dysfunction could 
theoretically result in uncontrolled trigeminovascular activation, as seen during a 
cluster headache attack. This hypothetical state of reduced somatostatinergic 
inhibitory activity may explain the observation of reduced somatostatin levels during 
CH (Caleri et al.,  1987), as well as the therapeutic effect of administering exogenous 
somatostatin (Sicuteri et al., 1984; Geppetti et al., 1985) and octreotide, as found in 
this study.
Finally, these results are interesting in the context of the negative migraine study. The 
striking difference between migraine and cluster headache in the pattern of brain 
activation on functional imaging, where cluster headache patients activate the 
posterior hypothalamus (May et al., 1998a; Sprenger et al., 2004), and both episodic 
(Weiller et al.,  1995; Bahra et al., 2001) and chronic (Matharu et al., 2003) migraine 
the brainstem without hypothalamic activation, is in keeping with greater prominence 
of a somatostatinergic mechanisms in cluster headache. If this were so, this study 
would be the first substantial evidence and pharmacologically based difference in the 
acute treatment of these disorders, which are so strikingly clinically different.
As discussed in Section 1.15.1, somatostatin has been found to differentially modify 
the release of a variety of neurotransmitters in several regions of the brain. Serotonin 
release from rat hypothalamic, cortical and hippocampal slices is enhanced by 
somatostatin (Tanaka & Tsujimoto,  1981), as is noradrenaline release from the cortex 
Tsujimoto & Tanaka, 1981), whilst noradrenaline release is inhibited in the rat 
hypothalamus (Gothert,  1980) and chick sympathetic ganglia (Boehm & Huck, 1996), 
and the release of y-amino butyric acid in the rat striatum is inhibited (Meyer et al.,
1851989). Further studies will be required to understand the mechanism of action of 
somatostatin and its analogues in CH.
In conclusion, this is the first adequately powered placebo-controlled study to 
demonstrate the effectiveness of a somatostatin analogue in the treatment of acute 
cluster headache attacks. In clinical practice, octreotide may have a particular utility 
in patients who are unresponsive to or intolerant of 5HTib/id agonists and oxygen, and 
as an alternative to oxygen in patients with cardiovascular disease.  Furthermore, this 
study demonstrates that somatostatin analogues which have no vasoconstrictor effect 
offer a novel therapeutic approach to the treatment of acute cluster headaches that 
may offer insights into understanding more fundamental aspects of this disabling form 
of primaiy headache.
1867.  General Discussion7.1  General Discussion
This thesis has investigated the role of the hypothalamo-pituitary axis in headache. 
The content of this thesis essentially consisted of two components. The first 
component investigated the structural, biochemical and clinical aspects of pituitary 
tumour-associated headache. The second component investigated the role of 
somatostatinergic pathways in primary headache.
The negative findings of Study 1  cast doubt on the accepted view that pituitary 
tumour-associated headache is a purely structural problem and suggest that other 
factors must be involved in its pathophysiology. This is an important observation 
because headache is widely regarded amongst many physicians to be a direct result of 
either dural stretch or irritation of pain-producing structures with in the cavernous 
sinus. Although the relevance of intrasellar pressure was not addressed in this thesis, 
the question of whether pituitary tumour-associated headache has a biochemical 
component is further emphasised.
Study 2 attempted to isolate potentially nociceptive peptides within pituitary tumours. 
Although both CGRP and substance P were isolated within a variety of tumour sub- 
types, there was no robust association with headache. Other candidate peptides 
presented in the general introduction include neuropeptide Y (NPY) and vasoactive 
intestinal polypeptide (VIP), and the possibility remains that these, or other peptides, 
may be involved in pituitary tumour-associated headache. However, although not 
presented in this thesis, preliminary data from our group also suggests that there is 
also no robust relationship between NPY (Classey et al., 2003) or VIP (Nathoo, 
unpublished data) with headache. This either raises the question of the validity of the 
nociceptive peptide hypothesis, or suggests that the relationship between pituitary 
tumours and headache is more complex than the production of a single nociceptive 
peptide.
Throughout this thesis, growth hormone- and prolactin- secreting tumours were 
particularly associated with headache. In Study 1, these tumour types were associated 
with the highest headache scores, and in Study 3, they were associated with the
188highest disability from headache. Although the precise mechanisms of nociception in 
these tumour types remain elusive, it strongly suggests that biochemical factors are 
important in the headache associated with these tumour types. This argument is re­
inforced by the observation in Study 3 that rare headache types such as SUNCT were 
exclusively associated with acromegaly and prolactinomas, and the finding that 
dopamine agonists and somatostatin analogues were able to alter the headache 
characteristics in these tumour types.
Pituitary tumour-associated headache is not a single phenotype but is a heterogenous 
clinical spectrum of presentation, which appears to be governed both by tumour- and 
patient- specific factors. Migraine was the commonest headache presentation, 
occurring in approximately 80% of cases. That migraine is the commonest headache 
type in pituitary tumours has since been confirmed by the findings of other groups 
interested in this topic (Afra & Cziijak, 2003). It is unclear whether the occurrence of 
migraine in the presence of a pituitary tumour is due to expression of migraine in 
predisposed individuals, or whether the tumour caused the migraine de novo in certain 
cases. The finding of trigeminal autonomic cephalgias in a relatively small cohort of 
patients in Study 3 further highlights the possibility that hypothalamo-pituitary 
disturbance is important in these headache syndromes. It was observed that patients 
with pituitary tumours may continue to suffer with debilitating headache after surgery, 
and that phenotype-driven medical therapy is helpful in many cases. It was observed 
that patients with ipsilateral cavernous sinus invasion were particularly refractory 
medical therapy, and there appears to be a sub-set of patients with unclassifiable 
headache that may be specific to pituitary disease. The observations of Study 3 have 
led to a proposed modification of the current classification of pituitary tumour- 
associated headache.
The theoretical reasons why somatostatin might play an important role in headache 
have been discussed in this thesis. The interesting difference in response between 
cluster headache patients and migraineurs to octreotide may raise important lessons 
regarding the pathophysiology of these two disorders. There appeared to be a real 
effect of octreotide on cluster headache, and further studies are required to determine 
whether this pharmacological approach may be useful in clinical practice. As regards 
octreotide and pituitary tumour-associated headache, Study 3 confirmed the
189impression that octreotide is often analgesic in pituitary tumours. This study also 
highlighted the less well recognised fact that octreotide overuse can lead to worsening 
headache in many situations, which provides a cautionary tale in the use of this agent 
for headache. In the case of somatostatin overexposure and headache triggering, it 
does not appear that this will be a useful tool for experimental headache induction.
7.2  Conclusion and further direction
The scientific study of headache is in its relative infancy compared to other areas of 
medical research, and it is an exciting time to be involved in the field. There is much 
to be learned regarding the role of the hypothalamo-pituitary axis in headache, and the 
findings in this thesis have contributed to this area. In recent years, there has been a 
large expansion in the number of publications regarding functional imaging and 
headache, in vivo models of trigeminal nociception, and clinical studies regarding the 
presentation and management of headache. The in vivo models allow for a great 
opportunity to further study the neuroendocrine mechanisms involved in headache. 
For example the effect of micro-injectionimg certain peptides into the hypothalamus 
on trigeminal activity may represent an exciting opportunity to further understand 
specific neuroendocrine pathways in headache. Although not presented in this thesis, 
our group has studied the effect of micro-injecting various compounds into the 
posterior hypothalamic nucleus, and have found these to have profound effects on 
trigeminal nerve firing. For example, we have shown that somatostatin antagonists 
inhibit trigeminal activity (Bartsch, unpublished data) and have also shown that 
injection of orexin A inhibits, whilst orexkn B significantly facilitates trigeminal 
activity (Bartsch et al., 2004). This opens up a relatively new area of research 
opportunities for both neurologists and neuroendocrinologists interested in headache.
In conclusion, the subject of headache has traditionally been within the realms of the 
neurologist and neuroscientist. The finding that disruption of the hypothalamo- 
pituitary axis can lead to interesting headache syndromes suggests that 
endocrinologists may contribute significantly to this rapidly expanding field of 
medicine.
1908.  Appendix
8.1  Case 1
Micro-prolactinoma and SUNCT-like headache
Levy MJ, Matharu MS, Goadsby PJ
Paper ref: European Journal of Neurology 2003;10:1-5
A 36-year-old female, with no headache history, presented in 1987 with secondary 
amenorrhoea, galactorrhoea and headache. The headache was described as a left-sided 
sharp ‘knife-like’ pain during acute exacerbations. An exacerbation would typically 
last between 10 seconds and 4 minutes and would occur up to 20 times a day. 
Precipitants for exacerbations included bending, walking and moving about.  In 
between these exacerbations, she had a continuous dull left-sided pain. During an 
exacerbation, she experienced prominent ipsilateral cranial autonomic symptoms of 
lacrimation, nasal stuffiness and ptosis. She felt irritable during the pain and would 
prefer to move around rather than lie still. There was no associated nausea, 
photophobia, phonophobia, osmophobia or nausea. Aggravating factors included 
alcohol (within two hours), tiredness, stress and hunger. During a severe attack, the 
patient would experience polyuria, polydipsia and low mood. On several occasions 
the pain woke her up at night. Sumatriptan was ineffective for the attacks.
Her serum prolactin was 700 mU/1 (27-525 mU/1) and an MRI scan showed a 10mm 
microadenoma (Figure 30). A diagnosis of a microprolactinoma was made, and she 
was prescribed bromocriptine 2.5mg. Within 30 minutes of taking the first dose of 
bromocriptine, she experienced the worst headache she had ever had, leading her to a 
remark that she felt suicidal due to the severity. The pain was an excruciating left- 
sided sharp pain with prominent conjunctival injection, lacrimation and ipsilateral 
ptosis. Simple analgesics, including acetaminophen- (paracetamol) and codeine- 
containing compounds, did not alleviate the symptoms and the pain lasted for 12 
hours. She described the attack as identical to her typical headaches, but without 
remission. Because of her reluctance to try further dopamine agonists, and persistent
191amenorrhoea, headaches and hyperprolactinaemia, transphenoidal removal of the 
prolactinoma was performed. Post-operatively, she was free from headache. Her 
serum prolactin normalised and she became pregnant within her menstrual first cycle. 
She did not experience headache during her pregnancy and her periods returned to 
normal post-partum.
In 1994 her headaches returned. These were a constant left-sided ‘knife-like’ pain as 
before with exacerbations. The exacerbations were the same as before but were more 
frequent, occurring up to 30 times per day. Several months later, her periods became 
irregular and she developed galactorrhoea. Her serum prolactin was 1436 mU/1 and a 
repeat MRI showed recurrence of the prolactinoma.
To avoid further surgery, she was given an in-patient trial of cabergoline 250 pg. She 
again developed an excruciating left-sided headache with cranial autonomic features, 
within an hour of taking the cabergoline, and lasting 12 hours until being aborted with 
indomethacin 200mg. Two weeks later she was prescribed quinagolide 250pg. Within 
30 minutes she experienced an identical left-sided headache that was of the same 
intensity and duration as that induced by cabergoline. Previous unsuccessful headache 
preventative medications include atenolol, pizotifen, and dothiepin. On indomethacin 
75mg three times daily for 1  month she had very modest benefit at best. She is 
currently taking 4800mg gabapentin, which has led to an only very moderate 
improvement in her symptoms and is being considered for re-exploration of the 
pituitary fossa.
192Figure 30. Left micro-prolactinoma
1938.2  Case 2
Micro-prolactinoma and indomethacin-sensitive headache
Levy MJ, Mat ham MS, Goadsby PJ
Paper ref: European Journal of Neurology 2003;10:1-5
A 40-year-old woman presented in 1997 with severe right-sided headaches. She had 
experienced headaches during her menarche and has a sister with migraine. She had 
not experienced headache for over 20 years.  The presenting headache was associated 
with nausea, vomiting, photophobia and phonophobia. Movement would exacerbate 
the headache. A typical attack would last 3-4 days, and occurred every 2 weeks. 
During an attack, she experienced ipsilateral conjunctival injection and lacrimation. 
Triggers included bright lights and sleep disturbance. Two months after the onset of 
symptoms, she developed secondary amenorrhoea and the frequency of headache 
increased. Serum prolactin was 2300 mU/L and an MRI scan showed a 9mm 
microadenoma (Figure 31). She was prescribed bromocriptine 2.5mg.
Within 1  hour of taking bromocriptine, she developed a severe right-sided headache 
similar to her previous headaches but worse. She continued to take the bromocriptine 
for 7 Vz months, and after each dose, she experienced headache. On several occasions, 
she developed bilateral scotomata 30 minutes prior to the onset of pain. Since starting 
the bromocriptine, she developed a second headache. This was a sharp, stabbing 
occipital pain that took her breath away. It would last no more than a few seconds and 
occurred several times a week. Her mood became low and the bromocriptine was 
discontinued.
She was prescribed cabergoline 250pg, because of the problems with bromocriptine. 
Initially, her headache severity was reduced. On day 14 after the first dose, she 
developed a sudden onset of right-sided severe headache associated with left 
hemiplegia. The hemiplegia resolved after 7 days and the cabergoline was stopped, 
although the headache has persisted at a variable level. Exacerbations have been 
associated with left hemiplegia that resolves leaving each time a background 
headache. Preventative treatments, including tricylics and flunarizine have been 
unhelpful. A trial of indomethacin produced a dramatic improvement in symptoms
194with abolition of headache within one hour and persistence of the response on 50mg 
three times daily.
Figure 31. Right micro-prolactinoma
1958.3  Case 3
Acromegaly-associated headache responsive to octreotide but not lanreotide
Levy MJ, Goadsby PJ, Meeran K
Paper ref: Headache 2003; 43(7): 794-798
A 29 year old lady presented in 1989 with a one year history of headaches and 
secondary amenorrhoea. Her headaches were characterised by a severe continuous 
sharp, left retro-orbital pain. In addition to the constant pain, there were excruciating 
exacerbations associated with a throbbing sensation, nausea, photophobia, 
phonophobia and aggravation with movement. The headaches were unresponsive to 
all conventional analgesics.
On examination she had typical features of acromegaly, including broad hands and 
feet and mild coarsening of her facial features. Her serum IGF-1 was elevated to 
150nmol/l (NR 13-64) and a subsequent oral glucose tolerance test (OGTT) 
confirmed active acromegaly (serum growth hormone nadir > 50mU/l). Her prolactin 
was 180mU/ 1  (NR < 360), total T4 107nmol/ 1  (NR 71-148), TSH l.lOmU/ 1  (NR 
0.3-4.7), LH 11.8U/1  (NR 2-10 mid-cycle), FSH 9.3U/1 (NR 9-12 mid-cycle). A CT 
scan showed a pituitary lesion with invasion of the left cavernous sinus.
Despite trans-sphenoidal resection and subsequent radiotherapy, her GH remained 
elevated and her headache persisted (growth nadir 29mU/l during OGTT)
She was given octreotide at a dose of 50pg tds. For the first time since presentation, 
she noticed an instant improvement in her headache. The analgesia from octreotide 
was completely reproducible, and she was pain-free on a maintenance dose of lOOpg 
tds. She would experience only mild headache one hour before each octreotide dose. 
An OGTT on octreotide showed a mean growth hormone level of 3.7mU/l, indicating 
a good response to medical therapy.
In 1998, she was converted to 30mg lanreotide LA fortnightly. Although her GH 
secretion was better controlled (mean value 2.5mU/l), her headaches returned.
196Subsequent conversion to monthly octreotide LAR led to an immediate improvement 
in headache symptoms. One week before each injection was due, her headache 
symptoms would return, and she required additional doses of short-acting octreotide 
(lOOmcg) until the next dose of octreotide LAR. Conversion to three-weekly 
injections of octreotide LAR has led to both excellent growth hormone and headache 
control. There has been no evidence of tachyphylaxis to the octreotide in terms of 
headache response for 4 years and her mean GH is now 1.0 mU/1.
1978.4  Case 4
Macro-prolactinoma and SUNCT-like headache 
Matharu MS, Levy MJ, Merry RT, Goadsby PJ
Paper ref: Journal of Neurology, Neurosurgery and Psychiatry 2003; 74 (11): 1590-2
A 37-year-old, right-handed, married, man presented with an 11-year history of 
headaches in December 1998. There were no precipitants at onset. Initially he had 1-2 
headaches per month but there was a gradual increase in the frequency over time. In 
the early to mid 1990s he had bouts of daily attacks alternating with remission 
periods; he had 2-3 remissions annually with each remission lasting 2-4 weeks. In the 
late 1990s he had no remissions at all. A typical attack was strictly unilateral on the 
right. It started as a dull ache in the neck or the occiput and then radiated to the 
parietal region, vertex, forehead and the temple before becoming centred on the retro- 
orbital region. The pain was very severe or excruciating and had a squeezing or 
pressing quality. The usual duration of the pain was 20-30 seconds though the range 
was 10-60 seconds. The pain came on rapidly, was maintained at a plateau phase and 
then resolved rapidly. He denied any super-imposed spikes or variations in the 
severity of the pain. He had 1-6 attacks daily at presentation. The attacks were 
associated with prominent ipsilateral conjunctival injection and lacrimation, and 
bilateral facial flushing. He denied all other cranial autonomic features, nausea, 
vomiting, photophobia, phonophobia or osmophobia. He felt restless during the pain 
and would often pace up and down. He denied any aura symptoms. Occasionally he 
had a dull interictal pain that lasted 10-60 minutes. The headaches could be triggered 
consistently by exercise, particularly cycling, and inconsistently by stressful 
situations. He denied having any other triggers for the headaches. He was unsure 
whether there was a refractory period after an attack; the shortest interval between 2 
spontaneous attacks was about 3 minutes. He could abbreviate the attack by coughing. 
There was no past history of headaches.
The patient had previously tried ibuprofen, aspirin, distalgesic and indomethacin 
50mgs three times daily for the headaches without any benefit. At presentation, he 
was not taking any drugs. In the past medical history he had a tonsillectomy in
198childhood. His sister was diagnosed as having cancer of the thyroid gland at the age of 
21 years. There is no family history of headaches. He is a non-smoker and drinks 25- 
30 units of alcohol per week.
General and a detailed neurological examination was entirely normal. A magnetic 
resonance imaging (MRI) scan of the brain revealed a pituitary adenoma on the right 
extending towards the right cavernous sinus, causing displacement of the right 
internal carotid artery; the pituitary adenoma also extended into the chiasmatic cistern 
but did not impinge on the optic chiasm (Figure 32). Formal visual field testing was 
normal. Blood tests showed that the serum prolactin level was markedly elevated at 
10,000 mU/L (normal range, 0 to 635) and testosterone was at the lower end of the 
normal range (10.1 nmol/L; normal range 9 to 33) with no elevation of luteinizing 
hormone (LH) or follicle stimulating hormone (FSH), while free thyroxine, thyroid 
stimulating hormone (TSH), basal cortisol, adrenocorticotropic hormone (ACTH), 
oestrogen and growth hormone levels were normal. A diagnosis of 
macroprolactinoma was made.
At that point the patient was re-interviewed to elicit features of pituitary disease. He 
reported that, in retrospect, there may have been a slight reduction in libido over the 
previous few years, although sexual function had otherwise been normal. He had 
always had scanty beard growth, but otherwise secondary sexual development and 
characteristics were normal. There was no galactorrhoea and vision was normal.
The patient was started on bromocriptine 2.5mg bd with which the prolactin level 
normalised within 3 months. The bromocriptine dose was thereafter reduced to lmg 
bd. The headaches started improving shortly after starting bromocriptine and resolved 
completely within 3 months. A repeat MRI scan of the brain in February 2000 showed 
that the pituitary adenoma had virtually disappeared. The patient continued taking 
bromocriptine for 18 months but began to develop nausea and nasal blockage; 
bromocriptine was therefore substituted with cabergoline 1.5mg per week. He has 
been on cabergoline over the last 18 months on which the prolactin level remains 
normal and there are no side-effects. He denies having had any further headaches and 
his libido and energy levels have significantly improved.
199Figure 32. Prolactinoma invading right cavernous sinus8.5  Case 5
Acromegaly and octreotide rebound headache
Levy MJ and Goadsby PJ
Abstract ref: Endocrine abstracts 2004; 7: PI 10
A 35 year-old lady presented with secondary amenorrhoea, coarsening of features, 
growth of hands and feet and persistent unilateral headache. The headache was a 
featureless continuous left-sided frontal pain. There were occasional exacerbations in 
the headache, but generally the pain was graded as 6 out of 10 on a visual analogue 
scale. A clinical diagnosis of acromegaly was suspected, and an oral glucose tolerance 
test (OGTT) confirmed this (growth hormone levels 21.6, 21.5, 27.0, 25.0 and 24.7 
mU/1 at 0, 30, 60 90 and 120 minutes respectively. An MRI scan confirmed a pituitary 
macro-adenoma, and the patient underwent a transphenoidal hypophysectomy. Post- 
operatively, the patient still complained of headache, and a repeat OGTT showed 
reduction in GH but lack of cure (growth hormone levels 10.2, 7.2, 8.1, 9.6, 9.3 mU/1 
at 0, 30, 60 90 and 120 minutes respectively). The patient went on to have external 
radiotherapy, after which growth hormone levels remained > 5mU/l and the headache 
persisted. Because of the disabling nature of the headaches, transcranial surgery was 
performed to remove any residual tumour. Post-operatively, there remained no 
improvement in headache.
An octreotide infusion (lOOpg/hour) was given to assess medical response of growth 
hormone. During this infusion, the patient noticed a dramatic improvement in her 
headache for the first time for many years. Although the octreotide improved her 
headache symptoms, there was no reduction in growth hormone during the infusion. 
Because of the impressive analgesic response to octreotide, the patient was keen to be 
started on this agent. With each octreotide injection, the patient experienced an 
immediate analgesic effect with rebound headache one hour before the next injection. 
After several months, the patient found that she needed to increase the frequency of 
octreotide injections as the time interval between headache had become increasingly 
short. The maximum frequency of octreotide injections was twelve administrations 
per day. Conversion to monthly injections of octreotide LAR led to recurrence of her 
persistent headache and she experienced no analgesic effect on this agent.
201An MRI of the pituitary fossa revealed residual pituitary tissue ipsilateral to the 
symptoms of headache (Figure 33). Two courses of gamma-knife radiotherapy were 
targeted at this residual tumour. Subsequent OGTT revealed cure of her acromegaly 
(mean growth hormone < 0.5 mU/1) but her headache persisted. She was admitted to 
the ward for investigation of her headache and withdrawal from octreotide. Numerous 
abortive agents have been administered in attempt to improve her headache including 
sumatriptan 6mg s/c, high flow oxygen, intranasal and intravenous lignocaine, 
intravenous dihydroergotamine and ketamine, and greater occipital nerve injection. 
Since this time, numerous preventative agents have also been administered, including 
amitriptyline 75mg, carbamazepine 400mg, gabapentin 5400mg and topiramate 
400mg, all without effect.
The patient was readmitted for investigation and a placebo controlled trial of 
octreotide confirmed that this agent continues to give immediate analgesia. To this 
date, octreotide is the only agent that has provided any pain relief in this patient. She 
is currently on the waiting list for an occipital nerve stimulator insertion.
Figure 33.  Residual GH-secreting tumour in right cavenous sinus
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